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Abstract 
 
Aims:  To study the effect of pre-existing maternal cardiac disease on 
cardiovascular function during pregnancy, and on obstetric and 
fetal/neonatal outcomes, and to investigate maternal risk factors for 
adverse events. 
Methods: Retrospective case note review. 
Results: Four hundred and eighty-nine pregnancies in 326 women were studied. 
Most pregnancies (50%) occurred in women with congenital heart 
disease. There were 4 maternal deaths, 6 stillbirths and 5 neonatal 
deaths. Cardiovascular events occurred in 7.4% of pregnancies, while 
obstetric and perinatal complications occurred in 34% and 30% of 
pregnancies respectively. 
Conclusions: Pregnancy in women with pre-existing heart disease continues to be 
associated with high rates of maternal and neonatal mortality and 
morbidity. This work highlights the importance of effective pre-
pregnancy counselling and meticulous surveillance during pregnancy, 
delivery and the puerperium by an experienced multidisciplinary team. 
Additionally there is an urgent need for well-designed randomised-
controlled trials to determine best practice. 
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Chapter 1:   Introduction 
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1.1 Aims and hypotheses 
 
The aims of the work reported in this thesis are: 
 
1. To study the effect of pre-existing maternal cardiac disease on cardiovascular 
function during pregnancy, and on obstetric and fetal/neonatal outcomes, and 
to investigate maternal risk factors for adverse events 
 
2. Within the framework of a retrospective case note analysis to test the 
following hypotheses: 
x Maternal cardiovascular and obstetric outcomes are impaired in the presence 
of pre-existing maternal cardiac disease 
x Fetal/neonatal outcomes are impaired in women with pre-existing maternal 
cardiac disease 
x Fetal growth is impaired in women with cardiac disease who have a limited 
ability to increase their cardiac output in response to pregnancy 
x Adverse outcomes from pregnancy can be predicted at least in part by 
maternal factors 
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1.2 Epidemiology 
 
It is estimated that 0.2 to 4% of all pregnancies in Western industrialized countries are 
complicated by cardiovascular disease.1 In the UK the incidence of heart disease 
during pregnancy has remained relatively constant at 0.9% over several decades.2  
 
Figure 1: Rates of cardiac maternal deaths; UK: 1985-2008; data from Centre for 
Maternal & Child Enquiries (CMACE)3  
 
 
The most recent report of the Confidential Enquiries into Maternal Deaths (2006-
2008) identified cardiac disease as the commonest single cause of maternal death with 
a maternal mortality rate of 23.1 per million maternities (up from 7.6 per million in 
the 1988-1990 enquiry).3 Care was felt to be substandard in 51% of cardiac deaths. 
Current management is based upon limited clinical experience and an inadequate 
body of prospective research as the heterogeneity of disease has hindered the 
development of randomized controlled trials or appropriate pregnancy management 
protocols. Neither the latest European Society of Cardiology (ESC) guideline on the 
management of cardiovascular disease during pregnancy,4 nor the Royal College of 
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Obstetricians and Gynaecologists (RCOG) good practice guidance on cardiac disease 
in pregnancy5 reference a single randomized controlled trial involving pregnant 
women.  
 
The increase in cardiac deaths in the UK is mainly attributable to a rise in deaths due 
to acquired heart disease (20.8 per million maternities in the last report), with the 
leading causes of death being sudden adult death syndrome (SADS), myocardial 
infarction (MI), dissection of the thoracic aorta and cardiomyopathy.  
 
Figure 2: Indirect maternal deaths from congenital and acquired heart disease;  
UK: 1985-2008; data from CMACE3 
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Figure 3: Causes of maternal death from cardiac disease: UK: 2000-2008; data from 
CMACE3 
 
MI – myocardial infarction; SADS – sudden adult death syndrome; PPCM – 
peripartum cardiomyopathy; RVH – right ventricular hypertrophy; LVH - left 
ventricular hypertrophy; PH – pulmonary hypertension; CHD – congenital heart 
disease 
 
This trend is likely to continue as more women delay pregnancy until later life and as 
rates of obesity and other chronic conditions such as hypertension and diabetes 
continue to rise. Moreover many women with acquired heart disease may be unaware 
of their condition, the diagnosis only being made when they become pregnant and 
develop symptoms.  
 
Conversely, the majority of women with congenital heart disease will be aware of 
their diagnosis and known to cardiac services, with over 80% having some knowledge 
about their treatment, frequency of follow up, dental practices, occupational choices, 
appropriateness of oral contraceptives and the risks of pregnancy.6 Although death 
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rates in women with congenital heart disease and pulmonary hypertension continue to 
fall, congenital heart disease has become the most frequent form of cardiovascular 
disease present during pregnancy in the western world (75-82%).4,7,8 Over 85% of 
infants with congenital heart disease now survive into adulthood such that adults with 
congenital heart disease now outnumber children.9,10 In particular, advances in 
diagnosis and treatment have led to an improvement in the survival of those with 
complex congenital heart disease.11 Nevertheless, most interventions are not curative 
and many adults with congenital heart disease will face the prospect of re-intervention 
and, if managed inappropriately, premature death. The increasing complexity of 
congenital heart disease in the pregnant population is further reflected by a significant 
rise in severe complications during delivery and the high-risk postpartum period.12  
Approximately 1600 people with congenital heart disease requiring on-going follow-
up enter adulthood per year in the UK.11 Half of these are women, many of whom will 
wish to become pregnant and start a family.  
 
There are few data describing either the spectrum or outcomes of cardiovascular 
disease related to pregnancy in developing nations. Patterns of disease appear to be 
markedly different from those seen in the developed world and are often complicated 
by HIV/AIDS as a co-morbidity. Rheumatic heart disease (RHD) is the commonest 
abnormality, although cardiomyopathies and undiagnosed or un-operated CHD are 
also major problems.13  
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1.3 Normal cardiovascular adaptation to pregnancy 
 
1.3.1 Changes in the cardiovascular system 
Pregnancy is associated with substantial physiological changes in the cardiovascular 
system. They are essential for successful pregnancy. The key elements – changes in 
peripheral vascular resistance, cardiac output and blood volume – have been well 
documented in normal pregnancy.14,15  
 
Figure 4: Changes in peripheral vascular resistance and cardiac output in 
pregnancy; data from Robson et al15 
 
 
The ‘unifying hypothesis’ suggests that body fluid regulation in pregnancy is 
principally determined by peripheral vasodilatation which triggers the haemodynamic 
and subsequent hormonal responses that result in sodium and water retention via 
activation of the renin-angiotensin-aldosterone system.16 Systemic vascular resistance 
falls to 70% of non-pregnant levels by 8 weeks of gestation, secondary to a marked 
peripheral dilatation induced by both endocrine and local factors.17,18  This state of 
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relative vascular under-fill is thought to lead to increases in blood volume and cardiac 
output. It is also associated with a fall in mean arterial blood pressure (predominantly 
due to a reduction in diastolic blood pressure) that occurs in the first trimester and 
continues until the third trimester when both systolic and diastolic blood pressure rise 
gradually towards pre-pregnancy values.15,19 Both high and low diastolic blood 
pressures during pregnancy have been shown to be associated with small babies and 
increased perinatal mortality.19 Similar haemodynamic changes (arterial 
vasodilatation, reduced mean arterial pressure and increased cardiac output) have 
been described during the luteal phase of the menstrual cycle and are suggested to be 
the result of an oestrogen-induced increase in prostacyclin levels.20 This suggests that 
the changes seen in early pregnancy occur independently of the placenta and may be 
dependent on the corpus luteum, as oestrogen is predominantly ovarian in origin at 
this stage of pregnancy. Other hormones, (such as relaxin and hCG), and vasodilatory 
peptides, such as calcitonin gene-related peptide and nitric oxide, may also play a 
role.14  
 
As a result of fluid retention plasma volume increases by 50%. There is a relatively 
smaller increase in total red cell mass, which results in an overall fall in haemoglobin 
concentration (haemodilution). Inadequate plasma volume expansion has been shown 
to be associated with fetal growth restriction.21 Cardiac output increases by 30-
60%15,22,23,24 with a rapid rise in the first trimester, reaching a peak at 20-24 weeks 
after which it plateaus or falls slightly. The rise in cardiac output is disproportionately 
greater than the increase in heart rate and is therefore attributable to augmentation in 
stroke volume. However, as pregnancy advances heart rate increases further, 
becoming the predominant factor in increasing cardiac output. The resultant increase 
! #'!
in pulmonary blood flow is balanced by a reduction in pulmonary vascular resistance, 
thereby preventing a rise in pulmonary artery pressure.15 During pregnancy, resting 
cardiac output fluctuates markedly, particularly with changes in maternal position, 
with compression of the inferior vena cava by the enlarging gravid uterus resulting in 
decreased venous return and a fall in cardiac output.  
 
1.3.2 Ventricular structure and function 
Pregnancy leads to structural and functional changes in the heart. Data regarding 
systolic and diastolic cardiac function in pregnancy are scarce, however, serial 
echocardiography during pregnancy has demonstrated an increase in left ventricular 
mass and dimensions, ejection fraction and fibre shortening.15,22 Thus normal 
pregnancy appears to be associated with a physiological left ventricular hypertrophy, 
similar to that seen in athletes.  
 
1.3.3 Labour and delivery 
Labour and delivery substantially alter the maternal haemodynamic state secondary to 
pain, anxiety and uterine contractions. Contractions increase venous return by up to 
500ml as uterine blood returns to the circulating pool.25  This results in an increase in 
stroke volume and subsequently cardiac output. Basal cardiac output has been 
reported to increase by about 12% during labour with a further rise during 
contractions of up to 20%.26 The magnitude of the increase in cardiac output during 
contractions increases as labour progresses.27 Pain and anxiety have a significant 
effect on both heart rate and blood pressure during labour. Both systolic and diastolic 
blood pressure rise during labour, peaking during the second stage. The pain of labour 
and delivery can be effectively interrupted by blocking the T10 to L1 nerve roots 
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before their entrance into the spinal cord (caudal, low epidural or low subarachnoid 
blocks). Reduction of pain by epidural anaesthesia may limit the haemodynamic 
changes and the progressive rise in cardiac output seen between contractions.28 
Carefully administered, regional anaesthesia is probably safe in patients with severe 
cardiac disease, although the optimum management is yet to be determined. 
 
In spite of the blood loss associated with delivery there is reported to be a 60-80% rise 
in cardiac output immediately after delivery.25 This occurs because of the increase in 
venous return due to relief of aorto-caval compression, and from additional blood 
moving from the contracting uterus back into the systemic circulation. It can result in 
a substantial rise in ventricular filling pressures and stroke volume, and may lead to 
clinical deterioration in women with severe cardiac disease. However, within 2 weeks 
of delivery, cardiac output falls considerably, returning to the non-pregnant state by 
six months post-partum.29 
 
1.3.4 Other considerations 
Of note, the physiological changes that occur during pregnancy can dramatically alter 
the pharmacokinetics of any drugs administered. The increase in plasma volume has a 
dilutional effect on many drugs while drug clearance is enhanced by the raised 
glomerular filtration rate and enhanced hepatic metabolism. Higher doses may be 
required to achieve therapeutic plasma concentrations.  
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1.4 Maternal and Fetal Risks 
 
 
The risk of adverse events (both maternal and fetal) during pregnancy for women with 
pre-existing heart disease is determined by the ability of their cardiovascular system 
to adapt to the associated physiological changes. This is dependent on the specific 
cardiac condition, the current haemodynamic status and functional capacity of the 
patient, and a prior history of adverse cardiac events.8,30,31,32 It may range from a risk 
of maternal death of up to 50% for women with pulmonary hypertension (PH), such 
that pregnancy is deemed to be inadvisable, to the same as the general population for 
women with minor lesions such as a successfully repaired ventricular septal defect 
(VSD).  
 
1.4.1 Maternal Cardiovascular Complications 
Previous studies have sought to develop scores to aid risk stratification. Assessing 
disease-specific risk is difficult as reports focusing on outcomes in women with 
particular types of heart disease are usually retrospective and tend to be too small to 
identify reliable predictors of poor outcome. Other investigators have included larger 
populations with a wide variety of forms of heart disease including congenital heart 
disease, ischaemic heart disease, cardiomyopathies, acquired valvular heart disease 
(VHD) and arrhythmias in women with structurally normal hearts. The CARPREG 
(CARdiac disease in PREGnancy) investigators led the way in identifying predictors 
of adverse pregnancy outcome in women with pre-existing heart disease30 and were 
the first to design a risk score8 which has subsequently been validated in several 
studies.33 Prior cardiac events (heart failure, transient ischaemic attack, stroke prior to 
pregnancy, arrhythmia), poor maternal functional capacity (New York Heart 
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Association (NYHA) class > II),34 presence of cyanosis, left heart obstruction and 
myocardial dysfunction (ejection fraction <40%) were identified as predictors of 
maternal cardiovascular events during pregnancy.8,30 However, it has been suggested 
that because the CARPREG cohort includes women with primary electrical and 
acquired heart disease, as well as congenital heart disease (some types of which, in 
particular complex congenital heart disease, are under-represented), it may 
overestimate risk in women with congenital heart disease35,36 Other investigators have 
identified additional predictors in this population including the presence of 
mechanical valve prostheses (MPVs), moderate/severe systemic and sub-pulmonary 
atrioventricular valve regurgitation, use of cardiac medication pre-pregnancy and 
maternal cigarette smoking,35,36 but these have not been validated in other studies. 
Current guidance4 advises use of the modified World Health Organization (WHO) 
risk classification to conduct maternal risk assessment.37 This includes all known 
maternal cardiovascular risk factors: the underlying disease and other co-morbidities, 
as well as contra-indications for pregnancy (such as PH and aortic dilatation) that are 
not incorporated in either the CARPREG8 or ZAHARA36 predictors and correlates 
well with cardiac, obstetric and fetal outcomes.38 Pregnancy related risks are additive 
and generally increase with increasing disease complexity.8,30,37,39 
 
There is also a suggestion that pregnancy may have an irreversible detrimental effect 
on cardiac function in women with certain types of congenital heart disease40 
(Tetralogy of Fallot41, transposition of the great arteries (TGA) corrected by atrial 
switch procedure (Mustard or Senning operation42). Larger studies are required to 
investigate this issue further.  
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Table 1: New York Heart Association (NYHA) functional classification34 
NYHA Class Functional Capacity 
I 
Patients with cardiac disease but without resulting limitation of 
physical activity. Ordinary physical activity does not cause undue 
fatigue, palpitation, dyspnoea or angina pain 
II 
Patients with cardiac disease resulting in slight limitation of physical 
activity. They are comfortable at rest. Ordinary physical activity 
results in fatigue, palpitation, dyspnoea or angina pain 
III 
Patients with cardiac disease resulting in marked limitation of 
physical activity. They are comfortable at rest. Less than ordinary 
activity causes fatigue, palpitation, dyspnoea or angina pain 
IV 
Patients with cardiac disease resulting in inability to carry on any 
physical activity without discomfort. Symptoms of heart failure or 
the angina syndrome may be present even at rest. If any physical 
activity is undertaken, discomfort is increased. 
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Table 2: Modified WHO classification of maternal cardiovascular risk: principles4,37 
Risk Class Risk of pregnancy by medical condition 
I 
No detectable increased risk of maternal mortality and no/mild 
increase in morbidity 
II 
Small increased risk of maternal mortality or moderate increase in 
morbidity 
III 
Significantly increased risk of maternal mortality or severe 
morbidity. Expert counselling required. If pregnancy is decided 
upon, intensive specialist cardiac and obstetric monitoring needed 
throughout pregnancy, childbirth and the pueperium 
IV 
Extremely high risk of maternal mortality or severe morbidity; 
pregnancy contraindicated. If pregnancy occurs termination should 
be discussed. If pregnancy continues, care as for class III 
 
 
 
 
 
 
 
 
 
 
 
 
! $#!
Table 3: Modified WHO classification of maternal cardiovascular risk: application4,37 
Conditions in which pregnancy is WHO I 
y  Uncomplicated, small or mild 
- pulmonary stenosis 
- patent ductus arteriosus 
- mitral valve prolapse 
y  Successfully repaired simple lesions (atrial or ventricular septal defect, patent  
    ductus arteriosus, anomalous pulmonary venous drainage) 
y  Atrial or ventricular ectopic beats, isolated 
Conditions in which pregnancy is WHO II or III 
WHO II (if otherwise well and uncomplicated) 
y  Unoperated atrial or ventricular septal defect 
y  Repaired tetralogy of Fallot 
y  Most arrhythmias 
WHO II-III (depending on individual) 
y  Mild left ventricular impairment 
y  Hypertrophic cardiomyopathy 
y  Native or tissue valvular heart disease not considered WHO I or IV 
y  Marfan syndrome without aortic dilatation 
y  Aorta <45mm in aortic disease associated with bicuspid aortic valve 
y  Repaired coarctation 
WHO III 
y  Mechanical valve 
y  Systemic right ventricle 
y  Fontan circulation 
y  Cyanotic heart disease 
y  Other complex congenital heart disease 
y  Aortic dilatation 40-45mm in Marfan syndrome 
y  Aortic dilatation 45-50mm in aortic disease associated with bicuspid aortic valve 
Conditions in which pregnancy is WHO IV (pregnancy contraindicated) 
y  Pulmonary arterial hypertension of any cause 
y  Severe systemic ventricular dysfunction (LVEF <30%, NYHA III-IV) 
y  Previous peripartum cardiomyopathy with any residual impairment of left 
ventricular function 
y  Severe mitral stenosis, severe symptomatic aortic stenosis 
y  Marfan syndrome with aorta dilated >45mm 
y  Aortic dilatation >50mm in aortic disease associated with bicuspid aortic valve 
y  Native severe coarctation 
 
LVEF: left ventricular ejection fraction 
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1.4.2 Obstetric Complications 
Women with pre-existing heart disease appear to be at increased risk of adverse 
obstetric outcomes, although reliable cardiac predictors for these have not been 
identified.36,39,43 Several studies have described an increased preterm birth rate in 
these women compared with the general population.7,8,30,32,33,39,43 While iatrogenic 
preterm delivery may result from concerns about maternal decompensation, it has 
been reported that preterm delivery rates remain high even after the exclusion of such 
patients, and that the risk of preterm delivery was higher in those with an intermediate 
CARPREG score.33 This concurs with the CARPREG investigators who found an 
association between cardiac complications and the onset of preterm labour.8,30,32 
Increased rates of preterm labour appear to be particularly marked in women with 
more complex congenital heart disease including Ebstein’s anomaly, TGA, cyanotic 
congenital heart disease, Eisenmenger syndrome, Fontan circulation and pulmonary 
atresia with VSD.39 A higher incidence of spontaneous preterm labour secondary to  
preterm premature rupture of membranes (PPROM) has also been reported in women 
with congenital heart disease (approximately 1.5 times that in the general 
population),43 especially in women with TGA or a Fontan circulation.38 The reason 
for this is unclear. Increases in amniotic fluid matrix metalloprotease (MMP) 1,8 and 
9 and a decrease in tissue inhibitors of MMP 1 and 2 leading to reduced membrane 
collagen content are thought to be an important factor in developing PPROM. Similar 
changes have also been implicated in aortic aneurysm formation and congenital 
valvular disease. Oxidative stress may also play a role.43 
 
Rates of post-partum haemorrhage (PPH) two to four times higher than that seen in 
the general population have been reported.33,43 This has been attributed both to a 
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prolonged second stage of labour (and subsequent uterine atony), and to the increased 
use of elective assisted vaginal delivery (with an increased risk of trauma, in 
particular with forceps) in an attempt to avoid repeated Valsalva manoeuvres which 
may increase cardiac stress. Use of anticoagulants and antiplatelet agents may also be 
a factor but the evidence for this is conflicting.33,43 
 
Overall, pre-existing heart disease does not appear to be associated with an increased 
risk of developing a hypertensive disorder of pregnancy (pregnancy-induced 
hypertension (PIH), pre-eclampsia (PET) and eclampsia). However, an increased 
incidence has been documented with certain types of congenital heart disease. 
Specifically, patients with aortic coarctation (COA) and TGA seem to be at increased 
risk, and a twofold higher incidence than that seen in the general population has been 
reported.39 
 
1.4.3 Fetal and Neonatal Complications 
Maternal cardiac disease is associated with increased fetal and neonatal complications 
including fetal loss, fetal growth restriction (FGR), preterm birth and intra-cranial 
haemorrhage. This risk is again highest in women with cyanosis and poor functional 
class (NYHA functional class III or IV) or left heart obstruction.30 It is further 
increased in the presence of maternal age <20 and >35 years, multiple pregnancy, 
maternal cigarette smoking and treatment with anticoagulants.8,32  
 
Normal fetal growth is regulated at multiple levels and is determined by the 
interaction between the genetically determined growth potential and various maternal, 
fetal and placental factors. FGR is defined as failure to realize this potential. It is not 
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only an important cause of perinatal morbidity and mortality, but epidemiological 
studies report an association between poor growth in utero and development of the 
metabolic syndrome in adulthood.44 
 
The fact that the risk of FGR is highest in women with poor functional class (NYHA 
functional class III or IV), cyanosis or left heart obstruction suggests two possible 
mechanisms for FGR in these pregnancies: hypoxia, and reduced placental perfusion 
as a consequence of restriction in cardiac output. Cyanotic congenital heart disease 
has been shown to be associated with a higher incidence of low birth weight infants 
compared to acyanotic congenital heart disease.31,45,46 Maternal oxygen saturations 
below 85% are predictive of poor pregnancy outcome with a livebirth rate of only 
12%.47 As a result of this hypoxaemia there is a compensatory polycythaemia which 
is independently related to lower birth weight.47 The effect of cyanosis may be 
exacerbated further by reduced cardiac output in, for example, single ventricle 
circulations, or the inability of the right heart to adapt to requirements for an increase 
in cardiac output, as seen in PH. Even after surgical repair fetal growth may continue 
to be affected, again presumably secondary to reduced cardiac output.48 In conditions 
with fixed outflow tract resistance (valvular aortic/sub-aortic stenosis, COA) there 
may be an inability to accommodate the increased cardiac output of pregnancy, which 
can lead to heart failure with a rise in left ventricular pressures but low cardiac output 
and subsequent restriction of fetal growth. 
 
Additionally, in pregnant women with congenital heart disease the risk of a congenital 
cardiac anomaly in the fetus is increased to 3-5% (dependent on the maternal lesion) 
compared with a background risk of 0.8% in the general population.49 
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1.5 Risks related to specific cardiac conditions 
 
In general, conditions associated with volume overload are better tolerated than those 
associated with pressure overload.8,30,32 
 
1.5.1 Pulmonary hypertension & Eisenmenger Syndrome 
Although pregnancy in women with pulmonary vascular disease is rare (estimated 
incidence of 1.1 per million maternities) it continues to be associated with a high 
maternal mortality. Women with pulmonary hypertension (PH) with an already 
pressure-overloaded right ventricle may struggle to cope with the additional 
cardiovascular demands of pregnancy. The fall in systemic vascular resistance may 
worsen the right to left shunt seen in Eisenmenger syndrome.50,51!Deterioration 
generally occurs during the second trimester with most deaths seen within the first 
month post-partum, usually from right heart failure as the acute increase in right 
ventricular preload at delivery leads to volume overload and an acute rise in 
pulmonary vascular resistance. The majority of complications occur at the end of 
pregnancy and during the first postpartum week.  Current guidelines continue to 
advise against pregnancy.4,37  
 
1.5.2 Cardiomyopathies 
In the 2006-2008 triennium,3 cardiomyopathy was the commonest cardiac cause of 
maternal death, with 13 deaths (two of which were late ie. more than 42 days after the 
pregnancy had ended) attributed to this condition. The aetiology of cardiomyopathies 
occurring in pregnant women is diverse, including both inherited and acquired forms 
of the disease. Cardiomyopathy is a significant predictor for the development of heart 
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failure during pregnancy, which is associated with high rates of adverse maternal and 
fetal outcomes.52 Labour, delivery and the early post-partum period are times of 
particular risk as a result of the acute changes in cardiac output caused by pain, 
anxiety and exertion, uterine contractions, bleeding, autotransfusion from the 
involuting uterus and resorption of oedema.25-28  
 
Peripartum cardiomyopathy (PPCM) and dilated cardiomyopathy (DCM) share 
similar clinical and diagnostic criteria (with the notable exception that PPCM has a 
temporal relationship to pregnancy), although their pathophysiologies are different. 
Death is usually from intractable heart failure, arrhythmia, or systemic or pulmonary 
embolism from mural thrombus.  
 
Hypertrophic cardiomyopathy (HCM) is the commonest inherited cardiac disease53 
and is generally well tolerated in pregnancy. Complications generally arise as a result 
of diastolic dysfunction due to the hypertrophic, non-compliant myocardium, severe 
left ventricular outflow tract obstruction (LVOTO) and arrhythmias. 
 
1.5.3 Obstructive left heart disease 
Obstructive left heart lesions (aortic and mitral stenosis, HCM, and unrepaired COA) 
may reduce the ability of the heart to increase cardiac output during pregnancy. The 
resultant limited increase in cardiac output may also restrict uteroplacental perfusion 
and fetal growth. In the developed world, aortic stenosis (AS) is usually congenital, 
and mitral stenosis (MS) rheumatic in origin.  
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Congenital bicuspid aortic valve (BAV) is the most common cause of AS   
complicating pregnancy and is generally well tolerated in those with mild to moderate 
disease and normal ventricular systolic function. In pregnant women with moderate to 
severe AS, (even in the absence of symptoms), their limited ability to increase cardiac 
output through a fixed obstructive lesion may result in excessive elevation of left 
ventricular diastolic filling pressures, which may precipitate or exacerbate heart 
failure or ischaemia, thus increasing the need for intervention – both cardiac and 
obstetric.8,35 Severe AS has been associated with high rates of both maternal (17%) 
and fetal (30%) mortality,54 although recent series report more encouraging data.55  
 
MS is particularly poorly tolerated in pregnancy. It is often diagnosed during 
pregnancy, as the inability to adapt to the cardiovascular changes of pregnancy 
precipitates symptoms for the first time. A combination of restricted flow through the 
stenotic mitral valve and the increase in stroke volume and heart rate lead to an 
increase in left atrial pressure. This may subsequently progress to pulmonary venous 
hypertension and right ventricular failure. Women with MS are especially vulnerable 
during the peripartum period, when the large fluid shifts seen during labour and 
immediately after delivery may precipitate pulmonary oedema.56 
 
1.5.4 Aortopathies 
Aortic dissection is now one of the commonest causes of maternal death from cardiac 
disease3. Normal pregnancy is associated with structural and functional changes in the 
aorta (dilatation, increased compliance and a reduction in mucopolysaccharides in the 
aortic wall57,58,59), which help to optimize cardiac function: reduction in vascular 
resistance and increased aortic compliance assist left ventricular ejection. However, 
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these factors may also contribute to the increased risk of dissection, which is most 
common in the third trimester or early postpartum period. A wide range of 
pathologies, both congenital (Marfan syndrome (MFS) and other connective tissue 
disorders such as Ehlers-Danlos syndrome, COA, BAV disease, Tetralogy of Fallot, 
Turner syndrome) and acquired (trauma, severe hypertension, atherosclerosis, 
infection, crack cocaine use) may predispose to aortopathy and dissection. Pregnant 
women with MFS carry an increased risk for spontaneous aortic dissection during 
pregnancy and the puerperium, even in the absence of aortic root dilatation.60,61  
 
Congenital BAV is present in 1-2% of the general population.62 It is associated with a 
proximal aortopathy and increased risk of aneurysm formation, aortic regurgitation 
(AR) and aortic dissection. Dilatation of the ascending aorta occurs in 30-50% of 
patients62 and is often maximal in the distal region, which is difficult to visualize 
adequately with echocardiography. Pre-pregnancy assessment with magnetic 
resonance imaging (MRI) is therefore important. The risk of adverse pregnancy 
outcomes in women with a bicuspid aortic valve is not known although many centres 
advise pre-pregnancy surgery in the setting of aortic diameters >5cm.4,62 
 
COA accounts for 5-8% of congenital heart disease63 and is commonly found in 
association with other cardiovascular abnormalities. Most women will have had 
previous surgical intervention, but nonetheless the risks of hypertension, re-
coarctation and aneurysm formation remain. Significant coarctation may lead to 
severe maternal hypertension which may be refractory to drug therapy, while 
hypotension in the lower body results in hypoperfusion of the placenta and an 
increased risk of fetal mortality and morbidity. However, pregnancy in women with 
! %+!
repaired coarctation is generally well tolerated provided there is no aneurysm at the 
site of repair.  
 
1.5.5 Cyanotic heart disease 
Cyanotic heart disease is associated with a high risk of maternal and fetal adverse 
outcomes. Maternal complications (such as heart failure, pulmonary or systemic 
thrombosis, supraventricular arrhythmias and infective endocarditis) occur in 30% of 
cyanotic women during pregnancy4 while the fetus is more likely to be affected by 
FGR.31,45,46 Maternal oxygen saturations below 85% are particularly predictive of 
poor outcomes.47 
 
1.5.6 Valvular heart disease (VHD) 
VHD may be congenital or acquired and is an important cause of maternal and fetal 
morbidity and mortality. Stenotic lesions are generally tolerated less well than 
regurgitant lesions, due to an inability to accommodate the significant increase in 
blood volume and cardiac output associated with pregnancy. Left-sided valve disease 
has a higher complication rate than right-sided valve disease.8,36,39 It is not uncommon 
for VHD to present for the first time in pregnancy, especially in unscreened 
immigrants, as the increasing demands on the heart lead to decompensation and the 
development of symptoms.  
 
Prosthetic heart valves (PHVs) continue to represent a particular challenge in 
pregnancy with both mechanical and bioprosthetic valves (BPVs) carrying specific 
risks. Although bioprostheses avoid the risks of valve thrombosis and the need for 
anticoagulation, these patients will almost certainly require reoperation in the future: 
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it is unclear whether pregnancy accelerates this deterioration. The debate in patients 
with MPVs relates to the type of anticoagulation and the need to balance the risk to 
the mother with the risk to the fetus.  
 
1.5.7 Right-sided heart disease 
Tetralogy of Fallot 
Figure 5: Tetralogy of Fallot64  
 
 
Tetralogy of Fallot  is the most common congenital heart defect associated with 
systemic cyanosis. It is characterized by a nonrestrictive VSD, overriding aorta, right 
ventricular outflow tract obstruction (RVOTO) and right ventricular hypertrophy. 
Women with repaired tetralogy of Fallot and little residual haemodynamic 
impairment generally tolerate pregnancy well. Residual shunts, right ventricular 
outflow tract obstruction (RVOTO), moderate to severe pulmonary regurgitation (PR) 
and right ventricular dysfunction are all risk factors for cardiovascular complications 
(including arrhythmias and heart failure) and obstetric complications.65 Repaired 
tetralogy of Fallot is also associated with low birth weight, particularly in women 
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with moderate to severe pulmonary insufficiency.66 Additionally there are some data 
to suggest that pregnancy has an irreversible detrimental effect on right ventricular 
function.41 
 
Complete and congenitally corrected transposition of the great arteries 
Figure 6: Transposition of the great arteries64 
 
 
In complete TGA there is atrioventricular concordance but ventriculoarterial 
discordance, resulting in the pulmonary and systemic circulations running in parallel, 
rather than in series as normally occurs. Survival prior to surgical repair is dependent 
upon mixing of the circulations, either naturally (via a VSD, atrial septal defect 
(ASD) or patent ductus arteriosus (PDA)) or by intervention (septostomy). Surgical 
management aims to redirect blood either at the atrial level using a baffle (Mustard 
and Senning operations, atrial switch) such that the morphologic right ventricle 
supports the systemic circulation, or at the arterial level by switching the aorta and 
pulmonary arteries such that the morphologic left ventricle becomes the subaortic 
ventricle and supports the systemic circulation (arterial switch). In congenitally 
corrected transposition of the great arteries (ccTGA) the connections of both the atria 
to the ventricles and the ventricles to the great vessels are discordant so that the 
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morphologic right ventricle supports the systemic circulation. It is usually associated 
with other anomalies including VSD (75%), pulmonary or subpulmonary stenosis 
(75%), left-sided valve anomalies (>75%) and complete atrioventricular block (2% 
per year).64 Surgical repair in patients with a VSD and RVOTO is either a classic 
repair (VSD patch closure and relief of RVOTO, leaving the morphologic right 
ventricle supporting the systemic circulation) or double switch (atrial and arterial 
switch, achieving ‘anatomic’ correction, with flow from the morphologic left 
ventricle being directed into the systemic circulation). 
 
During pregnancy, a systemic right ventricle may not be able to withstand the 
increased haemodynamic demands placed upon it, and such women have an increased 
risk of developing complications such as arrhythmias (including atrioventricular 
block) and heart failure.4 There is also an increased risk of thrombotic complications 
due to impaired blood flow through the atrial baffle in women who have undergone 
the Mustard procedure.64 Pregnancy following a Mustard operation, however well 
tolerated, may result in right ventricular dysfunction which is sometimes 
irreversible.42 PET has been reported to be more common in this group of patients,39 
and neonatal adverse events such as low birth weight and preterm delivery are also 
more frequent.67 
 
Only small series of women who have undergone the arterial switch have been 
described, but in those with good functional capacity pre-pregnancy the risk of 
adverse outcomes appears to be low.68 
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Ebstein’s anomaly 
Figure 7: Ebstein’s anomaly64 
 
 
Ebstein’s anomaly is a malformation of the tricuspid valve which is displaced 
apically, resulting in enlargement of the right atrium, a smaller ‘functional’ right 
ventricle and tricuspid regurgitation (TR) with subsequent reduced cardiac output. It 
is commonly associated with an ASD (which allows right-to-left shunting, thereby 
leading to cyanosis when the right-sided pressures exceed the left) and with atrial re-
entry tachycardias. The ability to tolerate the haemodynamic demands of pregnancy is 
dependent on the severity of TR and the functional capacity of the right ventricle. 
Women without cyanosis or heart failure usually cope well.69,70 
 
Fontan circulation 
The Fontan operation is a palliative procedure performed when a two-ventricle repair 
is not feasible (for example in tricuspid atresia, pulmonary atresia with an intact 
ventricular septum and univentricular hearts). Several operations exist, connecting 
either the right atrium or the caval veins to the pulmonary arteries and directing the 
systemic venous return directly to the pulmonary circulation. Blood flow to the lungs 
is driven by systemic venous pressure only and the systemic circulation is supported 
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by the single ventricle with subsequent low cardiac output. All women who have 
undergone a Fontan-type operation should be considered high risk in pregnancy 
(WHO class III or IV) and should be carefully assessed and counselled prior to 
becoming pregnant. Adverse maternal and fetal outcomes are directly related to the 
effect of pregnancy on ventricular function, a prothrombotic circulation, the degree of 
cyanosis (a result of right-to-left shunting across persistent systemic venous to left-
sided bypass tracts) and a tendency to atrial arrhythmias which may cause significant 
haemodynamic deterioration.71,72,73  
 
1.5.8 Ischaemic heart disease  
In the last triennium eleven women died as a result of acute MI or chronic ischaemic 
heart disease, a rate of 0.48 per 100,000 maternities.3 While pregnancy increases the 
risk of acute MI three to four times (and this is further increased 30-fold in women 
over the age of 40 compared with those less than 20 years of age), a high incidence of 
identifiable risk factors is consistently reported in these women.74 Pregnancy-related 
risk factors include PET and eclampsia, post-partum infection, thrombophilia and 
blood transfusion. The majority of cases of acute MI in pregnancy are associated with 
atherosclerosis; other causes are coronary dissection (the primary cause of infarction 
before and after delivery) and coronary artery thrombosis.3,74,75 Prompt diagnosis and 
treatment are crucial to reduce morbidity and mortality in both the mother and the 
fetus.76 Diagnostic criteria and principles of management are the same as in non-
pregnant patients with percutaneous coronary intervention (PCI) being the treatment 
of choice. Diagnosis is often delayed as a result of the presenting symptoms and signs 
being attributed to the normal manifestations of pregnancy and the physiologic 
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changes of pregnancy affecting ECG interpretation. Close liaison between 
obstetricians, cardiologists and anaesthetists is required.  
 
1.5.9 Arrhythmia 
Arrhythmias are common in pregnancy, in both women with structurally normal 
hearts and those with congenital heart disease. Premature extra beats and sustained 
tachyarrhythmias may present for the first time in pregnancy, or become more 
frequent. Most palpitations are benign, but new onset ventricular tachycardia (VT) in 
pregnancy should prompt investigation to rule out structural heart disease. All anti-
arrhythmics cross the placenta and no major controlled studies have been conducted 
during pregnancy. Beta-blockers and digoxin should be the first choice for 
tachyarrhythmias. Beta-blockers are relatively safe during pregnancy, although they 
are associated with a small but significant reduction in birth weight77,78 Higher doses 
of digoxin may be required to counteract the increased renal clearance and increased 
blood volume seen in pregnancy. Atrial flutter and atrial fibrillation (AF) are rare 
during pregnancy. However, they are associated with an increased risk of thrombo-
embolic events and therefore thromboprophylaxis is recommended.4 Indeed 
anticoagulation is mandatory for women undergoing electrical cardioversion for atrial 
flutter or AF in pregnancy. Electrical cardioversion is safe during pregnancy, however 
the defibrillator pads should be placed in such a way that the exposure of the fetus to 
the electrical discharge is minimized, as there is a theoretical risk of fetal ventricular 
arrhythmias.73 Some women have an implantable cardioverter-defibrillator (ICD) in 
situ at conception, although so far there are minimal data regarding outcomes.40 In 
cases where the arrhythmia is refractory to drugs, catheter ablation may be necessary. 
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Due to the high radiation exposure this should ideally be deferred until the second 
trimester, or other imaging modalities such as MRI should be utilized. 
 
SADS was identified in the most recent report of the Confidential Enquiries into 
Maternal Deaths as the leading cause of cardiac maternal death.3 It is a pathological 
diagnosis and is defined as sudden death in an adult for which no cause can be found. 
There may be an association with obesity and cardiac hypertrophy leading to 
arrhythmias and sudden cardiac death.79 High circulating non-esterified fatty acid 
concentrations and genetic causes have also been linked to SADS.80,81 
 
1.5.10 Septal defects 
Atrial Septal Defect (ASD) 
An ASD is a direct communication between the two atrial chambers which permits 
shunting of blood. Associated malformations are present in 30% of cases.64 Pregnancy 
is generally well tolerated unless PH or Eisenmenger syndrome are present. 
Haemodynamically significant ASDs should be closed prior to pregnancy. Thrombo-
embolic complications and arrhythmias may occur, and in women in whom the ASD 
is unrepaired there is an increased risk of PET and of the fetus being small for 
gestational age (SGA) at birth.4  
 
Ventricular Septal Defect (VSD) 
A VSD is a direct communication between the two ventricles and is one of the most 
common congenital heart defects. A restrictive VSD produces a significant pressure 
gradient between the left and right ventricles but is usually accompanied by a small 
shunt with minimal haemodynamic effect. A large or non-restrictive VSD results in 
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left ventricular volume overload and subsequent rise in pulmonary artery pressure in 
childhood. As with ASDs, if the defect is haemodynamically insignificant or has been 
repaired, and there is no pulmonary hypertension, VSDs have a good prognosis in 
pregnancy.4  
 
Atrioventricular septal defect (AVSD) 
AVSDs are caused by abnormal development of the endocardial cushions and are 
particularly common in patients with trisomy 21. Where there is minimal residual 
atrioventricular valve regurgitation and good ventricular function following repair, 
pregnancy is usually well tolerated (WHO risk class II). As with other septal defects 
haemodynamically significant lesions may be associated with pulmonary 
hypertension, so an assessment of pulmonary arterial pressures is indicated as part of 
the pre-pregnancy work-up. Arrhythmias and worsening atrioventricular valve 
regurgitation during pregnancy have been reported but the risk of heart failure is low.4 
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1.6 Principles of management 
 
1.6.1 Pre-pregnancy counselling and contraception 
All women with heart disease should have access to specialist counselling regarding 
reproductive issues such as future pregnancy, family planning and contraception.4 
Ideally this should begin in adolescence for those with congenital heart disease and at 
the time of diagnosis for women with acquired heart disease and be conducted by a 
multidisciplinary team of appropriately trained family planning specialists, 
cardiologists and obstetricians.4,10,37 In addition to identifying and quantifying the 
risks of pregnancy for both mother and fetus, thus allowing the woman to make an 
informed choice, it should also allow the woman to come to terms with the impact of 
her disease on her childbearing potential. Unfortunately many women fail to receive 
timely and competent family planning advice, thereby causing unnecessary risk to 
both mother and child.82 
 
Women should be given information on:10,37 
- maternal and fetal morbidity and mortality associated with pregnancy 
- the risk of recurrence of congenital heart disease in offspring 
- maternal life expectancy and the effect of pregnancy on this 
- timing of pregnancy – for example, in women with a systemic right ventricle 
or Fontan circulation maternal risk will increase with age, and therefore such 
women should be advised against delaying pregnancy until their late 30s 
- the need for an up-to-date assessment prior to conception – this should review  
functional status and current medications 
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- the possible need for pre-pregnancy interventions to reduce the risk of 
pregnancy 
- the level of surveillance, need for treatment and potential hospitalization 
required during pregnancy 
- contraception 
 
The ideal contraceptive should combine acceptability to the woman with a high 
degree of cardiovascular safety (this will vary according to the cardiac condition in 
question) and efficacy. 
 
Table 4: WHO classification of maternal cardiovascular risk from contraceptive use37 
Risk Class Risk for contraceptive method by cardiac condition 
I 
Always useable 
Risk no higher than the general population 
II 
Broadly useable 
Small increased risk, advantages of method generally 
outweigh risks 
III 
Caution in use 
Risks usually outweigh advantages of method. Other methods 
preferable. Exceptions if: 
1. Patient accepts risks and rejects alternatives 
2. Risk of pregnancy very high and other methods less 
effective 
IV 
Do not use 
Method contraindicated: represents unacceptable health risk 
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Contraceptives containing oestrogen are contraindicated (WHO IV) in women at high 
risk of thrombosis. This includes women with older MPVs (for example the single 
leaflet tilting disc mitral valve), with actual or potential right-to-left shunts, cyanosis, 
PH or a Fontan circulation.37 The levenogestrel-releasing intrauterine device is the 
safest and most effective contraceptive available that can be used in women with high 
risk conditions such as these, with a contraceptive efficacy that is superior to 
sterilization.4,37 It should be noted that up to 5% of women experience a vasovagal 
reaction during insertion, which could prove to be fatal in those with a Fontan 
circulation or pulmonary vascular disease. For this reason it should only be used in 
such women if progesterone-only pills or subdermal implants cause unacceptable 
vaginal bleeding, and it should be inserted by an experienced operator in a hospital 
environment.4,37 
 
For women requesting sterilization, hysteroscopically-inserted intratubal stents 
(Essure™) may be inserted under local anaesthesia and have a very low failure rate. 
This avoids the need for the pneumoperitoneum, head-down tilt and positive-pressure 
ventilation required for laparoscopic tubal ligation, which may cause haemodynamic 
instability in women with a Fontan circulation or pulmonary vascular disease. 4,37,73 
 
Termination of pregnancy should be discussed if pregnancy occurs in women for 
whom it would represent a major maternal and/or fetal risk (WHO IV). Ideally this 
should be performed as soon as possible as the risks increase with advancing gestation 
Suction termination is the safest method of termination in the first and second 
trimesters and should be carried out in a unit with appropriate expertise and on-site 
cardiac surgery. Medical termination using prostaglandins E1 or E2 may be 
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considered in both the first and second trimesters. However, systemic absorption may 
lead to a fall in systemic vascular resistance and hypotension, such that high risk 
women should be closely monitored.4,10,37 
 
1.6.2 Antenatal care 
It is important that antenatal and intrapartum care is individualized according to the 
woman’s cardiac condition and functional status. However, guidelines regarding the 
frequency of review and the personnel who should be involved are based on clinical 
experience rather than prospective studies or randomized controlled trials, and rely 
largely on Class C evidence (small studies, retrospective studies, registries and/or 
consensus of opinion of experts).4,5,10,73  
 
Risk assessment should be carried out early in pregnancy by an experienced 
multidisciplinary team consisting of an obstetrician, cardiologist and anaesthetist. 
Low risk women can be returned to routine care, while moderate to high-risk patients 
should be cared for in a tertiary centre with appropriate expertise. These women 
should be seen regularly (weekly in the third trimester), with cardiovascular 
assessment (including measurement of blood pressure and pulse rate/rhythm, and 
oxygen saturations in cyanotic women) performed carefully at each visit as changes 
may be suggestive of early signs of decompensation. Women with structural 
congenital heart disease should be offered fetal echocardiography at 18-22 weeks’ 
gestation and serial growth scans may be appropriate in pregnancies at high risk of 
fetal growth restriction. 
 
Delivery planning should take place in the early third trimester, again in the setting of 
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the multidisciplinary team. Factors such as mode and place of delivery, 
analgesia/anaesthesia, personnel to be present, appropriate prophylaxis against post-
partum haemorrhage and postpartum management (including monitoring and length 
of stay in hospital after delivery, and timing of postnatal review) should be discussed 
and agreed with the woman and recorded in the maternity notes.5,10!
 
1.6.3 Labour and delivery 
Timing and mode of delivery 
In the majority of cases the preferred mode of delivery is vaginal, with Caesarean 
section for the usual obstetric reasons.4 Vaginal delivery is generally associated with 
smaller haemodynamic changes and less risk of haemorrhage, infection and venous 
thromboembolism than delivery by caesarean section.83 However, Caesarean section 
may become necessary for a variety of reasons, both fetal (there is a high risk of FGR 
in many women with cardiac disease, and the growth-restricted fetus may be less able 
to tolerate the stresses of labour) and maternal (signs of cardiac decompensation), and 
when performed in labour may be associated with increased blood loss and rates of 
infection.83 It is often suggested that women with borderline cardiac dysfunction 
should avoid a prolonged active second stage of labour with a low threshold for 
assisted delivery aimed at reducing the cardiac work-load. There are however, no data 
to support this approach.78 Adequate pain relief with epidural anaesthesia is thought to 
attenuate the haemodynamic changes associated with labour and delivery.28 If a trial 
of vaginal delivery is considered appropriate labour should not be induced unless 
there are specific obstetric reasons or signs of cardiovascular decompensation. In 
particular preterm induction of labour is often prolonged and is associated with a 
higher rate of emergency Caesarean delivery than induction of labour at term. 
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Elective Caesarean section offers the advantage of timing the delivery to ensure 
optimal conditions, in particular, for high-risk conditions, the presence of senior and 
experienced staff. Caesarean section should also be considered in women on oral 
anticoagulants in preterm labour, patients with MFS and an aortic root >45mm, 
women with acute or chronic aortic dissection and those with acute heart failure.4  
 
Management of the third stage 
In normal pregnancy uterotonics have been shown to significantly reduce the risk of 
PPH by up to 50%.84 However, they have significant haemodynamic effects which 
may make them unsuitable in women with cardiac disease. It is well established that 
ergometrine causes vasoconstriction (especially in the coronary arteries) and 
hypertension.78 Bolus doses of oxytocin cause an increase in pulmonary vascular 
resistance and a reduction in systemic vascular resistance causing hypotension and 
tachycardia.85 Two recent randomized controlled trials have reported ECG changes 
suggestive of myocardial ischaemia associated with oxytocin administration in 
healthy women undergoing elective caesarean section with regional anaesthesia.86,87 
Recent advice from the RCOG5 and ESC4 recommends a low dose (<2U/min) 
syntocinon infusion, and consideration of the use of uterine compression sutures at 
Caesarean section.5  
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1.7 Summary 
 
 
Cardiac disease in pregnancy continues to be of growing importance both in terms of 
the number of women affected and maternal and neonatal morbidity and mortality. 
Although ischaemic heart disease, cardiomyopathy and aortic dissection are now the 
leading cardiac causes of maternal death, rheumatic heart disease is again becoming 
common due to increasing immigration from countries where rheumatic fever is 
endemic. Although considerable progress has been made in the management of 
congenital heart disease in pregnancy and maternal mortality rates in such women 
continue to fall, it remains the commonest type of cardiac disease seen in pregnancy, 
and women with increasingly complex disease are now becoming pregnant. Despite 
this care remains largely empirical; guidelines are based on evidence from case series 
and experience rather than randomised controlled trials.  
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Chapter 2:  Methods 
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2.1 Study design 
This study is a retrospective analysis of the effect of maternal cardiac disease on 
maternal and fetal/neonatal outcomes in a tertiary referral academic cardiac and 
obstetric unit. It was carried out at the Chelsea and Westminster and Royal Brompton 
Hospitals in London, UK, between April 2008 and October 2011.   
 
2.2 Data collection 
Women with cardiac disease cared for by the Joint Cardiac and Obstetric Service of 
the Chelsea and Westminster and Royal Brompton Hospitals were identified from a 
database commenced in 1994.  
 
Data were collected from a detailed review of case notes supplemented with data from 
the Circonia Maternity Information System (CMIS©, HD Clinical Ltd, Bishops 
Stortford, Herts, UK), used for routine maternity data collection at the Chelsea and 
Westminster Hospital. Demographic data including age at booking, parity, co-
morbidities, regular medication, tobacco smoking and use of illicit drugs, previous 
cardiac surgery and functional, echocardiographic and/or cardiac magnetic resonance 
(CMR) assessment were recorded in a spreadsheet, with appropriate safeguards 
regarding confidentiality. Information on cardiovascular, obstetric and anaesthetic 
management during pregnancy and labour, and maternal and neonatal outcomes was 
gathered and also entered into the spreadsheet.  
 
Control data, where required, were obtained about the women who delivered 
immediately before and immediately after the index case, thus allowing comparison 
with the overall obstetric population at the Chelsea and Westminster Hospital. If the 
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date of delivery was prior to 1998 then women who delivered on the same date in 
1999 were used as controls, as routine CMIS© data were not available before this 
time.  
 
Customised birth weight centiles, adjusted for gestational age, parity, maternal body 
mass index (BMI) and ethnic origin, were calculated using computer-generated 
charts.88,89 
 
Cardiac, obstetric and fetal/neonatal complications and intrapartum events were 
noted, according to the following definitions: 
 
2.2.1 Cardiac complications 
x cardiomyopathy (new onset in pregnancy) – structural and functional 
abnormalities of the ventricular myocardium that are unexplained by flow- 
limiting coronary artery disease or abnormal loading conditions90  
x myocardial infarction  
x heart failure – decline in NYHA functional class and/or evidence of 
pulmonary oedema on clinical examination or chest x-ray, and/or deterioration 
of ventricular function on echocardiography 
x sustained arrhythmia requiring treatment  
x aortic dissection 
x endocarditis  
x cardiac death  
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2.2.2 Obstetric complications 
x pregnancy-induced hypertension (PIH) - raised blood pressure >140/90 mmHg 
on two occasions at least two hours apart after 20 weeks of gestation  
x pre-eclampsia (PET) - PIH plus proteinuria of ≥300mg/L in a 24-hour urine 
collection, or persistent ++ proteinuria on dipstick  
x eclampsia - PET with major convulsive seizures 
x antepartum haemorrhage (APH) - bleeding from the genital tract after 24 
weeks of gestation  
x gestational diabetes  
x preterm pre-labour rupture of membranes (PPROM) - spontaneous rupture of 
membranes prior to 37 weeks’ gestation 
x spontaneous preterm labour - labour prior to 37 weeks’ gestation  
x post-partum haemorrhage (PPH) - blood loss of greater than 500ml at vaginal 
delivery or 1000ml at caesarean section 
x venous thromboembolism 
 
2.2.3 Intrapartum events 
x mode of delivery  
x use of regional and general anaesthesia  
x length of second stage of labour in vaginal deliveries 
 
 
2.2.4 Fetal/neonatal complications 
x preterm birth - delivery after 24 and before 37 completed weeks’ gestation 
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x small for gestational age (SGA) - birth weight less than the fifth customized 
centile  
x perinatal mortality - stillbirth after 24 completed weeks of pregnancy and 
neonatal death up to 1 week after birth  
x neonatal mortality - up to 1 month of life  
x recurrence of congenital heart disease in the offspring (diagnosed either pre-or 
postnatally) 
 
2.3 Data analysis 
Data were analysed using SPSS 22 for Windows and GraphPad Prism version 6.0d.  
 
Descriptive statistics are reported as frequency and median and range, or mean and 
standard deviation, as appropriate. Continuous variables were compared with the 
students t-test if the data were normally distributed and with the Mann-Whitney U-
test if they were not. The chi-square test or Fisher’s exact test with cell numbers of <5 
were used to test differences between relative frequencies of occurrence. All tests 
were two-tailed and p<0.05 was considered statistically significant.  
 
Where relevant, binary logistic regression was performed to identify patient 
characteristics associated with adverse pregnancy outcomes divided into the 3 
composite endpoints (as defined above): cardiac, obstetrics and fetal/neonatal 
complications. Multiple pregnancies were excluded because they pose special risks 
and the numbers were too small for meaningful analysis. Women with isolated mitral 
valve prolapse (ie. with no haemodynamic consequences) were also excluded. 
Univariable analysis was performed initially. Variables associated with an increased 
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incidence of the studied endpoints (p<0.1) were then brought forward to multivariable 
analysis, with sequential backward deletion of the least significant characteristic until 
all remaining variables were significantly (p<0.05) associated with the endpoint. 
Univariable analysis alone is limited by the fact that the independent variables in a 
series of univariable regressions may be correlated; if such correlated variables are 
treated as if they are independent this may lead to an overestimation of the likelihood 
of the outcome event. Subsequent multivariable analysis tests for interaction between 
variables, and thus adjusts for confounding. 
 
2.4 Ethical Approval 
This study received approval from the Brompton, Harefield and  NHLI Research 
Ethics Committee (ref. no. 06/Q0404/37). 
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Chapter 3: Pregnancy outcomes in women with  
pre-existing heart disease 
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3.1 Abstract 
 
3.1.1 Aims: 
To assess cardiac, obstetric and fetal/neonatal outcomes in pregnant women 
with heart disease and to investigate maternal risk factors for adverse events 
3.1.2 Methods: 
 Retrospective review of case records 
3.1.3 Results: 
There were 489 pregnancies in 326 women. Congenital heart disease was the 
largest group (50%), followed by valvular heart disease (28%). Two hundred 
and eighty-two pregnancies (58%) were in nulliparous women. There were 4 
maternal deaths. Significant cardiac complications occurred in 7.4% of 
pregnancies: the most frequently encountered complication was arrhythmia 
(4.3%), followed by heart failure (2.0%). A history of arrhythmia prior to 
pregnancy (p<0.0001) and presence of a mechanical heart valve (p=0.003) 
independently predicted cardiac events. Obstetric complications occurred in 
34% of pregnancies, most commonly postpartum haemorrhage (21.9%), which 
was independently associated with delivery by emergency caesarean secation 
(p<0.001) and use of dose-adjusted low molecular weight heparin (p=0.001). 
Delivery was by caesarean section in 39% of cases and regional anaesthesia 
was used in 73.6% of deliveries. There were 6 stillbirths and 5 neonatal 
deaths. Adverse perinatal outcomes occurred in 30.3% of pregnancies. Twenty 
percent of babies were small for gestational age, while 11.7% were born 
before 37 completed weeks of gestation. Factors independently associated 
with fetal/neonatal complications were poor maternal functional class pre-
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pregnancy (p=0.001), use of any cardiac medication (p=0.022), the presence 
of a mechanical prosthetic heart valve (p= 0.024) and the presence of a 
systemic right ventricle (p=0.007). 
3.1.4 Conclusions: 
Pregnancy in women with pre-existing heart disease is associated with 
significant rates of maternal and perinatal complications. Predictors previously 
described as being associated with adverse outcomes were confirmed and the 
presence of a systemic right ventricle was reported as a new association with 
fetal/neonatal events. 
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3.2 Introduction 
 
 
 
Up to 4% of pregnancies in developed countries are complicated by maternal 
cardiovascular disease. It is the commonest single cause of maternal death in the 
United Kingdom, and death rates are continuing to rise.3 Despite congenital heart 
disease being the most frequent form of cardiovascular disease present during 
pregnancy in the western world (75-82%),4,7,8 most deaths now occur in women with 
acquired heart disease, the leading causes being sudden adult death syndrome 
(SADS), myocardial infarction (MI), dissection of the thoracic aorta and 
cardiomyopathy.3 This trend may be attributable to rising rates of obesity, chronic 
conditions such as hypertension and diabetes, and the tendency for women to delay 
pregnancy until later in life. Furthermore, deaths in women with rheumatic heart 
disease are rising again due to increasing immigration from countries where 
rheumatic fever is endemic. 
 
Pregnancy in women with pre-existing heart disease is known to be associated with 
increased risks of cardiac events, and obstetric and perinatal complications.  
The risk of adverse events is dependent on the ability of the woman to adapt to the 
profound physiological and haemodynamic changes associated with pregnancy and 
delivery. Assessment of disease-specific risk is difficult. Current guidance4 
recommends use of the modified WHO risk classification (which includes all known 
maternal cardiovascular risk factors)37 to conduct maternal risk assessment, although 
other risk scores have also been developed.8,36  Conditions associated with volume 
overload are usually better tolerated than those associated with pressure 
overload.8,30,32 Previous cardiac events, poor functional class (NYHA III or IV) prior 
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to pregnancy, presence of central cyanosis, left heart obstruction, myocardial 
dysfunction and mechanical valve prostheses have all been identified as independent 
predictors of adverse maternal and fetal/neonatal outcomes.8,30,31,32,33,35,36,38,39  
Although significant improvements have been made in the management of pregnancy 
in women with pre-existing heart disease, care was felt to be substandard in half of 
the cardiac deaths reported to the 2006-2008 Confidential Enquiry,3 with current 
guidelines being based upon evidence from case series rather than randomised 
controlled trials.4,5 
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3.3 Aims 
 
 
To assess cardiac obstetric and fetal/neonatal outcomes in pregnant women with heart 
disease and to investigate maternal risk factors for adverse events. 
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3.4 Methods 
 
 
Women with cardiac disease cared for by the Joint Cardiac and Obstetric Service of 
the Chelsea and Westminster and Royal Brompton Hospitals were identified from a 
database commenced in 1994. 
 
Data were collected from a detailed review of the case notes, supplemented by the 
Circonia Maternity Information System (CMIS©, HD Clinical Ltd, Bishops Stortford, 
Herts, UK). Only singleton pregnancies progressing beyond 24 weeks of gestation 
were included. In all women, demographic data and information on obstetric and 
anaesthetic management during pregnancy and labour, and maternal and neonatal 
outcomes was obtained, noting cardiac, obstetric and fetal/neonatal complications and 
intra-partum events as previously described in chapter 2. 
 
Data were analysed using SPSS 23 and GraphPad Prism version 6.0d. Descriptive 
statistics for nominal data are expressed in absolute numbers and percentages. Mean 
value and standard deviations are presented for normally distributed continuous 
variables, and for non-normally distributed continuous variables, median and range. 
Binary logistic regression was performed to identify patient characteristics associated 
with adverse pregnancy outcomes divided into the 3 composite endpoints: cardiac, 
obstetrics and fetal/neonatal complications (as defined previously in chapter 2). 
Women with isolated mitral valve prolapse (ie. with no haemodynamic consequences) 
were also excluded. The following baseline variables and cardiac diagnoses were 
assessed: history of arrhythmias, the presence of pre-existing myocardial dysfunction 
(ejection fraction <40% prior to pregnancy), maternal NYHA class prior to 
pregnancy, the presence of central cyanosis, previous cardiac surgery, previous 
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cardiac events (heart failure, cerebrovascular accident, transient ischaemic attack, 
myocardial infarction, endocarditis), pre-existing hypertension, use of cardiovascular 
medication during pregnancy, use of anticoagulants, use of beta blockers, maternal 
cigarette smoking during pregnancy, presence of PH (pulmonary artery pressure 
>25mmHg at rest pre-pregnancy), coarctation of the aorta, Marfan syndrome, 
complex cyanotic congenital heart disease (pulmonary atresia, Fontan circulation), 
Ebstein’s anomaly, valvular heart disease, presence of a metallic prosthetic heart 
valve, tetralogy of Fallot (repaired), presence of a systemic right ventricle, presence of 
a patent shunt in the absence of pulmonary hypertension (atrial septal defect, 
ventricular septal defect, patent ductus arteriosus), left heart obstruction (arotic 
stenosis, mitral stenosis, coarctation of the aorta, hypertrophic cardiomyopathy), left 
heart regurgitation (aortic regurgitation, mitral regurgitation), right heart obstruction 
(pulmonary stenosis) and right heart regurgitation (pulmonary regurgitation, tricuspid 
regurgitation). Univariable analysis was performed initially. Variables that were 
associated with an increased incidence of the studied endpoints (p<0.1) were then 
brought forward to multivariable analysis, thus testing for interaction between them 
and adjusting for confounding. 
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3.5 Results 
 
3.5.1 Baseline characteristics and maternal cardiac diagnoses 
There were 489 pregnancies in 326 women. The distribution of the primary cardiac 
diagnoses is shown in table 1. Most occurred in women with congenital heart disease 
(50%), while valvular heart disease was the next most common diagnosis (28%). 
Fifty-eight percent of pregnancies (282) were in nulliparous women. 
 
Baseline characteristics are shown in table 2. Mean age at booking was 30 years (SD 
6.0). Fifty percent of pregnancies occurred in women who had undergone previous 
cardiac surgery, including repair of COA (10.4%), Fontan palliation (0.8%), repair of 
tetralogy of Fallot (10.9%), Mustard palliation for transposition of the great arteries 
(TGA) (3.5%) and closure of shunt lesions (6.3%). Six percent were in women who 
had previously suffered a cardiac event (heart failure, cerebrovascular accident, 
transient ischaemic attack, myocardial infarction, endocarditis). NYHA functional 
class was I in 449 (91.8%) pregnancies; 37 (7.6%) pregnancies occurred in women in 
NYHA functional class II and 3 (0.6%) were in women in NYHA functional class III. 
 
3.5.2 Maternal and fetal/neonatal outcomes 
Cardiac, obstetric, intrapartum and neonatal outcomes are detailed in tables 3, 4 and 5.  
 
Cardiac outcomes 
There were 36 (7.4%) pregnancies with at least one cardiac complication. The most 
frequent event was arrhythmia (4.3%), followed by heart failure (2.0%). There were 4 
maternal deaths: the 2 deaths in women with PH (one died as a result of a PH crisis 
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after developing PET at 26 weeks, and the other following a sustained arrhythmia at 
the time of delivery which led to profound hypotension and unrecoverable asystolic  
cardiac arrest) and that of another woman who suffered thrombosis of a mechanical 
aortic valve are described elsewhere in this thesis. A fourth woman with dilated 
cardiomyopathy (DCM) died unexpectedly in the postnatal period, presumably from 
an arrhythmia.  
 
Obstetric outcomes 
Caesarean section was performed in 39% of pregnancies (electively in 16.1% of 
cases), but there is limited data in most cases as to the reason for performing the 
Caesarean. Labour was induced in 21% of cases. Thirty-five percent of the vaginal 
deliveries were spontaneous, the remainder being assisted by use of ventouse or 
forceps. Regional anaesthesia was used in 73.6% of deliveries overall.  
 
There were 166 (34.0%) pregnancies with at least one obstetric complication, the 
most common being postpartum haemorrhage (PPH) which occurred in 21.9% of 
cases. Hypertensive disorders occurred in 8.2% of pregnancies. Spontaneous preterm 
labour (before 37 completed weeks of gestation) occurred in 4.9% of cases. 
 
Fetal/Neonatal outcomes 
Adverse perinatal outcomes occurred in 30.3% of pregnancies. Median gestational 
age at delivery was 39 weeks (range 25 to 42). The preterm delivery rate was 11.7% 
and in 58% of these, early delivery was undertaken for medical reasons. Median birth 
weight and customized birth weight centile were 3165g (range 420g to 5130g) and 
34th centile (range 0 to 98) respectively. The most frequently encountered 
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complication was being small for gestational age (birth weight less than the 5th 
customized centile) (20.9%). There were 6 stillbirths and 5 neonatal deaths (3 as a 
result of complications of prematurity in babies delivered iatrogenically preterm). 
 
Logistic regression 
Tables 6-9 illustrate the results of the univariable and multivariable logistic regression 
analyses. A history of arrhythmia and presence of an MPV were independently 
predictive of cardiac complications (p<0.0001 and 0.003 respectively). Known 
myocardial dysfunction was associated with development of heart failure during the 
pregnancy (OR 15.40, 95% CI 2.09-113.39, p=0.007). Use of cardiac medications 
was independently associated with obstetric complications (p=0.001); presence of 
pre-existing hypertension was predictive of development of PIH (OR 4.14, 95% CI 
1.54-11.14, p=0.005) while use of dose-adjusted LMWH and delivery by emergency 
caesarean section were both independently associated with PPH (p=0.001 and 
p<0.001 respectively). Maternal NYHA functional class ≥ 2 was predictive of 
neonatal complications (p=0.007) as was use of any cardiac medication (p=0.022), 
presence of an MPV (p=0.024) and the presence of a systemic right ventricle 
(p=0.007). Maternal NYHA functional class ≥ 2 was also independently associated 
with iatrogenic preterm delivery (p=0.033), as was use of any cardiac medication and 
the presence of left heart obstruction (p=0.018 and 0.029 respectively). Birth weight 
less than the 5th customised centile (SGA) was predicted by use of beta blockers 
(p=0.006), presence of a systemic right ventricle (p=0.001) and complex cyanotic 
congenital heart disease (p=0.016).  
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Table 1: Primary cardiac diagnoses  !
Primary cardiac diagnosis Number of pregnancies (%) 
 Total P0 P1 P2 P>2 
 489 (100.0) 282 (57.7) 149 (30.4) 42 (8.6) 16 (3.3) 
Pulmonary hypertension 9 (1.8) 5  2  2  0  
Cardiomyopathy 
- DCM 
- PPCM 
- HCM 
- ARVC 
23 (4.7) 
8 
5 
9 
1 
10 
5 
0  
5  
0  
10 
3 
3 
3  
1  
1 
0  
0  
1 
0 
2 
0  
2  
0  
0  
Coarctation of the aorta 
- unrepaired 
- repaired 
57 (11.7) 
6 
51 
30 
2  
28  
15 
1 
14 
6 
1  
5  
6 
2  
4 
Marfan syndrome 30 (6.2) 21  8  1  0  
Complex cyanotic congenital heart 
disease 
- pulmonary atresia with VSD 
- Fontan circulation 
12 (2.5) 
 
7 
5 
9 
 
5 
4 
3 
 
1  
2  
0 
 
0  
0  
0 
 
0  
0  
Valvular heart disease 
- AS 
- AR 
- mixed AVD 
- MS 
- MR 
- mixed MVD 
- Mixed AVD/MVD 
- bioprosthetic valve 
- mechanical valve 
- BAV – no AS/AR 
- PS 
- PR 
- TR 
138 (28.2) 
20 
15 
9 
16 
21 
4 
1 
10 
8 
6 
21 
5 
2 
77 
12  
7  
5  
8  
13  
1  
1  
5  
4  
3  
12 
4 
2 
48 
7  
5  
3  
5  
8  
1  
 0  
4  
3  
3  
8 
1 
0 
11 
1  
2  
1  
2  
0  
2  
0  
1  
1  
0  
1 
0 
0  
2 
0  
1  
0  
1  
0  
0 
0  
0 
0  
0  
0  
0  
0  
Tetralogy of Fallot (repaired) 53 (10.9) 35 12  4  2  
- Tetralogy of Fallot 
(repaired) with severe PR 13 9 2 2 0 
Complete TGA (repaired) 17 (3.5) 12 4  1  0  
- Atrial switch  17 12 4 1 0 
- Arterial switch 0 0 0 0 0 
Cc TGA (unrepaired) 6 (1.2) 4  2  0  0  
Ebstein’s anomaly 4 (0.8) 3  1  0  0  
Ischaemic heart disease 1 (0.2) 0  0  1  0  
Arrhythmia 
- AF 
- CCHB 
- L-L-G 
- Long QT syndrome 
- SVT 
- VT 
- WPW syndrome 
- sinoatrial disease 
- malignant vasovagal 
syndrome 
63 (12.9) 
12 
5 
6 
5 
19 
1 
13 
1 
1 
34 
7  
3  
3  
1  
10  
1  
7  
1  
1  
 
20 
4  
1  
2  
3  
6  
0  
4  
0  
0  
 
8 
0  
1  
1  
1  
3  
0  
2  
0  
0  
 
1 
1  
0  
0  
0  
0  
0  
0  
0   
0  
 
Shunt lesions (no PH) 
- unrepaired 
- repaired 
66 (13.6) 
35 
31 
37 
19  
18  
21 
12  
9 
6 
4  
2 
2 
0 
2  
Other 
- cardiac sarcoidosis 
- Cardiac syndrome X 
- DCRV 
- LA isomerism 
- repaired TAPVD 
9 (1.8) 
1 
1 
4 
2 
1 
4 
0  
0  
2  
1  
1  
3 
0  
0  
2  
1  
0  
1 
0  
1  
0  
0  
0  
1 
1  
0  
0  
0  
0  
 
DCM: dilated cardiomyopathy; PPCM: peripartum cardiomyopathy; HCM: hypertrophic cardiomyopathy; ARVC: 
arrhythmogenic right ventricular cardiomyopathy; AS: aortic stenosis; AR: aortic regurgitation; AVD: aortic valve disease; MS: 
mitral stenosis; MR mitral regurgitation; MVD: mitral valve disease; BAV: bicuspid aortic valve; MVP: mitral valve prolapse; 
PS: pulmonary stenosis; PR: pulmonary regurgitation; TGA: transposition of the great arteries; ccTGA: congenitally corrected 
transposition of the great arteries; AF: atrial fibrillation; CCHB: congenital complete heartblock; SVT: supraventricular 
tachycardia; VT: ventricular tachycardia; WPW syndrome: Wolff-Parkinson White syndrome; DCRV: double-chambered right 
ventricle; LA isomerism: left atrial isomerism; TAPVD: total anomalous pulmonary venous drainage 
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Table 2:  Baseline characteristics  
 
 mean (SD) 
Maternal age at booking (years) 30 (6.0) 
 n (%) 
Previous cardiac surgery 246 (50.3) 
Previous cardiac event 28 (5.7) 
NYHA  
- I 
- II 
- III 
 
449 (91.8) 
37 (7.6) 
3  (0.6) 
Cardiac medications 
- β-blocker* 
- calcium channel blocker* 
- diuretic* 
- antiarrhythmic* 
- any anticoagulant* 
-    Warfarin* 
-    dose-adjusted low molecular weight heparin* 
-    unfractionated heparin* 
- aspirin* 
- sildenafil* 
- iloprost* 
- taking more than 1 medication 
 
58 (11.9) 
6 (1.2) 
6 (1.2) 
7 (1.4) 
40 (8.2) 
1 (1.2) 
25 (5.1) 
1 (1.2) 
37 (7.6) 
7 (1.4) 
2 (0.4)  
37 (7.6) 
Haemodynamics  
- left heart obstruction 135 (27.6) 
- left heart regurgitation 80 (16.4) 
- right heart obstruction 38 (7.8) 
- right heart regurgitation 58 (11.9) 
Central cyanosis 17 (3.5) 
Previous sustained arrhythmia (not primary diagnosis) 110 (22.5) 
Pre-existing myocardial dysfunction 31 (6.3) 
Pre-existing hypertension 38 (7.8) 
Smoking 37 (7.6) 
 
* not mutually exclusive as some women were receiving more than one type of 
medication 
n = number of pregnancies 
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Table 3:  Event rate in absolute numbers (percentages) in 489 pregnancies  
 
 n (%) 
Maternal cardiac complications 
- Cardiomyopathy (new diagnosis during pregnancy) 
- Myocardial infarction 
- Heart failure 
- Arrhythmia 
- Endocarditis 
- Aortic dissection 
- Cardiac surgery during pregnancy 
- Death 
 
4 (0.8)  
3 (0.6) 
10 (2.0) 
21 (4.3) 
4 (0.8) 
1 (0.2) 
1 (0.2)  
4 (0.8)  
Maternal obstetric complications 
- Pregnancy-induced hypertension 
- Pre-eclampsia 
- Antepartum haemorrhage 
- Post-partum haemorrhage 
- Gestational diabetes mellitus 
- Preterm pre-labour rupture of membranes 
- Preterm labour 
- Venous thromboembolism 
 
24 (4.9) 
16 (3.3) 
13 (2.7) 
107 (21.9) 
5 (1.0) 
2 (0.4)  
24 (4.9) 
4 (0.8)  
Fetal/neonatal complications 
- Preterm delivery 
            Iatrogenic preterm delivery 
- Small for gestational age 
- Stillbirth 
- Neonatal death 
 
57 (11.7) 
33 (6.7) 
102 (20.9) 
6 (1.2) 
5 (1.0) 
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Table 4: Overview of pregnancies with adverse events, organized by primary cardiac 
diagnosis (n=number of affected pregnancies) 
 
Primary cardiac diagnosis 
Total 
number of 
pregnancies 
Pregnancies affected by ≥ 1 adverse event: 
n (%) 
 
 
Cardiac 
event 
Obstetric 
event 
Fetal/neonatal 
event 
Pulmonary hypertension 9 3 (33.3) 7 (77.8) 7 (77.8) 
Cardiomyopathy 23 4 (17.4) 9 (39.1) 7 (30.4) 
Coarctation of the aorta 57 3 (5.3) 16 (28.1) 14 (24.6) 
Marfan syndrome 30 2 (6.7) 9 (30.0) 13 (43.3) 
Pulmonary atresia with VSD 7 0 (0.0) 3 (42.8) 6 (85.7) 
Fontan circulation 5 1 (25.0) 4 (80.0) 5 (100.0) 
Valvular heart disease 138 9 (6.5) 45 (32.6) 40 (29.0) 
Tetralogy of Fallot 
(repaired) 53 4 (7.5) 20 (37.7) 13 (24.5) 
Complete TGA (repaired) 17 3 (17.6) 7 (41.2) 11 (64.7) 
ccTGA 6 0 (0.0) 2 (33.3) 1 (16.7) 
Ebstein’s anomaly 4 0 (0.0) 3 (75.0) 4 (100.0) 
Ischaemic heart disease 1 1 (100.0) 1 (100.0) 0 (0.0) 
Arrhythmia 63 9 (14.3) 19 (30.2) 13 (20.6) 
Shunt lesion (without 
pulmonary hypertension) 66 0 (0.0) 17 (25.8) 12 (18.2) 
Other 9 0 (0.0) 4 (44.4) 2 (22.2) 
Overall 489 36 (7.4) 166 (34.0) 148 (30.3) 
 
 
Table 5: Intrapartum outcomes 
 
 n (%) 
Mode of delivery  
SVD 171 (35.0) 
assisted vaginal delivery 127 (26.0) 
Elective CS 79 (16.1) 
Emergency CS 112 (22.9) 
Anaesthesia  
regional 360 (73.6) 
general 34 (7.0) 
neither 95 (19.4) 
 median (range) 
Gestational age at delivery (weeks) 39 (25 – 42) 
Birth weight (g) 3165 (420 - 5130 
Customised birth weight centile 35 (0 – 98) 
 
SVD: spontaneous vaginal delivery; CS: Caesarean section 
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Table 6: Univariable analysis for predictors of complications during pregnancy in 
women with pre-existing heart disease 
 
Complications Predictor Odds Ratio 95% CI p 
Cardiac History of arrhythmia 3.68 1.74-7.81 0.001 
 
Myocardial dysfunction (prior 
to pregnancy) 
3.22 1.14-9.09 0.028 
 
Mechanical valve 7.93 1.39-45.16 0.020 
 
    
Obstetric Previous cardiac surgery 1.53 1.05-2.24 0.028 
 
Any cardiac medication 2.84 1.86-4.32 <0.0001 
 
Dose-adjusted LMWH 5.57 2.01-16.05 0.001 
 
Pulmonary hypertension 5.89 1.57-22.05 0.009 
 
Mechanical valve 9.69 1.12-83.68 0.039 
PPH Delivery by emergency CS 3.34 2.06-5.40 <0.001 
 
Central cyanosis 2.72 0.99-7.49 0.050 
 
Dose-adjusted LMWH 10.78 3.79-30.69 <0.001 
 
Mechanical valve 17.75 2.05-153.6 0.009 
 
    
Fetal/Neonatal NYHA ≥ 2 7.34 3.54-15.23 <0.0001 
 
Previous cardiac surgery 1.68 1.13-2.51 0.011 
 
Central cyanosis 3.53 1.32-9.48 0.012 
 
Any cardiac medications 3.21 2.09-4.93 <0.0001 
 
Dose-adjusted LMWH 2.34 1.24-4.45 0.009 
 
Beta blocker 2.97 1.71-5.16 <0.0001 
 
Pulmonary hypertension 4.95 1.47-16.71 0.010 
  
Mechanical valve 12.28 1.42-106.08 0.007 
 
Systemic right ventricle 6.14 2.12-17.77 0.001 
 
Complex cyanotic CHD 4.92 1.21-19.95 0.026 
Iatrogenic PTD NYHA ≥ 2 10.08 4.63-21.93 <0.001 
 
Central cyanosis 5.53 1.84-16.68 0.002 
 
Any cardiac medication 5.38 2.67-10.83 <0.001 
 
Dose-adjusted LMWH 20.31 7.73-53.34 <0.001 
 
Pulmonary hypertension 9.64 2.90-32.10 <0.001 
 
Mechanical valve 26.61 4.70-150.66 <0.001 
 
Complex cyanotic CHD 12.54 1.72-91.76 0.013 
 
Left heart obstruction 2.06 1.04-4.07 0.039 
SGA NYHA ≥ 2 3.50 1.76-6.97 <0.001 
 Central cyanosis 4.32 1.53-12.21 0.006 
 Any cardiac medications 2.33 1.46-3.72 <0.001 
 Dose-adjusted LMWH 3.03 1.16-7.89 0.023 
 Beta blocker 2.59 1.46-4.60 0.001 
 Mechanical valve 7.43 1.34-41.15 0.022 
 Systemic right ventricle 5.58 2.07-15.04 0.001 
 Complex cyanotic CHD 9.38 1.79-49.10 0.008 
 
 
95%CI: 95% confidence interval; LMWH: low molecular weight heparin; PPH: post partum 
haemorrhage; CS: caesarean section; PTD: pre-term delivery; SGA: small for gestational 
age; CHD: congenital heart disease 
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Table 7: Multivariable analysis for predictors of complications during pregnancy in 
women with pre-existing heart disease 
 
 
Complications Predictor Odds Ratio 95% CI p 
Cardiac History of arrhythmia 4.43 2.02-9.72 <0.0001 
 
Mechanical valve 15.56 2.58-93.9 0.003 
 
    
Obstetric Any cardiac medication 2.33 1.43-3.79 0.001 
PPH Delivery by emergency CS 3.25 1.98-5.35 <0.001 
 
Dose-adjusted LMWH 7.96 2.31-27.40 0.001 
 
    
Fetal/Neonatal NYHA ≥ 2 4.66 1.86-11.89 0.001 
 
Any cardiac medication 2.88 1.16-7.12 0.022 
 
Mechanical valve 8.68 1.32-57.09 0.024 
 
Systemic right ventricle 5.73 1.62-20.28 0.007 
Iatrogenic PTD NYHA ≥ 2 3.34 1.11-10.10 0.033 
 
Any cardiac medication 2.70 1.19-6.18 0.018 
 
Left heart obstruction 2.57 1.10-5.99 0.029 
SGA Beta blocker 3.56 1.42-8.86 0.006 
 Systemic right ventricle 6.88 2.27-20.86 0.001 
 Complex CHD 16.58 1.70-102.33 0.016 
 
95% CI: 95% confidence interval; LMWH: low molecular weight heparin; PPH: post partum 
haemorrhage; CS: Caesarean section; PTD: pre-term delivery; SGA: small for gestational 
age; CHD: congenital heart disease 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
! (*!
3.6 Discussion 
 
Pregnancy in women with pre-existing cardiac disease continues to be associated with 
a high frequency of adverse cardiac events, and obstetric and fetal/neonatal 
complications.  
 
3.6.1 Baseline characteristics and cardiac diagnoses 
Congenital heart disease was the largest subgroup in this series (50%) followed by 
valvular heart disease (28%). This is a similar distribution to that described in the data 
from the ROPAC registry.38 Women with cardiomyopathy (4.7%) and ischaemic 
heart disease (1 pregnancy only) were encountered less frequently. Despite the 
increase in cardiac deaths in the UK being attributed to an increase in rates of 
acquired heart disease, congenital heart disease remains the most frequent form of 
cardiovascular disease seen during pregnancy in the western world.4,7,8  
 
Most pregnancies occurred in mothers who were in NYHA functional class I prior to 
pregnancy (91.8%); 7.6% were in women in NYHA functional class II, and 0.6% in 
women who were in functional class III. 8,9,33,43 The risk of adverse events during 
pregnancy for women with pre-existing heart disease is strongly associated with the 
functional capacity of the patient.8,30,31,32 The cohort of women with heart disease 
described in this study have comparable functional status to those reported elsewhere 
in the literature.8,9,33 
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3.6.2 Maternal outcomes 
Cardiac complications 
Cardiovascular complications occurred in 7.4% of pregnancies, consistent with the 
findings of the ZAHARA investigators.36 Maternal mortality was 0.8%, and was 
highest among women with cardiomyopathy. High rates of heart failure (20%) and 
ventricular arrhythmias (20%) were also seen in this group of women, which is 
consistent with the ROPAC data.38 Cardiomyopathy was the commonest cardiac 
cause of maternal death in the 2006-2008 CMACE report.3 In women with DCM poor 
functional capacity prior to pregnancy and/or moderate to severe left ventricular 
systolic dysfunction are predictive of adverse maternal and fetal outcomes and also of 
further cardiac events in the 16 months following delivery.91  
 
Clinically significant arrhythmias (4.3%) and heart failure (2.0%) were the most 
frequent adverse cardiac events overall. This is a lower rate of heart failure than that 
reported in many series8,35,38,39 but is comparable with the ZAHARA data.36 Several 
of the symptoms of early heart failure (such as increasing shortness of breath on 
exertion) are seen in healthy pregnancy. A strict definition of heart failure was applied 
to the patients in this study: a decline in NYHA functional class and/or evidence of 
pulmonary oedema on clinical examination or chest x-ray, and/or deterioration of 
ventricular function on echocardiography; this may account for the lower rate 
observed in the study. Myocardial dysfunction prior to pregnancy strongly predicted 
the development of heart failure (OR 15.40, 95% CI 2.09-113.39, p=0.007). 
 
A history of arrhythmias and the presence of an MPV were identified on multivariable 
logistic regression analysis as being independently associated with adverse 
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cardiovascular events, consistent with the observations of other investigators.8,30,33,36 
In women with pre-existing arrhythmias, exacerbation during pregnancy is common.92 
Cardiac complications arose in 2 of the 8 pregnancies in women with MPVs (25%), a 
similar rate to that reported in the elsewhere in the literature.93 Valve thrombosis 
occurred in both and resulted in the death of one woman. The optimal anticoagulant 
regimen during pregnancy for such women remains contentious.78 In contrast to the 
findings of the CARPREG and ZAHARA investigators, NYHA functional class > II 
and the presence of central cyanosis were not identified as independent predictors of 
cardiovascular events and may be explained by the low numbers of such women in 
this series.  
 
Obstetric complications 
Obstetric complications were observed in 34% of pregnancies. PPH was the most 
frequent, occurring in 21.9% of pregnancies. There was an association with delivery 
by emergency Caesarean section (OR 3.25, 95% CI 1.98-5.35, p<0.001) which is 
generally associated with higher rates of haemorrhage compared with both elective 
Caesarean section and vaginal delivery.83 Use of anticoagulants (specifically dose-
adjusted low molecular weight heparin) was unsurprisingly an independent predictor 
for PPH (OR 7.96, 95% CI 2.31-27.40, p=0.001), although the evidence from other 
studies is conflicting.33,38,43 The presence of central cyanosis was associated with PPH 
in the univariable, but not the multivariable analysis. Many patients with cyanotic 
heart disease have haemostatic defects8, and additionally in this series there was an 
association between use of anticoagulant medication and presence of central cyanosis 
(r=0.241, p=<0.001), both of which may explain this trend. 
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Rates of hypertensive disease were similar to those seen in the general population.94 
Women with COA were most likely to develop PIH (OR 4.56, 95% CI 1.66-12.57, p 
= 0.005); however, there was a strong association with pre-existing hypertension in 
these women (r=0.512, p < 0.001), which was an independent predictor for 
developing hypertensive disease during pregnancy (p=0.005). 
 
Delivery was by Caesarean section in 39% of pregnancies. Although this is higher 
than the national average (and that recommended by the World Health Organisation), 
many high-risk obstetric units in London teaching hospitals (including Chelsea and 
Westminster Hospital) have Caesarean section rates of around 30% of deliveries, and 
this is not significantly different to the rate in this cohort of women with heart disease 
(p=0.23). 
 
3.6.4 Fetal/Neonatal Outcomes 
Fetal/neonatal complications occurred in 30.3% of pregnancies. There were 6 
stillbirths and 5 neonatal deaths: higher than stillbirth and neonatal death rates in 
England and Wales in 2012, as reported by the Office for National Statistics,95,96 but 
similar to rates reported by the ZAHARA investigators.39  
 
Birth weight below the fifth customized centile was the commonest adverse outcome, 
occurring in 20% of pregnancies, and was independently predicted by use of beta 
blockers (p=0.006), a systemic right ventricle (p=0.001) and complex cyanotic 
congenital heart disease (p=0.016). The association between reduced cardiac output 
and lower birth weight has been well documented in healthy pregnancies and those in 
women with cardiac disease.30,77,97 Ventricular function and degree of cyanosis are the 
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major determinants of fetal outcome in women with cyanotic congenital heart 
disease.31 Use of beta-blockers (which have a negative inotropic effect),43,77,78,98 and 
the presence of a systemic right ventricle67 have also been shown to be associated 
with lower birth weight.  
 
Preterm delivery (before 37 completed weeks of gestation) occurred in 11.7% of 
pregnancies, similar to that generally reported in developed countries,39 and consistent 
with the preterm birth rate reported in the CARPREG8,30 and ZAHARA36 studies. In 
58% of these, early delivery was undertaken for medical reasons. Independent 
predictors of iatrogenic preterm delivery were NYHA functional class ≥ II (OR 3.34, 
95% CI 1.11-10.10, p=0.033), use of any cardiac medication (OR 2.70, 95% CI 1.19-
6.18, p=0.018) and presence of left heart obstruction (OR 2.57, 95% CI 1.10-5.99, 
p=0.029). Spontaneous preterm labour occurred in 4.9% of pregnancies, (which is 
lower than that reported in other series30,32). Although an association between cardiac 
events during pregnancy and the onset of preterm labour has been described30,32, it is 
likely that improvements in the survival of preterm infants over the past decade have 
led to an increased willingness among obstetricians to undertake preterm delivery 
when there are signs of maternal and/or fetal decompensation.  
 
NYHA functional class ≥ II was an independent predictor for perinatal complications 
(OR 4.66, 95% CI 1.86-11.89, p=0.001), which is consistent with the CARPREG 
study.8,30 In common with the findings of the ZAHARA investigators36 there was also 
an association with use of any cardiac medication (OR 2.88, 95% CI 1.16-7.12, 
p=0.022) and the presence of an MPV (OR 8.68, 95% CI 1.32-57.09, p=0.024). The 
presence of a systemic right ventricle (OR 5.73, 95% CI 1.62-20.28, p=0.007) as a 
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predictor for adverse perinatal outcomes is a new finding. A systemic right ventricle 
may be unable to support the additional haemodynamic demands of pregnancy, 
(indeed pregnancy may result in irreversible right ventricular dysfunction4,42), and 
neonatal complications including low birth weight and preterm delivery have been 
reported as more frequent in this group of women than in normal pregnancy.67 
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3.7 Conclusions 
 
Adverse cardiovascular, obstetric and fetal/neonatal outcomes occur frequently in 
pregnant women with pre-existing heart disease. A history of arrhythmias prior to 
pregnancy, myocardial dysfunction and presence of an MPV predicted cardiac events. 
Use of cardiac medications was independently associated with obstetric 
complications, mainly due to a significant association of use of anticoagulants with 
PPH. NYHA functional class ≥ II, the use of cardiac medications and the presence of 
an MPV were predictive of poor perinatal outcomes and a new association of a 
systemic right ventricle with fetal/neonatal complications is reported. 
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Chapter 4: Pulmonary hypertension 
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4.1 Abstract 
 
4.1.1 Aims: 
To investigate maternal and neonatal outcomes in a series of pregnancies in 
women with pulmonary hypertension  
4.1.2 Methods: 
 Multidisciplinary review of case records 
4.1.3 Results 
There were twelve pregnancies in nine women. There were two maternal 
deaths (in 1995 and 1998), one related to pre-eclampsia and one to arrhythmia. 
Maternal morbidity included postpartum haemorrhage (three cases), and one 
post-Caesarean evacuation of a wound haematoma. There were three first-
trimester miscarriages, nine live births and no perinatal deaths. Mean birth 
weight was 2197g, mean gestational age was 34 weeks (range 26 - 39), and 
mean birth weight centile was 36 (range 5 - 60). Five babies required 
admission to the neonatal intensive care unit but all were eventually 
discharged home. All women were delivered by Caesarean section (seven 
elective and two emergency deliveries) and all under general anaesthetic, 
except for one emergency and one elective Caesarean performed under 
regional block. 
4.1.4 Conclusions 
Maternal and fetal outcomes for women with pulmonary hypertension may be 
improving. However, the risk of maternal mortality remains significant, so that 
early and effective counselling about contraceptive options and pregnancy 
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risks should continue to play a major role in the management of such women 
when they reach reproductive maturity. 
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4.2 Introduction 
 
Pulmonary hypertension (PH) is defined at cardiac catheterization as a mean 
pulmonary artery pressure (PAP) of greater than 25mmHg at rest.89 The causes are 
multifactorial (table 1).90  
 
Table 1: Updated classification of pulmonary hypertension; from Simmoneau et al90 
1   Pulmonary Arterial Hypertension (PAH) 
x Idiopathic (IPAH) 
x Heritable (HPAH) 
x Drug and toxin induced 
x Associated with connective tissue disorder (eg. scleroderma), congenital heart 
disease (including Eisenmenger physiology), portal hypertension, HIV 
infection, schistosomiasis 
x unknown 
1’  Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis 
1’’ Persistent pulmonary hypertension of the newborn (PPHN) 
2   Pulmonary hypertension due to left heart disease  
3   Pulmonary hypertension due to lung diseases and/or hypoxia 
4   Chronic thromboembolic pulmonary hypertension (CTEPH) 
5   Pulmonary hypertension with unclear multifactorial mechanisms  
x haematologic disorders: eg. chronic haemolytic anaemia, splenectomy 
x systemic disorders: eg. sarcoidosis 
x metabolic disorders: eg. glycogen storage disease 
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In its extreme form pulmonary pressures equal or even exceed systemic pressures (as 
seen with Eisenmenger physiology where a reversed central shunt leads to a 
progressive rise in pulmonary vascular resistance) and may subsequently have a 
detrimental effect on right ventricular function.  
 
Figure 1. Diagram illustrating the progressive reversal of a left-to-right shunt and 
development of Eisenmenger syndrome101 
 
 
 
The severity of PH is determined by the WHO functional class, a modification of the 
NYHA functional classification system recognising the importance of pre-syncope or 
syncope as a poor prognostic sign in patients with PH.102  
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Table 2: WHO functional classification of PH102 
WHO Class Definition 
I 
Patients with PH but without resulting limitation of physical activity. 
Ordinary physical activity does not cause undue dyspnoea or fatigue, 
chest pain or near syncope 
II 
Patients with PH resulting in slight limitation of physical activity. 
They are comfortable at rest. Ordinary physical activity causes 
undue dyspnoea or fatigue, chest pain or near syncope 
III 
Patients with PH resulting in marked limitation of physical activity. 
They are comfortable at rest. Less than ordinary activity causes 
undue dyspnoea or fatigue, chest pain or near syncope 
IV 
Patients with PH resulting in inability to carry on any physical 
activity without symptoms. These patients manifest signs of right-
heart failure. Dyspnoea and/or fatigue may even be present at rest. 
Discomfort is increased by any physical activity 
 
 
Women with PH tolerate pregnancy poorly, with the rate of functional deterioration 
increasing from the second trimester onwards and the majority of deaths occurring 
within the first postnatal month, usually as a result of right heart failure.104 Series 
from the 1990s reported a maternal mortality of 30-56%,51 probably due to the limited 
ability of women with PH to adapt to the cardiovascular demands of pregnancy. 
However, more recent data from a systematic review103 and two case series104,105 
suggest that maternal mortality may in fact be lower, with reported rates of 10-25%. 
Poor fetal outcomes have been well documented with high rates of preterm delivery 
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(85-100%), fetal growth restriction (FGR) (3-33%) and fetal/neonatal loss (7-
13%).51,103,106 Current guidelines continue to recommend discouraging pregnancy, 
with use of maximally effective contraception and early termination should pregnancy 
occur.4,37 However, despite the risks, some women with PH still choose to become 
pregnant or to continue with an unplanned pregnancy. 
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4.3 Aims 
 
To investigate maternal and neonatal outcomes in a series of pregnancies in women 
with PH.  
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4.4 Methods 
 
Women with a diagnosis of PH (defined by a mean pulmonary artery pressure of  
> 25 mmHg at rest) cared for by the Joint Cardiac and Obstetric Service of the 
Chelsea and Westminster and Royal Brompton Hospitals were identified from a 
database started in 1994. Data were collected from a detailed review of case notes 
supplemented by the Circonia Maternity Information System (CMIS© HD Clinical 
Ltd, Bishops Stortford, Herts, UK). Information on patient characteristics, functional 
and echocardiographic assessment, cardiological, obstetric and anaesthetic 
management during pregnancy and labour and follow-up postnatal assessment was 
obtained. 
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4.5 Results 
 
There were twelve pregnancies in nine women. Their baseline characteristics, 
together with maternal and neonatal outcomes, are recorded in Table 3. Their mean 
age at the initial clinic visit was 27 years (median 25 years, range 19-38). There were 
seven primigravidas. In four women (A, B, D and E) the diagnosis of PH was made 
using echocardiography during the index pregnancy. The remaining women were 
diagnosed before pregnancy at cardiac catheterization, with the exception of patient I 
who was diagnosed by echocardiography but not referred to tertiary care until she 
became pregnant. The PH aetiologies were varied – one each for idiopathic, HIV, left 
heart disease and primary lung disease, and five congenital heart disease. 
 
4.5.1 Maternal mortality and morbidity 
There were two maternal deaths, both before 1999. Patient A (1995) died on postnatal 
day 15 following a PH crisis, having been delivered at 26 weeks’ gestation for 
fulminating pre-eclampsia (PET). Patient B (1998) died at Caesarean section having 
developed intractable supraventricular tachycardia (SVT) following manual delivery 
of the placenta and administration of repeated intravenous bolus doses (5U x 2) of 
oxytocic drugs (Syntocinon©). 
 
All women were delivered by Caesarean section (seven elective and two emergency 
deliveries), all under general anaesthetic except for one elective and one emergency 
Caesarean performed under regional block. Estimated blood loss at delivery ranged 
from 300 to 1000 ml (mean 711). In the five most recent cases the third stage was 
managed with a low-dose oxytocin infusion (Syntocinon© 8-12 mU/minute over 4 
! *'!
hours) rather than a bolus (Syntocinon© 5-10IU), and in four women compression 
sutures were also used.107 In one case the third stage was managed with compression 
sutures alone, and no oxytocics were given. 
 
Symptomatic and functional assessment and echocardiographic measurements at 
baseline, during pregnancy and at follow-up, are summarized in Table 4. Patients 
were monitored throughout their pregnancies by echocardiography and clinical 
examination. Estimations of PAP were assessed from tricuspid and pulmonary artery 
Doppler studies.  
 
Medical treatment is summarized in Table 5. Patient A received intravenous 
unfractionated heparin (UFH) following delivery. Subsequently seven women were 
anticoagulated with subcutaneous low-molecular-weight heparin (LMWH). The target 
level of anticoagulation to be achieved was determined by their thrombotic risk: 
patients E, F and H (who had been taking warfarin before pregnancy) received 
therapeutic doses of LMWH and were monitored by measurement of anti-Factor Xa 
levels. The other women were given prophylactic doses of LMWH. Patient A 
received intravenous iloprost post-partum. Six of the nine women (all from 2007 
onwards) were treated with sildenafil throughout pregnancy; one of them (E) was 
given add-on therapy with nebulized iloprost during the pregnancy because of a 
significant deterioration in her symptoms. Table 3 also reports the anaesthetic 
management at delivery. Six cases had invasive monitoring with peripheral arterial 
lines and central venous pressure lines. In five cases, cardiac output was monitored 
intra-operatively using transoesophageal echocardiography. 
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4.5.2 Perinatal mortality and morbidity 
Three pregnancies resulted in miscarriage (two in patient D, one attributed to the 
development of thyrotoxicosis) and nine pregnancies resulted in a surviving child. 
Five women were delivered iatrogenically preterm because of maternal 
decompensation, their babies requiring admission to the neonatal intensive care unit 
(NICU). One of the babies was small for gestational age (SGA) (< 5th centile). None 
of the babies in this series had any congenital abnormalities.
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Table 3: Baseline characteristics, maternal and neonatal outcomes in women with PH 
Year 
Patient  
(pregnancy 
no.) 
Age Parity GA at diagnosis  Aetiology 
WHO 
class 
PASP 
(mmHg) 
RV 
function 
GA at 
delivery 
(weeks) 
Mode 
of 
delivery 
EBL 
(ml) 
BW 
(g) 
BW 
centile 
Maternal 
complications 
Maternal 
outcome 
Neonatal 
complications 
Neonatal 
outcome 
1995 A 28 0 Pre-pregnancy 
CHD (VSD, 
Eisenmenger) I 104 
Moderately 
impaired 26 
Em 
LSCS 1000 620 5 
Fulminating 
PET 
Death 
D15 
PH crisis 
PTD 
SGA 
NICU 
Alive 
and well 
1998 B 33 0 Pre-pregnancy 
CHD (secundum ASD 
closed with Dacron patch 
aged 19) 
I-II 55-60 Good 36+4 Em LSCS 300 2570 35 
Non-sustained 
VT, 3rd 
trimester 
Sustained 
SVT at LSCS 
Intra-
operative 
death 
PTD Alive and well 
2003 C 24 0 24 weeks 
CHD (ToF variant with 
complex pulmonary 
atresia and MAPCAs) 
III 
Assumed 
to be 
systemic 
Good 34 El LSCS 600 2080 27 PPH 
Still 
living 
PTD 
NICU 
Alive 
and well 
2007 D (1) 19 0 Pre-pregnancy 
L heart disease 
(restrictive LA) II 38 Good 
Misc. 
6/40 
ERPC 
    Nil Still living   
2007  E 25 0+1 Pre-pregnancy iPH II 106 
Severely 
impaired 32 
El 
LSCS 400 1650 37 
Worsening LV 
function 
Still 
living 
PTD 
NICU 
Alive 
and well 
2007 F 38 2 23+5 weeks 
Thromboembolic/primary 
lung disease 
(emphysema) 
III 102 Mildly impaired 33+2 
El 
LSCS 500 2090 50 
Return to 
theatre to 
evacuate 
wound 
haematoma 
Still 
living 
PTD 
NICU 
Alive 
and well 
2008 G (1) 24 1 36 
CHD (repaired PDA, 
VSD; absent LPA and 
hypoplastic L lung) 
II 65 Good 37 El LSCS 800 2356 9 PPH 
Still 
living SGA 
Alive 
and well 
2008 G (2) 25 2 Pre-pregnancy CHD    
Misc 
12/40     Nil 
Still 
living   
2008 H 28 0 23 CHD (AVSD with Eisenmenger) I-II 90 Good 34 
El 
LSCS 1000 2184 50 PPH 
Still 
living 
PTD 
NICU 
Alive 
and well 
2009 D (2) 21 0+1 Pre-pregnancy L heart disease III 60 Good 
Misc. 
7/40 
ERPC 
    
Atrial 
tachycardia 
Thyrotoxicosis 
Still 
living   
2009 I 32 1 Pre-pregnancy HIV I-II 45 Good 39 
El 
LSCS 800 3440 60 PPH 
Still 
living Nil 
Alive 
and well 
2009 G (3) 26 2+1 Pre-pregnancy CHD II-III 70 
Mild 
dysfunction 37 
El 
LSCS 1000 2786 50 
PPH 
Post-op ileus 
Still 
living Nil 
Alive 
and well 
ASD: atrial septal defect; AVSD: atrioventricular septal defect; BW: birth weight; CHD: congenital heart disease; EBL: estimated blood loss; ERPC: evacuation of retained products of conception; FGR: fetal growth restriction; iPH: 
idiopathic pulmonary hypertension; LA: left atrium; LPA: left pulmonary artery; LSCS: lower segment caesarean section; MAPCAs: major aortopulmonary collaterals; misc.: miscarriage; NICU: neonatal intensive care unit; PASP: 
pulmonary artery systolic pressure; PDA: patent ductus arteriosus; PPH: post-partum haemorrhage; PTD: pre-term delivery; RV: right ventricle; SaO2: oxygen saturations in air as measured by pulse oximetry; SVT: supraventricular 
tachycardia; ToF: tetralogy of Fallot; VSD: ventricular septal defect; VT: ventricular tachycardia; WHO: World Health Organisation; still living: status at one year post delivery 
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Table 4: Functional and echocardiographic assessment of women with PH during pregnancy and the puerperium 
Year Patient 
(pregnancy 
no.) 
WHO Class RSVP RV Function 
  Baseline Worst during 
pregnancy 
6-12 month 
follow-up 
Baseline Worst during 
pregnancy 
6-12 month 
follow-up 
Baseline Worst during 
pregnancy 
6-12 month 
follow-up 
1995 A I I-II N/A 104 104 N/A Moderately 
impaired 
Moderately 
impaired 
N/A 
1998 B I-II II N/A 55-60 65 N/A Good Good N/A 
2003 C III III II Assumed 
systemic 
(120) 
Systemic * Good Good * 
2007 D (1) II II II 38 38 * Good Good * 
2007 E II II-III III 106 120 110 Severely 
impaired 
Severely 
impaired 
Severely 
impaired 
2007 F III III-IV III 102 102 101 Mildly 
impaired 
Mildly 
impaired 
Mildly 
impaired 
2007 G (1) II III III 65 65 70 Good Good Good 
2008 G (2) Spontaneous 1st trimester miscarriage – no data available 
2008 H I-II II-III II 90 90 87 Good Good Good 
2009 D (2) III III III 60 70 90 Good Good Good 
2009 I I-II I-II I-II 45 45 25 Good Good Good 
2009 G (3) II-III III-IV III 70 80 51 Mild 
dysfunction 
Mild 
dysfunction 
Good 
 
RVSP: right ventricular systolic pressure; WHO: World Health Organisation; * Patient did not attend for follow-up echocardiogram 
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Table 5: Medical, obstetric and anaesthetic management of women with PH 
 
Year Patient 
(pregnancy 
no) 
Medical 
therapy 
Third stage GA/RA CO 
monitoring 
Lines Induction Maintenance Vasoconstrictors IV fluids Intraoperative 
complications 
1995 A IV UFH (PN) 
IV iloprost 
(PN) 
Oxytocin 
bolus x2 
GA None CVC 
Arterial line 
Fentanyl 
Etomidate 
Vecuronium 
IPPV with 
O2/N20/halothane 
Phenylephrine 
boluses 
Crystalloid 
1000ml 
Colloid 
1750ml 
RBCs 4 units 
Sinus 
tachycardia 
treated with 
esmolol 
1998 B Diltiazem Oxytocin 
bolus x2 
RA (labour 
epidural 
topped up) 
None CVC 
Arterial line 
N/A 14ml 0.5% 
bupivacaine (3ml 
aliquots over 30 
minutes) 
100mcg fentanyl 
Phenylephrine 
boluses 
Crystalloid 
1000ml 
SVT 5 minutes 
post 2nd dose 
syntocinon 
during removal 
of placenta, 
hypotension 
and aystole 
Intubated and 
CPR initiated 
Resuscitation 
for >1 hour 
2003 C SC LMWH  GA Anaesthetic notes not available 
2007 D(1) SC LMWH 
Sildenafil 
Miscarriage 
2007 E SC LMWH 
Sildenafil 
Nebulised 
iloprost 
Furosemide 
Compression 
suture 
GA TOE 
Trans-
oesophageal 
Doppler 
Wide-bore 
peripheral 
access 
Arterial line 
PAC 
introducer 
Fentanyl 
Etomidate 
Suzamethonium 
Propofol infusion 
Atracurium 
Fentanyl 
Morphine 
Paracetamol 
Ilio-inguinal 
blocks 
  Bradycardia 
after induction 
2007 F SC LMWH 
Sildenafil 
Oxytocin 
infusion 
Compression 
suture 
GA TOE Wide-bore 
peripheral 
access 
Arterial line 
PAC 
introducer 
Fentanyl 
Etomidate 
Suxamethonium 
IPPV with 
O2/isoflurane 
Vecuronium 
Morphine 
Paracetamol 
Ilio-inguinal 
blocks 
 Crystalloid 
1000ml 
Bradycardia 
after induction 
2007 G(1) SC LMWH 
Sildenafil 
Oxytocin 
infusion 
Compression 
suture 
GA TOE Wide-bore 
peripheral 
access 
Arterial line 
CVC 
PAC 
introducer 
Etomidate 
Fentanyl 
Suxamethonium 
Atropine 
IPPV with 
O2/isoflurane 
Morphine 
Paracetamol 
Ilio-inguinal 
blocks 
 Minimal 
crystalloid 
Colloid 500ml 
RBCs 2 units 
Persistent 
tachycardia 
2008 G(2) SC LMWH 
Sildenafil 
Miscarriage 
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2008 H SC LMWH 
Sildenafil 
Oxytocin 
infusion 
Compression 
suture 
GA TOE Wide-bore 
peripheral 
access 
Arterial line 
CVC 
PAC 
introducer 
Etomidate 
Fentanyl 
Suxamethonium 
Atropine 
IPPV with 
O2/isoflurane 
Morphine 
Paracetamol 
Vecuronium 
Ilio-inguinal and 
rectus sheath 
blocks 
 Crystalloid 
500ml 
Colloid 500ml 
None 
2009 D(2) SC LMWH 
Sildenafil 
Miscarriage 
2009 I SC LMWH 
Sildenafil 
Anti-
retrovirals 
Oxytocin 
infusion 
Compression 
suture 
RA (spinal) None Wide-bore 
peripheral 
access 
Spinal of 2.5ml 
0.5% heavy 
bupivacaine, 
300mcg 
diamorphine 
N/A Phenylephrine 
300mcg 
Crystalloid 
1000ml 
Colloid 500ml 
None 
2009 G(3) SC LMWH 
Sildenafil 
Furosemide 
Oxytocin 
infusion 
GA TOE Anaesthetic notes not available 
CO: cardiac output; CVC: central venous catheter; GA: general anaesthetic; RA: regional anaesthetic; ICU: intensive care unit; IPPV: intermittent positive pressure ventilation; IV: 
intravenous; LMWH: low molecular weight heparin; PAC: pulmonary artery catheter; PCA: patient-controlled analgesia; RBCs: red blood cells; SVT: supraventricular tachycardia; TOE: 
trans-oesophageal echocardiography; UFH: unfractionated heparin 
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4.6 Discussion 
 
4.6.1 Maternal mortality and morbidity 
There were two maternal deaths in 12 pregnancies, illustrating the high maternal 
mortality associated with PH. However both these deaths occurred before 2000. 
Patient A developed fulminating PET with concomitant coagulopathy, necessitating 
emergency delivery at 26 weeks. She died on the 15th postnatal day as a result of a PH 
crisis, emphasizing the commonly fatal effect of PET when it occurs in women with 
PH.108-110 Patient B developed a sustained SVT shortly after a manual removal of the 
placenta at Caesarean section. She also received two bolus doses of oxytocin 
intravenously. The resulting hypotension precipitated an asystolic cardiac arrest, 
which was unrecoverable. Oxytocin is now known to cause an increase in pulmonary 
vascular resistance, a reduction in systemic vascular resistance and tachycardia.85 
These effects, in combination with a sudden autotransfusion consequent on the rapid 
manual delivery of the placenta, may have contributed to the haemodynamic 
instability that led to cardiac arrest and the death of patient B. Subsequent to this 
event, the third stage in women with PH has been managed with a low-dose oxytocin 
infusion (8-12mU/minute of Syntocinon©) and delivery of the placenta by controlled-
cord traction (CCT).4,5 Both deaths occurred during the early postnatal period, 
supporting earlier observations that this is the time of highest risk.51 Previous series 
have reported refractory right heart failure as the commonest cause of death,103 but 
this was not observed in this series.  
 
Both deaths in this series occurred in women with PH secondary to congenital heart 
disease, one of whom (patient A) also had Eisenmenger physiology. Patients with 
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Eisenmenger syndrome have significantly increased risks of bleeding, thrombotic 
complications and arrhythmia, with multi-organ involvement being the norm.111 
However, a recent systematic review found no significant difference in mortality 
between different subgroups of PH.103 
 
Advanced therapies 
Five out of nine women (all cases since 2007) were treated with sildenafil during 
pregnancy, covering a wide range of diagnostic groups: one associated with HIV 
infection, one IPAH, one PH associated with lung disease and two PH associated with 
congenital heart disease. Two women were treated with prostacyclin analogues. 
Prostacyclin is produced by vascular endothelial cells. It binds to endothelial 
prostacyclin receptors thereby increasing production of cyclic adenosine 
monophosphate (cAMP), resulting in vasodilatation and inhibition of platelet 
aggregation. It also has anti-inflammatory and anti-proliferative effects. PH patients 
have reduced levels of endogenous prostacyclin and reduced expression of 
prostacyclin synthase in the lungs. The synthesis of stable analogues of prostacyclin, 
with differing pharmacokinetic properties but similar pharmacodynamics effects, has 
enabled its clinical use in patients with PH. Both women who died did so before the 
introduction of sildenafil. Sildenafil reduces degradation of cyclic guanosine 
monophosphate (cGMP) by inhibiting cGMP-specific phosphodiesterase type 5, 
resulting in local release of nitric oxide and subsequent vasodilatation. However, the 
Food and Drug Adminstration (FDA) only approved the use of sildenafil for treatment 
of PH in 2005 and there are limited data on its safety during pregnancy and 
breastfeeding. Animal studies have not shown evidence of teratogenicity, but there are 
no adequate and well-controlled studies in pregnant women. Sildenafil is excreted in 
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breast milk but there are no data at all regarding its use in breastfeeding mothers. 
Development of advanced therapies such as sildenafil have revolutionized the 
management of PH, with improvements in symptoms, functional capacity and 
survival being demonstrated.112 However there is no clear consensus on the use of 
advanced therapies for PH in pregnancy and the evidence is limited to case series and 
a few small reviews; however it is tempting to attribute the recent reduction in 
maternal mortality to the increased availability of these therapies.103 
 
Anticoagulation 
Seven of the nine women in this series were anticoagulated with subcutaneous 
LMWH; (the degree of anticoagulation was based on their estimated thrombotic risk). 
There were no thrombotic complications during pregnancy or the puerperium. PH is 
characterized by hypertrophy, vasoconstriction and thrombus formation in the 
pulmonary microvasculature. Additionally pregnancy is associated with a six-fold 
increase in thrombosis risk compared with age-matched pregnancy controls (a risk 
which is doubled again in the puerperium). This is further increased in patients with 
Eisenmenger physiology in whom there is also a risk of paradoxical embolism due to 
the right-to-left shunt and significant arrhythmias in these patients. There remains 
however, uncertainty regarding the most effective and safest regimen for 
thromboprophylaxis, particularly for women with Eisenmenger physiology in whom a 
balance must be struck between their increased tendency to bleeding (in particular 
pulmonary haemorrhage) and their thrombotic risk.  
Patients who had been taking warfarin before pregnancy were fully anticoagulated 
with subcutaneous LMWH, monitored by measuring anti factor-Xa levels (target 0.6-
1.0). They were restarted on warfarin as soon as it was established that there were no 
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ongoing bleeding problems following surgery. Those women on prophylactic LMWH 
during pregnancy continued this after delivery for 6-12 weeks.  
 
Delivery 
All nine deliveries were by Caesarean section; seven were elective, and only two were 
emergency (patients A and B, both of whom subsequently died). The ideal mode of 
delivery continues to be contentious.4,51,74,103,109 While vaginal delivery is thought to 
be associated with smaller haemodynamic changes and carries benefits of lower risks 
of haemorrhage, infection and venous thromboembolism, a planned Caesarean 
delivery has the advantages of allowing the delivery to take place under optimal 
conditions (for example with attendance of senior staff) and avoids the possibility of 
emergency caesarean section in labour which may be associated with increased risks 
compared with both elective Caesarean section and vaginal delivery.83 Also, as many 
women will be delivered preterm when the cervix is still unfavourable, induction of 
labour is likely to be difficult. 
Mean blood loss at delivery was 711ml (range 300-1000ml), with a blood loss of 
1000ml in three women. One of these women was patient A who had a coagulopathy 
associated with severe PET. This, in combination with her delivery at 26 weeks 
gestation, is likely to have contributed to the relatively high blood loss. Uterotonics 
have adverse haemodynamic effects which make them unsuitable for women with 
PH, and they may have contributed to the death of patient B. Avoidance of bolus 
doses of oxytocic drugs in preference for a low-dose oxytocin infusion and a low 
threshold for insertion of uterine brace sutures was introduced following the death of 
patient B, and is now also recommended by the ESC4 and RCOG5. General 
anaesthesia, specifically the use of volatile agents such as halothane, isoflurane and 
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nitrous oxide, is known to increase uterine atony. Of the six cases with an estimated 
blood loss of greater than 500ml at delivery in association with a general anaesthetic, 
five (83%) women had anaesthesia maintained with either halothane or isoflurane.  
 
Anaesthetic considerations 
All forms of regional anaesthetic have been used successfully for the delivery of 
women with PH.113-116 However consideration must be given to anticoagulation, the 
women’s ability to tolerate lying flat and the potentially profound sympathetic block 
which may occur with regional anaesthetic which may result in reduced venous return 
and significant hypotension, both of which are poorly tolerated in women with PH. 
The avoidance of vasodilatation and reduced venous return is best achieved by using a 
slow incremental infusion of local anaesthetic. Use of a general anaesthetic, as was 
the case for seven of the nine women in this series, is well described in the literature 
and facilitates use of trans-oesophageal echocardiography to monitor cardiac output 
and diminishes the work of breathing, while allowing the anaesthetist to manipulate 
metabolic parameters.117-119 Furthermore, direct pulmonary vasodilators such as 
nebulized prostacyclins and nitric oxide can be given more easily, and in the event of 
major complications the woman can be put onto cardiopulmonary bypass with the 
minimum of delay.  
 
4.6.2 Fetal and neonatal outcomes 
Maternal PH is associated with an increased risk of fetal and neonatal 
complications,51,103,106 which is highest in women with poor functional class pre-
pregnancy (NYHA functional class III or IV), cyanosis or left heart obstruction.30 The 
direct effects of the underlying cardiac disease (reduced cardiac output and 
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consequently placental perfusion and maternal hypoxia) may be compounded by 
iatrogenic preterm delivery. Only one of the babies in this series was SGA (less than 
the 5th customized centile). This was the baby of patient A, who also developed 
severe, early-onset PET (which is also associated with poor fetal growth). There were 
three first trimester miscarriages (2 in patient D and 1 in patient G), and no stillbirths 
or neonatal deaths. Five out of nine women were delivered preterm, all for maternal 
reasons. Of these five, only one (patient A) was severely preterm (26 weeks). This 
relatively high rate of preterm delivery reflects reported trends.103 It seems likely that 
improvements in neonatal care and thus in the survival of preterm infants over the 
past decade have led to an increased willingness among obstetricians to undertake 
iatrogenic preterm delivery in the maternal interest. 
 
4.6.3 Predictors of outcome 
This retrospective series does not identify any particular predictors of maternal 
outcome. This is likely to be a result of the small number of women and their ability 
to adapt to their PH (particularly when associated with congenital heart disease) 
which may give a misleading NYHA class status. Right ventricular function remained 
relatively stable with only one women (E) having objective evidence of right 
ventricular decompensation prior to delivery. However, concerns regarding 
incomplete right ventricular recovery following pregnancy have been raised in 
women with congenital heart disease,120 and this issue should be addressed in pre-
pregnancy counselling. 
 
Two of the women (B and D) experienced sustained arrhythmia and of these one died. 
Data from non-pregnant women with PH suggest that sustained atrial arrhythmias 
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occur in 11.7% of women.121 The additional volume load and haemodynamic stress 
imposed by pregnancy on the already pressure-overloaded right heart may increase 
the tendency for both atrial and ventricular arrhythmia. This has previously been 
reported in other congenital lesions, where right ventricular dilatation has been shown 
to be associated with a higher incidence of arrhythmia.122,123 Although this patient 
group is too small to make any statement about the relationship of arrhythmia to 
prognosis, maternal arrhythmia has been associated with increased adverse cardiac 
events during pregnancy8 and adverse fetal outcomes.35 
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4.7 Conclusions 
 
PH in pregnancy is rare making this is one of the largest consecutive series reported. 
Nonetheless, the small numbers limit the conclusions which can be drawn. Use of 
advanced therapies has revolutionized the treatment of PH outside of pregnancy and 
although data on their use in pregnancy are limited, the safety of prostacyclin 
analogues and sildenafil during pregnancy is now supported by numerous case reports 
and several small series in the literature.2,112 Maternal and fetal outcomes for women 
with PH seem to be improving, but maternal risk remains extremely high such that 
timely and effective counselling on contraception and the hazards of pregnancy 
remain vital. It goes without saying that pregnancies in women with PH should be 
managed in a tertiary setting with ready access to the full multidisciplinary team. 
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Chapter 5:   Marfan Syndrome 
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5.1 Abstract 
 
5.1.1 Aims: 
To investigate maternal and neonatal outcomes in a series of pregnancies in 
women with Marfan syndrome  
5.1.2 Methods: 
 Retrospective review of case records 
5.1.3 Results: 
There were twenty-nine pregnancies in 21 women with no maternal deaths. 
Significant cardiac complications occurred in five pregnancies (17%): one 
woman experienced a type-A aortic dissection; two women required cardiac 
surgery within 6 months of delivery and a further two women developed 
impaired left ventricular function during the pregnancy. Women with Marfan 
syndrome were also more likely to have obstetric complications (OR 3.29, 
95% CI 1.30-8.34), the most frequent of which was postpartum haemorrhage  
(OR 8.46, 95% CI 2.52-28.38). There were no perinatal deaths, although 
babies born to mothers with Marfan syndrome were delivered significantly 
earlier than those born to the control group (median 39 versus 40 weeks of 
gestation, Mann-Whitney U-test, p = 0.04). The babies were also significantly 
more likely to be small for gestational age (SGA) (24% in the Marfan group 
versus 6% in the controls; OR 4.95, 95% CI 1.58-15.55). 
5.1.4 Conclusions: 
Pregnancy in women with Marfan syndrome continues to be associated with 
significant rates of maternal, fetal and neonatal complications. Effective pre-
pregnancy counselling and meticulous surveillance during pregnancy, delivery 
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and the puerperium by an experienced multidisciplinary team are warranted 
for these women.  
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5.2 Introduction 
 
Marfan syndrome (MFS) is a hereditary multisystem connective tissue disorder with 
autosomal dominant inheritance. It affects approximately 1 in 5000 of the 
population124 and is caused by a mutation in the fibrillin-1 gene (FBN1) on 
chromosome 15q21, (although heterozygous mutations in the tissue growth factor-B 
receptor 2 (TGFBR2) gene on chromosome 3p24.2-25 have also been identified in 
other Marfan-like syndromes).125 However, the defects are usually unique in each 
family or sporadic case and over 200 mutations have been identified. Diagnosis is 
based on the 2010 revised Ghent nosology124, rather than genetic markers; (mutations 
are not always found in those diagnosed with MFS, and conversely may be found in 
individuals who do not meet the diagnostic criteria). Eighty percent of patients have 
some cardiovascular involvement (such as aortic dilatation, aortic incompetence and 
mitral or tricuspid valve prolapse, with or without regurgitation), with abnormalities 
of the skeletal and ocular systems being the other prominent manifestations.126 The 
major causes of death associated with MFS are aortic aneurysm rupture and aortic 
dissection.127  
 
Normal pregnancy is associated with aortic dilatation and increased aortic 
compliance.57,58 A reduction in mucopolysaccharides in the aortic wall has also been 
documented.59 These factors, in combination with the haemodynamic changes of 
pregnancy, may contribute to the increased risk of aortic dissection.128,129  Recent 
guidelines suggest a 1% risk of aortic dissection or significant cardiac event in women 
with an aortic root diameter of <40mm.4 This risk in increased when the aortic root 
diameter is >40mm, if there is a rapid increase in aortic dimensions, or in the context 
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of a family history of dissection.130 Body surface area is also important, particularly in 
women of short stature: an aortic diameter index of >27mm/m2 is associated with an 
increased risk of dissection, and prophylactic surgery should be considered.4 The risk 
factors for distal dissection are less well characterized. Additionally, aortic dissection 
may occur even in the absence of dilatation.131 
        
 
Fibrillin-1 is present in the myocardium, where abnormalities of its structure may predispose 
patients with MFS to left ventricular dilatation and impairment of left ventricular function, even 
in the absence of valvular pathology.132-134 Such an effect has not yet been described in 
pregnancy.  
 
MFS may also be associated with an increase in obstetric complications, including 
preterm delivery, preterm pre-labour rupture of the membranes (PPROM), cervical 
incompetence, poor fetal outcome and postpartum haemorrhage (PPH).135-138 
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5.3 Aims 
 
To investigate maternal and neonatal outcomes in a series of pregnancies in women 
with MFS.  
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5.4 Methods 
 
Women with a diagnosis of MFS, cared for by the Joint Cardiac and Obstetric Service 
of the Chelsea and Westminster and Royal Brompton Hospitals, were identified from 
a database commenced in 1994. Only singleton pregnancies progressing beyond 24 
weeks were included. For each woman with MFS there were four controls: the two 
women who delivered immediately before and immediately after each index case, 
allowing comparison with the overall obstetric population at the Chelsea and 
Westminster Hospital while controlling for changes in demographics and practice 
over time. Four women with MFS delivered before 1998; data for control women 
were not available before this date and so women who delivered on the same date in 
1999 were used as controls. 
 
Data were collected from a detailed review of case notes supplemented by the Ciconia 
Maternity Information System (CMIS©, HD Clinical Ltd, Bishops Stortford, Herts, 
UK). In all women, demographic data and information on obstetric and anaesthetic 
management during pregnancy and labour, and maternal and neonatal outcomes was 
obtained, noting cardiac, obstetric and fetal/neonatal complications as previously 
described in chapter 3. In the Marfan group data on the aortic root diameter pre-
pregnancy (as measured at echocardiography), as well as left ventricular dimensions 
and function, and aortic root diameter during pregnancy (at serial echocardiographic 
assessments) were also gathered. The aortic root diameters were measured at the four 
standard levels (the annulus, the sinuses of valsalva, the sinotubular junction and the 
ascending aorta) in all cases (see figure 1). Any worsening of mitral or aortic 
regurgitation (as seen at echocardiography), or aortic dissection was also noted.  
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Figure 1: Diagram of the aortic root as seen at echocardiography.139  
Aortic annulus (1), sinus of valsalva (2), sinotubular junction (3), ascending aorta (4) 
 
 
 
 
Data were analysed using SPSS 22 for windows. Differences in outcomes between the 
Marfan and control groups, and between first and subsequent pregnancies in the 
Marfan group, were evaluated. Continuous variables were compared with Students t-
test if they were normally distributed and with the Mann-Whitney U-test if they were 
not. The chi-squared test or Fisher’s exact test with cell numbers <5 were used to test 
differences between relative frequencies of occurrence. All tests were two-tailed and 
p<0.05 was considered statistically significant.  
 
The echocardiographic data could not be analysed by combining all the 
measurements, as this would create an ascertainment bias (those with any observed 
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deterioration would be more likely to have more echocardiograms and would 
therefore contribute disproportionately to the results). Each case with at least two 
echocardiograms more than 6 weeks apart was analysed by calculating a regression 
line of each echocardiographic parameter measured against gestational age, and 
deriving from it the predicted measurement at 12, 28 and 36 weeks of gestation.  
Thus, every subject contributed three values to the pooled results. This also had the 
advantage of smoothing some of the inter-observer variability. 
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5.5 Results 
 
Twenty-nine pregnancies in 21 women with MFS were compared with 116 controls. 
Their baseline characteristics are shown in table 1. There was no statistically 
significant difference in age or parity between the two groups (p=0.10 and p=0.19 
respectively). Mean age at booking in the MFS group was 31.1 years (range 17 to 42) 
compared with 32.8 years (range 17 to 43) in the controls. Outcomes in nulliparous 
(n=21) and parous (n=8) women with MFS were similar (table 2). 
 
Thirteen pregnancies occurred in 9 women with mutations in the FBN1 gene. There 
were 2 pregnancies in 1 woman who tested negative for mutations in both the FBN1 
and TGFBR2 genes. Outcomes in both groups were similar. Information on genotype 
was not available in the remaining cases (14 pregnancies, 11 women).  
 
5.5.1 Cardiac outcomes 
There were three pregnancies in women with MFS who had undergone cardiac 
surgery prior to pregnancy; two of these had valve-sparing aortic root replacement 
and one had both aortic root and valve replaced.  
 
Sequential echocardiography data from 11 pregnancies (figures 1-4) were available 
for analysis as described previously and showed no significant change in either aortic 
root diameter, or left ventricular dimensions and function during pregnancy. The 
mean aortic root diameter pre-pregnancy was 39.5mm (median 40, range 26 to 81); in 
12 pregnancies it was greater than 40mm. The mean increase in aortic root diameter 
during pregnancy was 0.47mm (median 0.40mm, range 0.00 to 0.90), although on 
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regression analysis this change was not statistically significant. Beta-blockers 
(thought to confer some protection against long-term dilatation of the aortic root125,140-
142) were taken throughout 26 pregnancies (2 of the 3 pregnancies where a beta-
blocker was not taken were in women with an aortic root >40mm). The women 
concerned had declined to take them due to side effects and because they were 
concerned about published reports of an increase in fetal growth restriction associated 
with their use. 
 
There were no maternal deaths. However, significant cardiac complications occurred 
in 5 pregnancies (17%). One woman experienced a type A aortic dissection 10 days 
post-delivery which required emergency root and valve replacement. Two women 
required cardiac surgery within 6 months of delivery due to increasing dilatation of 
the aortic root in one and worsening aortic regurgitation in the other. A further two 
women developed impaired left ventricular function during the pregnancy.  
 
5.5.2 Obstetric outcomes 
Fifty-nine percent (17) of the index pregnancies resulted in vaginal delivery compared 
with 74% (86) of the controls (although this is not statistically significantly different, 
p = 0.1127). However, births in women in the MFS group who delivered vaginally 
were more likely to be assisted (using forceps or ventouse) than those in unaffected 
women (71% (12/17) and 17% (15/86) respectively, OR 11.36, 95% CI 3.48 to 
37.08). There was a trend towards a longer second stage in the MFS group ((median 
67 minutes (range 7-136) in the MFS group and 30.5 minutes (4-187) in the controls 
(p=0.0673)), although the difference did not quite reach statistical significance. There 
was no statistically significant difference in the overall Caesarean section rate 
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between the groups (12/29 (41%) in the MFS group compared with 30/116 (26%) in 
the controls, p=0.11); proportions of elective versus emergency Caesarean section 
were also similar (p=0.32 and p=0.65 respectively). Nine of the Caesarean sections in 
the MFS group were performed for obstetric reasons (1 emergency, 8 elective) and 3 
for cardiac reasons (all elective): progressive aortic root dilatation or deteriorating left 
ventricular function. Of the pregnancies in the MFS group which resulted in vaginal 
delivery, 13 (76%) had regional anaesthesia compared with 40 (47%) of the controls 
(OR 3.7, 95% CI 1.13 to 12.39). Of those which ended in Caesarean section, two 
cases (16%) in the MFS group required general anaesthesia compared with two (7%) 
in the controls (p=0.56). 
 
The rate of obstetric complications was significantly higher in the MFS group (OR 
3.6, 95% CI 1.48 to 8.76) with obstetric complications occurring in 12 (41%) 
pregnancies. One woman developed pregnancy-induced hypertension (PIH); one had 
a significant antepartum haemorrhage (APH) and 10 had PPH. In the control group, 
19 (16%) women had obstetric complications: One woman developed PIH, 5 pre-
eclampsia (PET), 1 had a significant APH, 8 PPH and 4 women experienced 
spontaneous preterm labour. In particular, the women with MFS had a higher 
incidence of PPH (OR 7.1; 95% CI 2.49 to 20.30). 
 
5.5.3 Fetal and Neonatal Outcomes 
There were no fetal or neonatal deaths, but complications occurred more often in the 
MFS group (OR 3.12; 95% CI 1.272 to 7.652). Median gestational age at delivery in 
the MFS group was 39 weeks (range 35 to 42), significantly earlier than in the control 
group (median 40, range 27 to 42; p=0.04, MWU test). Pre-term delivery rates were 
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similar in both groups. Of the babies born to mothers with MFS, two (7%) were 
delivered pre-term compared with 5 (4%) of those with unaffected mothers. Both of 
the pre-term babies in the MFS group were delivered iatrogenically early for maternal 
reasons compared with only one of the 5 pre-term babies in the control group. Mean 
and median birth weight and birth weight centile were lower in the MFS group: 3068g 
(median 3030g, range 2300 to 3900g), 29th centile (median 20, range 0  to 92) versus 
3324g (median 3380g, range 920 to 4450g), 49th centile (median 48, range 0 to 100) 
in the controls (p=0.0067 (t test) and p=0.0012 (MWU test) respectively). The MFS 
group babies were also more likely to be small for gestational age (SGA) with 7 
(24%) of babies in the MFS group being SGA compared with 7 (6%) of those born to 
control women (OR 4.95; 95% CI 1.58 to 15.55). Additionally in the MFS group, 
there was no relationship between birth weight and maternal height (r=0.03, p=0.346) 
(Fig 5). Six of the babies born to index cases were subsequently found to have the 
same genotype as their mothers, with 8 found to be unaffected. In 15 babies the 
genotype is unknown. There were insufficient data to determine whether any of the 
offspring met the Ghent criteria for diagnosis of MFS.  
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Table 1: Baseline characteristics, mode of delivery, use of anaesthesia, birth weight 
and birth weight centiles, and complications in women with MFS and controls 
 
 MFS Controls  
Number of women 21 116  
Number of pregnancies 29 116  
 mean (SD) mean (SD)  
Age at booking(yrs) 31.1 (5.0) 32.8 (5.5) p=0.1 
Maternal Height (cm) 179 SD 8.7 164 SD 7.7 p<0.0001 
 median (range) median (range)  
Maternal Weight (kg) 69 (49 – 120) 60 (45 – 102) p=0.007 
 n (%) n (%)  
Parity 
Nulliparous 
Para 1 
   
21 (72) 69 (59)  
8 (28) 47 (41)  
Mode of delivery 
 
SVD 
 
Assisted vaginal 
delivery 
 
Elective CS 
 
Emergency CS 
 
 
 
 
 
 
 
5(17) 
 
12(41) 
71 (61) 
 
15(13) 
OR 0.13 
(0.04 - 0.37) 
OR 4.75 
  (1.9 – 11.9)  
9 (31) 24 (21)  
3 (11) 6 (5)  
Regional anaesthesia for 
vaginal delivery 13 (76) 40 (47) 
OR 3.7 
(1.13 – 12.39) 
 median (range) median (range)  
Length of 2nd stage 
(mins) 67 (7-136) 30.5 (4-187) p=0.07 
Gestational age at 
delivery(wks) 39 (35-42) 
40 (27-42) 
 p=0.04 
 mean (SD)  mean (SD)  
Birth weight(g) 3068 (471) 3324 (505) p=0.007 
 median (range)  median (range)   
Customised birth weight 
centile 
 
29 (0-92) 
 
 
49 (0-100) 
 
p=0.001 
 n (%) n (%)  
Distribution of birth 
weight centiles 
90-100 
75-89 
50-74 
25-50 
10-24 
0-9 
 
 
2 (7) 
0 (0) 
6 (21) 
4 (13) 
6 (21) 
11 (38) 
 
 
11 (10) 
20 (17) 
25 (22) 
34 (29) 
12 (10) 
14 (12) 
 
Obstetric complications 10 (34) 16 (14) OR 3.29 (1.3 – 8.34) 
PPH 8 (28) 5 (4) OR 8.46 (2.52 – 28.38) 
Neonatal complications 9 (31) 12 (10) OR 3.9 (1.45 – 10.47) 
SGA 7 (24) 7 (6) OR 4.95 (1.58 – 15.55) 
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Table 2: Comparison of 1st and 2nd pregnancies in women with MFS 
 
 
 
 
1st Pregnancy 2nd Pregnancy 
 
Number of 
pregnancies 21 8 
 
 mean (SD) mean (SD)  
Maternal age at 
booking 30.19 (5.4) 33.5 (2.3) p=0.03 
 median (range) median (range)  
Maternal Weight 
(kg) 63 (49 – 120) 71 (59 – 120) p=0.21 
 n (%) n (%)  
Mode of Delivery    
SVD 3 (14) 2 (25)  
Assisted vaginal 
delivery 9 (43) 3 (38) 
 
Elective CS 7 (33) 2 (25)  
Emergency CS 2 (10) 1(12)  
 median (range)  median (range)  
Gestational age at 
delivery (weeks) 39.1 (35 – 42) 38.4 (37 – 40)  
 
p=0.19 
 
 mean (SD) mean (SD)  
Birth weight (g) 2995 (476.8) 3258 (430.1) p=0.18 
Birth weight centile 25.2 (25.8) 40.5 (36.9) p=0.31 
Aortic root pre-
pregnancy (mm) 39 (1.3) 40 (0.5) 
 
p=0.86 
 
 n (%) n (%)  
Cardiac 
complications 4 (19) 1(12) 
 
Obstetric 
complications 7 (33) 3 (38) 
 
Neonatal 
complications 7 (33) 2 (25) 
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Figure 2: Echocardiographic measurement of left ventricular diastolic dimensions 
during pregnancy in women with MFS 
(Women who developed LV dysfunction in red) 
 
 
 
 
LVEDD: left ventricular end-diastolic diameter 
 
Figure 3: Echocardiographic measurement of left ventricular systolic dimensions 
during pregnancy in women with MFS 
(Women who developed LV dysfunction in red)  
 
 
 
LVEDS: left ventricular end-systolic diameter  
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Figure 4: Echocardiographic measurement of fractional shortening during pregnancy 
in women with MFS 
(Women who developed LV dysfunction in red) 
 
 
 
FS: fractional shortening 
 
 
Figure 5: Echocardiographic measurement of ejection fraction during pregnancy in 
women with MFS 
(Women who developed LV dysfunction in red) 
 
 
 
EF: ejection fraction 
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Figure 6: Relationship between maternal height and birth weight in Marfan women 
 
 
     r=0.03, p=0.346 
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5.6 Discussion 
 
Pregnancy in women with MFS is associated with a high risk of maternal and fetal 
complications. In this series of 29 pregnancies in 21 women with MFS, there were no 
maternal or fetal deaths, but there was a significantly higher rate of obstetric and fetal 
adverse outcomes in the MFS group compared with healthy controls. Other than age 
at booking, baseline characteristics and outcomes between first and second 
pregnancies in the MFS group were similar (table 2). This may reflect a selection bias 
in that women with signs of deterioration in their first pregnancy may have been 
counselled against a further pregnancy, but there is no direct evidence that this was 
the case.  
 
5.6.1 Maternal Outcomes 
Cardiovascular complications 
Significant cardiovascular complications occurred in 5 pregnancies (17%) with 3 
women requiring surgery within 6 months of delivery. There was one case of aortic 
dissection (3% of pregnancies). Pregnancy in the general population has been shown 
to increase the risk of aortic dissection;128,143 this risk is even higher in women with 
MFS. Several studies have sought to evaluate the rate of aortic dissection in women 
with MFS during pregnancy135,144,145-148. European Guidelines4 suggest that women 
with minimal cardiovascular involvement and an aortic root diameter of <40mm have 
an estimated risk of 1% of dissection or other serious cardiac complications, whereas 
in high risk women (aortic root diameter > 40mm, rapid aortic dilatation or previous 
dissection) the risk may be as high as 10%.4 The 5 patients in this study who 
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experienced serious cardiovascular complications all had pre-pregnancy aortic root 
diameters in excess of 40mm. However, there is still disagreement over the aortic root  
diameter above which pregnancy should be discouraged: in their prospective study of 
127 women with MFS, Meijboom and colleagues suggest that in low-risk women, 
without prior history of cardiovascular complications, a root diameter of up to 45mm 
appears to be relatively safe.130 In this study aortic dissection occurred in one woman 
with a pre-pregnancy root diameter of 42mm and no previous history of 
cardiovascular events, and left ventricular dysfunction developed in a woman with a 
pre-pregnancy root-diameter of 41mm who had in fact undergone a previous elective 
valve-sparing aortic root replacement. Elective aortic root replacement in high risk 
Marfan women has been shown to reduce the risk of complications during pregnancy, 
and prophylactic surgery has been suggested if the diameter is >44mm in women who 
desire pregnancy; this could potentially have been offered to 3 women4. Four of the 
five women who developed cardiac complications during pregnancy did not have pre-
pregnancy counselling, highlighting the need to raise awareness of the issues of heart 
disease and pregnancy among professionals and patients alike. Three women had their 
care transferred to the Chelsea and Westminster and Royal Brompton Hospitals 
during the pregnancy and it is not clear what, if any, pre-pregnancy counselling they 
had received. Aortic dissection has been reported in MFS women with a normal aortic 
root diameter.149 Therefore it may be prudent to recommend that all pregnant women 
with MFS (regardless of aortic root diameter) remain in hospital for seven days 
following delivery, with echocardiography prior to discharge to exclude rapid 
postnatal aortic dilatation. 
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Two women developed impaired left ventricular function during their pregnancies. 
Although this may occur in MFS as a consequence of significant aortic or mitral valve 
disease, it has also been described (in non-pregnant subjects) in the absence of 
valvular pathology.132,134,150  In this series one woman had no valvular pathology prior 
to pregnancy and another had mild to moderate mitral regurgitation, which remained 
stable throughout the pregnancy. The pathogenesis of MFS-related left ventricular 
dysfunction is poorly understood. It has been suggested that mutations in the FBN1 
gene may cause structural or functional abnormalities in the microfibrils which 
subsequently lead to impairment of myocardial contraction.134 It is important to 
distinguish the deterioration in left ventricular function seen in these two women from 
that seen in peripartum cardiomyopathy (PPCM). PPCM is defined as ‘an idiopathic 
cardiomyopathy presenting with heart failure secondary to left ventricular systolic 
dysfunction towards the end of pregnancy or in the months following delivery, where 
no other cause of heart failure is found. It is a diagnosis of exclusion. The left 
ventricle may not be dilated but the ejection fraction is nearly always reduced below 
45%’.151 The incidence of PPCM is estimated to be around 0.025 to 0.04%.151 This 
compares with an incidence of left ventricular dysfunction in our index group of 
6.8%. Neither of our patients displayed signs or symptoms of heart failure; the 
diagnosis was based entirely on echocardiographic findings. In the first case a dilated 
left ventricle was found in the second trimester and in the second it was discovered in 
the third trimester. Both women showed a rapid improvement in left ventricular 
function at one week postnatal, and by the sixth postnatal week left ventricular 
function had returned to baseline in both, although the dilatation persisted. Left 
ventricular dysfunction in MFS patients may be mediated through the transforming 
growth factor-β (TGF-β) signalling pathway and elevated TGF-β1 gene expression 
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has been noted in ventricular biopsies from patients with dilated cardiomyopathy 
(DCM).134 In contrast, it is now accepted that PPCM is not simply an aggravation of 
underlying DCM, but is a separate entity.151 It is likely that the changes in left 
ventricular function seen in MFS are accelerated by the physiological volume 
overload of pregnancy. 
 
Beta-blockers were taken in 26 of the 29 pregnancies studied. Three women declined 
them due to their inability to tolerate the side effects of dizziness, tiredness and 
hypotension, and concern about fetal growth. In non-pregnant patients, beta-blockers 
have been shown to have a small impact on the rate of growth of the aortic root.125,140-
142 In addition to their negative inotropic effect, they also increase aortic distensibility 
and reduce aortic stiffness.125,140-142 Beta-blockers  have been used extensively in 
pregnancy, especially for treatment of hypertension. However they are excreted in 
breast milk and their use is associated with side effects including fetal growth 
restriction, and neonatal hypoglycaemia, hyperbilirubinaemia and bradycardia. Use of 
beta-blockers may account for the significant difference in birth weight seen between 
the study group and the control population.  
 
Obstetric Complications 
Obstetric complications occurred in 12 (41%) of pregnancies in the index group, a 
significantly higher rate than in the controls. The most frequent complication seen 
was PPH, which occurred in 10 of the 29 (34%) MFS pregnancies studied compared 
with 8 of 116 (6.7%) pregnancies in the control group. Rates of other complications 
such as PET, PIH and gestational diabetes were similar in both groups. Higher rates 
of PPH have previously been reported in women with MFS and other connective 
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tissue disorders.138,152 FBN1 is present in the myometrium153 and might explain the 
higher rate of PPH as a result of uterine atony.  There may also be an association with 
the low dose syntocinon infusion (to prevent the systemic hypotension associated with 
its use) used to manage the third stage of labour in women with significant cardiac 
disease.4,5 However, a recent double-blind, randomised controlled trial reported that 
higher doses of oxytocin did not reduce rates of PPH when compared to a low dose,154 
(the low dose was similar to that used for the patients in this study, and recommended 
by the RCOG5 and the ESC4). 
 
Vaginal delivery rates in the two groups were similar (59% for the MFS group versus 
74% for the controls), however the rate of assisted delivery was significantly higher 
for women with MFS. This reflects the policy at the Chelsea and Westminster and 
Royal Brompton Hospitals to recommend either an elective assisted delivery or a 
shortened active second stage in women with serious cardiac disease in order to 
minimise the cardiovascular stress associated with active bearing down (despite a lack 
of evidence proving any benefit78). It is therefore surprising that the length of the 
second stage was longer in the Marfan group (median 67 minutes (range 7-136) in the 
MFS group and 30.5 minutes (4-187) in the controls (p=0.0673)), although the 
difference did not quite reach statistical significance. This may be due to the women 
with MFS having a relatively longer passive second stage to allow for adequate 
descent of the fetus prior to commencement of active pushing or assisted delivery. 
Epidural analgesia is recommended as it thought that the avoidance of pain will limit 
the haemodynamic changes and progressive rise in cardiac output seen with 
contractions.28 Caesarean section rates were similar between the two groups. The data 
presented in this study suggests that vaginal delivery under controlled conditions 
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would appear to be safe for MFS women, and avoids the increased risks of 
haemorrhage, infection and thromboembolism associated with caesarean section.83 
 
5.6.2 Fetal and Neonatal Outcomes 
There were no fetal or neonatal deaths. However, complications were more likely for 
babies born to mothers with MFS. The MFS group had a significantly earlier 
gestational age at delivery (median 39 weeks) than the control group (median 40 
weeks), although there was no significant difference in preterm delivery rates. MFS 
and other connective tissue disorders have been associated with PPROM and 
spontaneous preterm labour and it has also been suggested that there is a relationship 
between PPROM and connective tissue disease in the neonate.136,137 However, none 
of the women with MFS in this series experienced either of these complications. This 
may be a chance finding due to small numbers.  
 
Significantly more babies in the MFS group were SGA (24% versus 7%). 
Mean/median birth weight and birth weight centile were also significantly lower. This 
may be explained by the use of beta-blockers in the majority of these women, 
whereby the negative inotropic effect reduces cardiac output and thus utero-placental 
perfusion; (beta-blockers were taken throughout 26 of 29 pregnancies). A computer 
generated chart was used to calculate customized birth-weight centiles, taking into 
account maternal ethnicity, parity, height and weight.88,89 The women with MFS were 
significantly taller than the controls (p<0.0001) as might be expected, and this might 
explain some of the difference between the two groups. However, even when standard 
centile charts (ie. not customized for maternal ethnicity, height and weight) were 
used, the MFS group neonates still had significantly lower birth weight centiles 
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compared with the controls (mean 42 +/- 29 versus mean 54 +/- 27; p=0.0485). 
Additionally there was no relationship between maternal height and birth weight in 
the MFS group (figure 5), which is contrary to that usually found (taller mothers 
usually have bigger babies). It is possible that this is a reflection of the severity of 
MFS in these women.  
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5.7 Conclusions 
 
This study demonstrates that pregnancy in women with MFS continues to be 
associated with significant rates of maternal, fetal and neonatal complications. 
Unfortunately the small numbers limit the conclusions that can be drawn; further 
prospective multi-centre studies, in particular investigating changes in cardiac 
function, dimension and haemodynamics in these women, are indicated. The cohort 
studied reflects women under the care of the Royal Brompton and Chelsea and 
Westminster Hospitals and therefore a referral bias is possible, if not likely. However, 
the findings reinforce the need for effective pre-pregnancy counselling, as well as 
meticulous surveillance during pregnancy, delivery and the puerperium by an 
experienced multidisciplinary team. 
 
 
 
 
 
  
! "$'!
Chapter 6: Valvular Heart Disease 
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6.1 Abstract 
 
6.1.1 Aims:  
To investigate maternal and neonatal outcomes in a series of pregnancies in 
women with valvular heart disease   
6.1.2 Methods: 
 Retrospective review of case records 
6.1.3 Results: 
There were one hundred and thirty-one pregnancies in 73 women with 
valvular heart disease. Significant cardiac complications occurred in nine 
pregnancies (6.5%), and were most frequent in women with left heart 
obstruction or mechanical valves (19.4% and 25% respectively). There was 
one maternal death in a woman who suffered thrombosis of a mechanical 
aortic valve. Cardiac events during the pregnancy correlated with adverse 
perinatal outcomes (r=0.24, p=0.0006). Rates of obstetric complications in 
women with valvular heart disease and controls were similar, although 
postpartum haemorrhage occurred more frequently in women with mechanical 
prostheses than in the control women (OR 8.98, 95% CI 2.07-39.07, p=0.004). 
Perinatal complications occurred more frequently in women with valvular 
heart disease, (and were most frequent in those with left heart obstruction and 
mechanical valves) than in the control women. Presence of a mechanical 
prosthetic valve was independently associated with adverse perinatal outcome 
(OR 7.26, 95% CI 1.33-44.73, p=0.01). There were three neonatal deaths and 
one pregnancy was terminated at 25 weeks following diagnosis of severe 
intracranial haemorrhage in the fetus. Babies born to women with valvular 
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heart disease were significantly more likely to be delivered preterm (before 37 
completed weeks’ gestation) for medical reasons (OR 11.92, 95% CI 54.62, 
p=<0.001) and to be small for gestational age  (birth weight less than the 5th 
customized centile) (20.6% in the valve group versus 2.7% in the controls; OR 
9.46, 95% CI 3.99-22.40, p<0.001).  
 
6.1.4 Conclusions: 
Pregnancy in women with valvular heart disease, in particular those with left 
heart obstruction, mechanical prosthetic valves and those who have undergone 
previous surgery, is associated with significant rates of maternal, fetal and 
neonatal complications. Previous cardiac surgery is an independent predictor 
for adverse fetal/neonatal outcomes. 
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6.2 Introduction 
 
Valvular heart disease (VHD) is common in pregnancy (25% of patients enrolled in 
an international registry between 2007 and 2011 had VHD38) and significantly 
increases maternal and fetal risk. Furthermore, patients with VHD are often not 
known to have heart disease prior to pregnancy, the diagnosis only being made when 
the haemodynamic challenges of pregnancy lead to decompensation and development 
of symptoms. The aetiologies are varied and may result from congenital abnormalities 
or acquired lesions (table 1)155  and one or more valves may be involved. In pregnant 
women in the developed world, aortic stenosis (AS) is usually congenital, and mitral 
stenosis (MS) usually rheumatic, in origin.  
 
Despite a decline in the incidence of rheumatic heart disease (RHD) in Europe and 
North America it accounts for over 90% of cardiac disease in pregnancy worldwide, 
with rheumatic MS the most common lesion.156,157 One in four women giving birth in 
the UK are born abroad, many having emmigrated from countries where rheumatic 
fever is endemic.79 Approximately 3% of patients with untreated group A 
streptococcal pharyngitis go on to develop rheumatic fever. It is thought that cross-
reactivity of either the streptococcus toxin or a bacterial antigen, with proteins in the 
valvular endocardium results in inflammatory changes and formation of scar-tissue, 
and subsequent valve dysfunction.157,158 RHD in developing countries is characterized 
by the occurrence of severe VHD at a younger age than that generally seen in 
developed countries.  
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Table 1: Aetiology of valvular heart disease in women of childbearing age (adapted 
from Nanna & Stergiopoulos, 2014)155 
 
Aortic valve  
x Congenital bicuspid valve 
x Rheumatic valvular disease 
x Connective tissue disorder 
x Marfan syndrome, Ehlers Danlos syndrome, Turner’s syndrome or other aortic 
disease resulting in or associated with aortic valve disease 
x Prosthetic valve (mechanical or bioprosthesis) 
x Prior history of infective endocarditis 
x Ross procedure 
Mitral valve  
x Congenital valvular stenosis 
x Myxomatous valve disease (mitral valve prolapse) 
x Rheumatic valvular disease 
x Prior infective endocarditis 
x Prosthetic valve (mechanical or bioprosthesis) 
x Hypertrophic cardiomyopathy with systolic anterior motion of the mitral valve 
x Tethered mitral valve related to dilated cardiomyopathy 
Pulmonary valve  
x Congenital pulmonary stenosis, Noonan syndrome, post-operative Tetralogy 
of Fallot 
x Pulmonic regurgitation (native or residual after interventional or surgical 
correction of more complex congenital heart disease) 
x Prosthetic valve (bioprosthesis) 
 
Increases in aortic root dimensions and the size of the mitral and tricuspid annuli have 
been observed in normal pregnancy using echocardiography.57,58,159 As a result, mild 
valvular regurgitation is a common occurrence in healthy pregnant women with the 
mitral, tricuspid and pulmonary valves exhibiting a degree of insufficiency in up to 
28%, 94% and 94% of pregnancies respectively.159 
 
Maternal and fetal risks vary with the type and severity of the valve lesion; the 
presence of resulting abnormalities of functional capacity, left ventricular function 
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and pulmonary artery pressure are important prognostic factors. Left-sided stenotic 
lesions are particularly poorly tolerated.4,52,54-56,155-158 
 
The first successful heart valve replacement in a human was reported in the US in 
1960.160 Prosthetic heart valves (PHVs) may be bioprosthetic (heterografts 
(commonly of porcine origin), homografts and autografts (as used in the Ross 
procedure)) or mechanical. While bioprosthetic valves (BPVs) are associated with a 
low risk of thromboembolism during pregnancy, (thus obviating the need for 
anticoagulation and the haemorrhagic risks to both mother and fetus associated with 
this), if they are used in young women there is a high risk of structural valve 
deterioration and the need for re-operation over time. Early mortality for re-operation 
in such populations has been reported to be as high as 8.7%.160 It has been suggested 
that pregnancy accelerates this process, although the data are conflicting.78,160 
Mechanical prostheses (MPVs) have been shown to have excellent long-term 
durability and have a superior haemodynamic profile compared with bioprostheses. 
However, they are highly thrombogenic and life-long anticoagulation is required. This 
presents particular problems during pregnancy, with a need to balance the risk of 
valvular thromboembolism with haemorrhagic risk. There remains contention as to 
the ideal anticoagulant regimen in pregnancy for women with MPVs.4,78 
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6.3 Aims 
 
To investigate maternal and neonatal outcomes in a series of pregnancies in women 
with VHD.  
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6.4 Methods 
 
Women with VHD cared for by the Joint Cardiac and Obstetric Service of the Chelsea 
and Westminster and Royal Brompton Hospitals, were identified from a database 
commenced in 1994. For each birth to a woman with VHD there were two controls 
(matched for parity): the first woman who delivered immediately before and after 
each index case. Seventeen women with VHD delivered before 1998; data for control 
women were not available prior to this date and so the first women who delivered on 
the same date in 1999 were used as controls. 
 
Data were collected from a detailed review of case notes supplemented by the Ciconia 
Maternity Information System (CMIS©, HD Clinical Ltd, Bishops Stortford, Herts, 
UK). In all women, demographic data and information on obstetric and anaesthetic 
management during pregnancy and labour, and maternal and neonatal outcomes was 
obtained, noting cardiac, obstetric and fetal/neonatal complications and intra-partum 
events as previously described in chapter 3. The VHD population was divided into six 
subgroups: those associated with left heart obstruction (LHO), left heart regurgitation 
(LHR), right heart obstruction (RHO), right heart regurgitation (RHR), and those 
associated with bioprosthetic (BPV) and mechanical prosthetic valves (MPV). 
Women with isolated mitral valve prolapse and isolated bicuspid aortic valve (ie. with 
no haemodynamic consequences) were excluded. 
 
Data were analysed using SPSS 22 and GraphPad Prism version 6.0d. Descriptive 
statistics for nominal data are expressed in absolute numbers and percentages. Mean 
value and standard deviations are presented for normally distributed continuous 
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variables and for non-normally distributed continuous variables, median and range. 
Differences in outcomes between the VHD and control groups, and between first and 
subsequent pregnancies in the VHD group, were evaluated. Continuous variables 
were compared with the Student t-test if they were normally distributed and the 
Mann-Whitney U-test if they were not. When comparing frequencies the chi-squared 
test or Fisher exact test where applicable, was used. All tests were two-tailed and 
p<0.05 was considered statistically significant. Binary logistic regression was 
performed to identify patient characteristics associated with adverse pregnancy 
outcome divided into 3 composite endpoints (as defined previously): cardiac, obstetric 
and fetal/neonatal complications. The following baseline variables were assessed: 
LHO, LHR, RHO, RHR, presence of a BPV, presence of an MPV, use of any 
anticoagulant, use of warfarin, use of therapeutic doses of LMWH, use of 
prophylactic doses of LMWH, use of beta-blockers, parity, maternal cigarette 
smoking during the pregnancy, previous cardiac surgery and cardiac events prior to 
pregnancy. Variables that were associated with an increased incidence of the studied 
endpoints (p<0.1) were brought forward to multivariable analysis. 
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6.5 Results 
 
 
One hundred and thirty-one pregnancies in 73 women with VHD were compared with 
262 controls.  
 
6.5.1 Baseline characteristics 
Baseline characteristics for women with VHD and controls are shown in table 2. 
Women with VHD were significantly younger than the control women. Mean age at 
booking in the VHD group was 30 years (SD 5.7) compared with 34 years (SD 5.0) in 
the controls (p<0.0001, student t-test). Women with VHD were also significantly 
more likely to be taking cardiac medication, in particular anticoagulants (OR 18.09, 
95% CI 4.09-79.98, p<0.001) or aspirin (OR 8.71, 95% CI 2.41-31.44, p<0.001).  In 
women with VHD outcomes in nulliparous (n=73) and parous (n=58) women were 
similar (table 3), although as was expected nulliparous women were more likely to 
require an assisted vaginal delivery (ventouse or forceps) than parous women (OR 
3.99, 95% CI 1.50-10.61, p<0.01).  
 
6.5.2 Diagnoses 
The types of valvular lesions are shown in figure 1 below. Most pregnancies were in 
women with aortic valve disease (34%), followed by mitral valve disease (32%). 
Eighteen pregnancies (14%) occurred in women with PHVs: ten of these were in 
women with BPVs and eight in women with MPVs.  
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6.5.3 Maternal and fetal/neonatal outcomes 
Table 4 outlines the mode of delivery, gestational age, birth weight, birth weight 
centile and cardiac, obstetric and neonatal complications in women with VHD and the 
controls. Table 5 displays the subgroup analysis, with outcomes in each subgroup of 
valvular heart disease (LHO, LHR, RHO, RHR, BPV and MPV) being compared with 
those in the control group. Outcomes in women taking anticoagulants are detailed in 
Table 6.  
 
Cardiac outcomes 
Significant cardiac complications occurred in 9 pregnancies (6.5%) in the VHD 
group. There was one maternal death. Cardiac complications were most likely to arise 
in women with LHO or MPVs. There were 7 adverse events in pregnancies in women 
with LHO, including myocardial infarction (1), pulmonary oedema (1) (in women 
with moderate and severe MS respectively), clinically significant arrhythmia (2) and 
acute angina (1) (all in women with severe AS) and endocarditis (2 – in one woman 
with a previous mitral valve repair, and in another with moderate AS). 3 
complications arose in 2 pregnancies in women with MPVs: a woman with a Starr-
Edwards mitral valve developed endocarditis and subsequent valve thrombosis at 25 
weeks’ gestation, requiring emergency valve replacement and delivery by caesarean 
section. The baby did not survive. A further woman with a St Jude’s aortic valve 
suffered valve thrombosis at 36 weeks’ gestation and died. 
 
Obstetric outcomes 
Frequencies of the different modes of delivery (spontaneous vaginal delivery (SVD), 
assisted vaginal delivery and Caesarean section – both elective and emergency) were 
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similar in both the women with VHD and the controls. Overall there was no 
statistically significant difference in rates of obstetric complications between the two 
groups (p=0.08). However, women with MPVs were more likely than control women 
to have obstetric complications (87.5% versus 27.9%, OR 18.12, 95% CI 2.19-150.0, 
p=0.0010), specifically an increased rate of postpartum haemorrhage (PPH) (71.4% 
versus 15.6%, OR 8.98, 95% CI 2.07-39.07, p=0.004), although there was a 
correlation between the presence of an MPV and the use of anticoagulants (r=0.66, 
p=0.01). 
 
Fetal and neonatal outcomes 
Neonatal complications occurred in 40 (30.5%) of the index pregnancies compared 
with 18 (6.9%) in the controls (OR 5.54, 95% CI 3.01-10.19, p<0.0001) and arose 
most frequently in pregnancies in women with LHO or MPVs (41.7% and 75.0% 
respectively).  
 
There were 3 neonatal deaths in the VHD group. The baby born to the woman who 
suffered mitral valve thrombosis and was delivered at 25 weeks, died of 
complications of prematurity. In her next pregnancy she was delivered at 32 weeks 
after developing pre-eclampsia. The baby developed necrotizing enterocolitis and 
died on the 7th postnatal day. The last neonatal death occurred in an SGA baby born at 
35 weeks’ gestation to a woman with moderate to severe AS, following an abruption 
and preterm labour. One woman with a metallic mitral valve who was taking warfarin 
opted for termination of pregnancy at 24 weeks following diagnosis of severe 
intracerebral haemorrhage in the fetus. 
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Women with VHD were more likely than control women to be delivered preterm for 
medical reasons (OR 11.92, 95% CI 2.60 to 54.62, p<0.001), especially if they had 
LHO or PHVs. Iatrogenic preterm delivery occurred more frequently in women being 
treated with dose-adjusted LMWH than in those taking prophylactic doses (71.4% vs 
12.5%, OR 20.0, 95% CI 1.42-282.6, p=0.035). Median birth weight and mean birth 
weight centile were lower in women with heart disease: 3230g (range 420-4630) and 
38th centile (SD 28) versus 3420g (range 1500-4650) and 49th centile (SD 54) in the 
controls (p=0.0006 (MWU test) and p=0.003 (student t-test) respectively). The VHD 
babies were also more likely to be small for gestational age with 27 (20.6%) of the 
babies in this group having a birth weight less than the 5th customized centile 
compared with 7 (2.7%) of the control women (OR 9.46, 95% CI 3.99-22.40, 
p<0.001).  
 
Perinatal complications were associated with both maternal cardiac complications and 
obstetric complications (r=0.24, p=0.0006 and r=0.27, p=0.02 respectively).  
 
6.5.4 Logistic Regression  
Tables 7-8 illustrate the results of the univariable and multivariable logistic regression 
analysis. There were no independent predictors of cardiac or obstetric complications 
in women with VHD. Presence of an MPV was independently associated with 
neonatal complications (OR 7.26, 95% CI 1.33-44.73, p=0.01).  
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Table 2: Baseline characteristics in women with VHD and controls 
 
 
 VHD Controls  
Number of women 73 262  
Number of pregnancies 131 262  
 mean (SD) mean (SD)  
Age at booking (years) 30 (5.7) 34 (5.0) p<0.0001 
 n(%) n(%)  
Parity    
Nulliparous 73 (55.7) 141 (55.7)  
Para 1 
Para >1 
45 (34.4) 
13 (9.9) 
90 (34.4) 
321(9.9) 
 
Cardiac medications    
Any 22 (16.7) 5 (1.9) OR 10.37 (3.83-28.11)*** 
β-blocker 1 (0.8) 0 (0.0)  
Other antiarrhythmic 1 (0.8) 0 (0.0)  
Diuretic 1 (0.8) 0 (0.0)  
Anticoagulant 16 (12.2) 2 OR 18.09 (4.09-79.98)*** 
Warfarin 1 (0.8) 0  
Therapeutic LMWH 7 (5.3) 0 OR 36.63 (1.79-558.6)*** 
Prophylactic LMWH 8 (6.1) 2 (0.8) OR 8.46 (1.77-40.4)** 
Aspirin 12 (9.2) 3 (1.1) OR 8.71 (2.41-31.44)*** 
Other antihypertensive 0 (0.0) 2 (0.8)  
Smoking 9 (6.9) 12 (4.6)  
 
VHD: valvular heart disease; LMWH: low molecular weight heparin; OR: odds ratio 
 
P values: Fisher’s exact test   
*p<0.05   
** p<0.01 
*** p<0.001 
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Table 3: Comparison of pregnancy outcomes in nulliparous and parous women with 
VHD 
 
 1st pregnancy Subsequent pregnancies  
Number of pregnancies 73 58  
 mean (SD) mean (SD)  
Age at booking (years) 29 (6.0) 32 (5.0) p=0.0048 
 n (%) n (%)  
Previous cardiac 
surgery 32 (43.8) 36 (62.1)  
Previous cardiac events 5 (6.8) 6 (10.3)  
Cardiac medications    
None 62 (84.9) 48 (82.8)  
B-blocker 0 (0.0) 1 (1.7)  
Other antiarrhythmic 1 (1.4) 0 (0.0)  
Diuretic 0 (0.0) 1 (1.7)  
Anticoagulant 9 (12.3) 7 (12.1)  
Warfarin 1 (1.4) 0 (0.0)  
Therapeutic LMWH 4 (5.5) 3 (5.2)  
Prophylactic LMWH 4 (5.5) 4 (6.9)  
Aspirin 6 (8.2) 5 (8.6)  
Other antihypertensive 0 (0.0) 0 (0.0)  
Smoking 5 (6.8) 4 (6.9)  
Mode of delivery    
SVD 26 (35.6) 33 (57.0) OR 0.42 (0.21-0.85)* 
Assisted vaginal delivery 23 (31.5) 6 (10.3) OR 3.99 (1.50-10.61)** 
Elective CS 8 (11.0) 9 (15.5)  
Emergency CS 16 (21.9) 10 (17.2)  
 median (range) median (range)  
Gestational age at 
delivery (weeks) 40 (25-42) 39 (29-42)  
Birth weight (g) 3230 (420-4630) 3235 (1225-4370)  
 mean (SD) mean (SD)  
Customised birth weight 
centile 40 (27) 36 (29)  
 n (%) n (%)  
Cardiac complications 5(6.8) 3 (5.2)  
Obstetric complications 25 (34.2) 20 (34.5)  
Neonatal complications 23 (31.5) 17(29.3)  
 
VHD: valvular heart disease; LMWH: low molecular weight heparin; SVD: spontaneous vaginal delivery;  
CS: Caesarean section; OR: odds ratio 
 
P values: Fisher’s exact test   
*p<0.05   
** p<0.01 
*** p<0.001 
  
! "&"!
Figure 1: Distribution of VHD in the pregnancies studied 
 
a.  All diagnoses 
 
 
 
MS: mitral stenosis; MR: mitral regurgitation; AS: aortic stenosis; AR: aortic 
regurgitation; PS: pulmonary stenosis; PR: pulmonary regurgitation; TR: tricuspid 
regurgitation; PHV: prosthetic heart valve 
 
b.  Prosthetic Heart Valves 
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Table 4: Outcomes in all women with VHD vs controls 
 
 VHD Controls  
Number of 
pregnancies 131 262  
 n (%) n (%)  
Mode of delivery    
SVD 59 (45.0) 138 (52.7)  
Assisted vaginal 
delivery 29 (22.1) 44 (16.8)  
Elective CS 17 (13.0) 45 (17.2)  
Emergency CS 26 (19.9) 35 (13.3)  
 median (range) median (range)  
Gestational age 
at delivery 
(weeks) 
39 (25-42) 40 (33-42) p=0.0019 
Birth weight (g) 3230 (420-4630) 3420 (1500-4650) p=0.0006 
 mean (SD) mean (SD)  
Customised birth 
weight centile 38 (28) 49 (54) p=0.003 
 n (%) n (%)  
Cardiac 
complications 9 (6.5) 0 (0.0) 
OR 40.71  
(2.35-705.7)*** 
Obstetric 
complications 45 (34.3) 73 (27.9)  
Neonatal 
complications 40.0 (30.5) 18 (6.9) 
OR 5.96 
(3.25-10.93)*** 
Preterm delivery 16 (12.2) 11 (4.2) OR 3.16 (1.43-7.06)** 
Iatrogenic 
preterm delivery 11 (8.4) 2 (0.8) 
OR 11.92 
(2.60-54.62)*** 
SGA 27 (20.6) 7 (2.7) OR 9.46 (3.99-22.40)*** 
 
VHD: valvular heart disease; SVD: spontaneous vaginal delivery; CS: Caesarean section; SGA: small for 
gestational age 
 
P values: Fisher’s exact test   
*p<0.05   
** p<0.01 
*** p<0.001 
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Table 5: Outcomes in women with VHD: subgroups  
 
 LHO LHR RHO RHR Mixed valvular disease BPV MPV 
Number of pregnancies 36 36 21 7 13 10 8 
        
Mode of delivery 
SVD 
Assisted vaginal delivery 
Elective CS 
Emergency CS 
 
15 (41.7) 
10(27.8) 
7 (19.4) 
4 (11.1) 
 
20 (55.6) 
8 (22.2) 
2 (5.5) 
6 (16.7) 
 
8 (38.1) 
6 (28.6) 
2 (9.5) 
5 (23.8) 
 
3 (42.8) 
2 (28.6) 
1 (14.3) 
1 (14.3) 
 
7(53.9) 
1 (7.7) 
2 (15.3) 
3 (23.1) 
 
4 (40.0) 
2 (20.00) 
0 (0.0) 
4 (40.0) 
 
2 (25.0) 
0 (0.0) 
3 (37.5) 
3 (37.5) 
 
   
    
Gestational age at delivery 
(wks) 
39 
(29-42) 
40 
(33-42) 
39  
(35-42) 
39  
(38-41) 
40 
(34-41) 
39 
(36-42) 
36  
(25-40) 
Birth weight (kgs) 3155 (1225-4320) 
3375 
(1816-4630) 
3354 
(2380-4090) 
3110 
(2880-3970) 
3200 
(1525-3840) 
3205 
(2450-3940) 
2025 
(420-3206) 
 
   
   
 
Customised birth weight 
centile 42 (30.3) 43 (27.2) 52 (32) 38 (44) 26 (20.9) 55 (25) 15 (23) 
 
   
   
 
Cardiac complications 7 (19.4) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 2 (25.0) 
Obstetrics complications 12 (33.3) 8 (22.2) 11 (52.4) 1 (14.3) 0 (0.0) 6 (54.5) 7 (87.5) 
PPH 5 (13.9) 5 (13.9) 7 (33.3) 1 (14.3) 0 (0.0) 4 (36.3) 5 (71.4) 
Neonatal complications 15 (41.7) 8 (22.2) 4 (19.0) 2 (28.6) 2 (15.3) 3 (27.3) 6 (75.0) 
Preterm delivery 5 (13.9) 2 (5.5) 1 (4.8) 0 (0.0) 1 (7.7) 2 (18.2) 5 (71.4) 
Iatrogenic preterm delivery 3 (8.3) 1 (2.8) 0 (0) 0 (0.0) 0 (0.0) 2 (18.2) 5 (71.4) 
SGA 9 (25.0) 6 (16.7) 3 (14.3) 2 (28.6) 2 (15.3) 1 (9.1) 4 (57.1) 
 
VHD: valvular heart disease; LHO: left heart obstruction; LHR: left heart regurgitation; RHO: right heart obstruction; RHR: right heart regurgitation;  
BPV: bioprosthetic valve; MPV: mechanical prosthetic valve; SVD: spontaneous vaginal delivery; CS: caesarean section; PPH: postpartum haemorrhage; SGA: small for gestational age 
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Table 6: Outcomes in women with VHD taking anticoagulants 
 
 
 Warfarin (n=1) 
Therapeutic 
LMWH 
(n=7) 
Prophylactic 
LMWH 
(n=8) 
 n (%) 
Maternal cardiac complications    
x Cardiomyopathy 0 (0.0) 0 (0.0) 0 (0.0) 
x Myocardial infarction 0 (0.0) 0 (0.0) 1 (12.5) 
x Heart failure 0 (0.0) 0 (0.0) 1 (12.5) 
x Aortic dissection 0 (0.0) 0 (0.0) 0 (0.0) 
x Arrhythmia 0 (0.0) 0 (0.0) 0 (0.0) 
x Endocarditis 0 (0.0) 2 (28.6) 0 (0.0) 
x Valve thrombosis 0 (0.0) 2 (28.6) 0 (0.0) 
x Cardiac death 0 (0.0) 1 (14.3) 0 (0.0) 
Maternal obstetric complications    
x Pregnancy-induced hypertension 0 (0.0) 0 (0.0) 0 (0.0) 
x Pre-eclampsia 0 (0.0) 1 (14.3) 0 (0.0) 
x Eclampsia 0 (0.0) 0 (0.0) 0 (0.0) 
x Antepartum haemorrhage 0 (0.0) 0 (0.0) 0 (0.0) 
x Gestational diabetes mellitus 0 (0.0) 0 (0.0) 0 (0.0) 
x Preterm pre-labour rupture of 
membranes 
0 (0.0) 0 (0.0) 0 (0.0) 
x Spontaneous preterm labour 0 (0.0) 0 (0.0) 0 (0.0) 
x Postpartum haemorrhage 1 (100.0) 5 (71.4) 5 (62.5) 
x Venous thromboembolism 0 (0.0) 0 (0.0) 0 (0.0) 
Fetal/neonatal complications    
x Preterm delivery 0 (0.0) 5 (71.4) 1 (12.5) 
x Iatrogenic preterm delivery 0 (0.0) 5 (71.4) 1 (12.5) 
x Fetal intracranial haemorrhage 1 (100.0) 0 (0.0) 0 (0.0) 
x Small for gestational age 0 (0.0) 4 (57.1) 0 (0.0) 
x Stillbirth 0 (0.0) 0 (0.0) 0 (0.0) 
x Neonatal death 0 (0.0) 3 (42.9) 0 (0.0) 
 
n=number of pregnancies  
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Table 7: Univariable analysis for predictors of complications during pregnancy in 
women with VHD 
 
 
Complications  Predictor Odds Ratio 95% CI p 
Cardiac Left heart obstruction 6.13 1.45-26.04 0.014 
 Mechanical valve prosthesis 14.75 2.68-81.30 0.002 
 Use of therapeutic LMWH 19.83 3.28-119.77 0.001 
 Previous cardiac event 7.13 1.50-33.92 0.014 
     
Obstetric Mechanical valve prosthesis 5.88 1.09-31.68 0.039 
 Use of any anticoagulant 5.25 1.67-16.56 0.005 
 Previous cardiac surgery 2.45 1.14-5.27 0.022 
     
Fetal/neonatal Mechanical valve prosthesis 6.12 1.15-36.12 0.002 
 Use of any anticoagulant 3.59 1.20-10.79 0.023 
 Previous cardiac surgery 3.95 1.68-9.31 0.021 
 Previous cardiac event 3.60 1.03-12.65 0.046 
 
VHD: valvular heart disease; 95% CI: 95% confidence interval; LMWH: low molecular weight 
heparin 
 
 
 
Table 8: Multivariable analysis for predictors of complications during pregnancy in 
women with VHD 
 
   
Complications Predictor Odds Ratio 95% CI p 
Fetal/neonatal Mechanical valve prosthesis 7.26 1.33-44.73 0.010 
 
VHD: valvular heart disease; 95% CI: 95% confidence interval 
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6.6 Discussion 
 
Pregnancy in women with VHD is frequently associated with adverse maternal and 
fetal/neonatal outcomes. In this series of 131 pregnancies in 73 women there was 1 
maternal death and 3 neonatal deaths, as well as a significantly higher rate of cardiac, 
obstetric and fetal/neonatal complications in the VHD group compared with healthy 
controls.  
 
6.6.1 Baseline characteristics 
Women with VHD were significantly younger than the control women (mean 30 
years, SD 5.7, and 34 years, SD 5.0 respectively, p<0.0001). VHD is often 
progressive; for example degenerative dystrophic calcification of a bicuspid aortic 
valve gradually worsens over time with increasing valve dysfunction. This may result 
in women being advised to, or feeling the need to, complete their families at an earlier 
age, although there is no evidence to support this.  Parity did not appear to have a 
deleterious effect on outcomes. This may reflect a selection bias in that women who 
with adverse outcomes in their first pregnancy may choose (or be advised) to avoid 
further pregnancies. Interestingly the usual increase in birth weight seen in second or 
subsequent pregnancies in healthy women did not appear to occur in this cohort of 
women with VHD, although ideally this should be studied by paired comparison. 
 
6.6.2 Diagnoses 
Aortic valve disease was the most common diagnosis (34%) followed by mitral valve 
disease (32%). The ROPAC registry reported mitral valve disease as the commonest 
type of VHD (63% of all VHD reported).38  However, this is an international registry 
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with contributions from 28 countries, including several developing countries where 
the incidence of rheumatic fever and RHD is higher than in the UK. 
 
6.6.3 Maternal outcomes 
Cardiac complications 
Cardiovascular complications occurred in 6.5% of pregnancies in women with VHD, 
including 1 maternal death. These findings are consistent with those reported by the 
CARPREG and ZAHARA investigators, among others.8,30,33,35-37,161 Cardiac 
complications occurred most frequently in women with LHO (19.4%) or an MPV 
(25.0%) and were associated with adverse perinatal outcomes (r=0.24, p=0.0006).  
 
Cardiac complications occurred in 25% (2) of pregnancies in women with MPVs: 
valve thrombosis leading to cardiac death in a woman with a St Jude aortic valve, and 
endocarditis with subsequent thrombosis of a Starr Edwards mitral valve in the other. 
This is a similar rate to that reported in the literature.36,93 Women with well-
functioning MPVs are generally able to tolerate the haemodynamic challenges of 
pregnancy. The need for anticoagulation due to the risk of valve thrombosis, (which is 
increased during pregnancy), raises specific concerns. The optimal anticoagulant 
regimen for pregnant women with MPVs remains a topic for debate and to date there 
are no adequate randomized controlled trials comparing the different options.78 The 
two options described in the ESC guidelines4 are to either continue with oral 
anticoagulants (OACs) throughout pregnancy or to convert to either unfractionated 
heparin (UFH) or low molecular weight heparin (LMWH) between weeks 6 and 12. 
In both regimens, OACs should be converted to either UFH or LMWH for delivery. 
Use of oral anticoagulation, under strict INR control, is safest for the mother and is 
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associated with the least risk of valve thrombosis when used throughout 
pregnancy.4,162 However, OACs such as warfarin cross the placenta and their use in 
the first trimester results in embryopathy in up to 10% of cases4,162 (although this 
relationship appears to be dose dependent with a lower incidence of embryopathy 
(2.6%) reported when the warfarin dose is less than 5mg daily).163 Fetal haemorrhage 
may also occur throughout pregnancy. A particular problem is intracranial 
haemorrhage in the second trimester because of the vulnerability to rupture of the 
developing choroid plexus. Although UFH and LMWH do not cross the placenta, 
UFH is associated with a significantly increased risk of valve thrombosis, both when 
used only in the first trimester and when used throughout pregnancy.4,162  In 
comparison the risk of valve thrombosis when LMWH is used instead of UFH 
appears to be lower, but strict dose control according to anti-Xa levels is required. 
The optimal timing for checking anti-Xa levels (peak versus trough) is unclear. 4,164,165 
In this series, 7 out of 8 pregnancies in women with MPVs were managed with dose-
adjusted LMWH throughout, with anti-Xa generally being measured about four hours 
after the last dose. The woman with a Starr Edwards mitral valve had taken OACs in a 
previous pregnancy. Unfortunately intracranial fetal haemorrhage was diagnosed at 
23 weeks and she opted for a termination of pregnancy. Consequently she refused to 
take warfarin in subsequent pregnancies and in her next pregnancy was treated with 
dose-adjusted UFH. However, she developed endocarditis and suffered a valve 
thrombosis at 25 weeks’ gestation. She underwent an emergency valve replacement 
and was delivered by caesarean section, but the baby did not survive. Another woman 
with two metal valves had terminations of pregnancy in her first 2 pregnancies at 20 
and 25 weeks due to fetal intracranial haemorrhage whilst taking warfarin; (the first 
pregnancy is not included in the study as termination occurred prior to 24 weeks of 
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gestation). In her third (and successful) pregnancy (included in the analysis) she chose 
to take dose-adjusted LMWH instead. 
 
The remaining cardiac complications all occurred in women with LHO. There was 1 
case of pulmonary oedema (0.8% of all pregnancies in women with VHD) in a 
woman with severe MS. The same woman had required open valvotomy within a few 
months of her first delivery, but did not attend for follow-up for several years and was 
again found to have severe MS when she booked in her second pregnancy. Heart 
failure is the most frequently observed maternal complication in women with VHD 
with rates of up to 31% reported in association with MS, (commonly in association 
with atrial tachyarrhythmia),38,55,56,166 significantly higher than described in this series. 
The risk of decompensation is related to the severity of the stenosis.56,157,161,166-167  
In this cohort, 2 pregnancies were complicated by severe MS (valve area ≤ 1.0cm2 at 
echocardiography in the year prior to pregnancy), and 6 by severe AS (peak gradient 
≥ 80mmHg). However, echocardiographic estimation of the degree of valvular 
stenosis is subject to both intra- and inter-observer variability and it may be that this 
cohort actually represents a group of women with less severe disease.  
 
There was one myocardial infarction in a woman with moderate MS. Myocardial 
infarction in women with MS is commonly embolic in origin particularly in the 
presence of atrial arrhythmia. A woman with severe AS developed acute angina at the 
beginning of the third trimester. The increase in left ventricular pressure and in the 
pressure gradient across a stenotic aortic valve leads to a fall in systemic venous 
return with subsequent reduction in coronary perfusion pressures, resulting in 
ischaemia. 
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Clinically significant arrhythmias occurred in 2 pregnancies (1.5%), which is similar 
to the rate of arrhythmia in women with VHD reported to the ROPAC registry38 
(2/131 (1.5%) versus 12/334 (3.6%), p=0.53). Both occurred in women with severe 
AS. Mortality in pregnant women with AS is now rare. However, severe AS 
continues to be associated with high levels of maternal morbidity, with heart failure in 
approximately 10% and arrhythmias in 3-25%.55,161 
 
Three pregnancies were complicated by endocarditis: in the woman described above 
with a metallic mitral valve, in another woman who had previously undergone mitral 
valve repair and had residual mild MS, and in a third woman with moderate sub-aortic 
stenosis. The incidence of endocarditis in pregnant women with VHD is 0.5% and is 
associated with high levels of maternal and fetal mortality and morbidity.4,168,169  
Antibiotic prophylaxis is now only recommended for those women deemed to be at 
greatest risk of endocarditis (those with PHVs, previous endocarditis, untreated 
cyanotic congenital heart disease and those with cyanotic congenital heart disease 
who have postoperative palliative shunts, conduits or other prostheses) during high 
risk procedures such as extensive dental work. It is not recommended for vaginal 
(spontaneous or assisted) or caesarean delivery as there is a lack of evidence showing 
benefit.4,170,171 Despite this some clinicians continue to advise prophylaxis at delivery 
for these women.74 However, the 3 women in this series who developed endocarditis 
did so during the pregnancy, unrelated to any procedure, highlighting the need for a 
high index of suspicion, and prompt treatment when the diagnosis is made.  
 
 
 
! "'"!
Obstetric complications 
There were no significant differences in mode of delivery between women with VHD 
and healthy controls. The rate of obstetric complications in the VHD group and the 
controls was also similar (34.3% in the women with VHD and 27.9% in the controls, 
p=0.15). However, in the subgroup analysis, women with MPVs were shown to have 
significantly more obstetric complications than the control women because of an 
increased rate of PPH (OR 8.98, 95% CI 2.07-39.07, p=0.004). This may be 
associated with administration of anticoagulants, (in this cohort there was a 
significant correlation between the presence of an MPV and the use of anticoagulants 
(r=0.66, p=0.01) and also between the use of anticoagulants and PPH (r=0.57, 
p=0.03)). However the evidence for this from other studies is conflicting.33,38,43 
 
6.6.4 Fetal/neonatal outcomes 
Perinatal outcomes are impaired in women with VHD, particularly in women with 
LHO or MPVs. Fetal/neonatal complications occurred in 30.5% of women with VHD 
(similar to rates reported in the literature55,56,167) compared with 6.9% of the control 
population and were significantly correlated with maternal cardiac complications 
(r=0.24, p=0.0006). Multivariable analysis identified the presence of MPVs as being 
independently associated with adverse perinatal outcomes (p=0.010), which is 
consistent with the findings of the ZAHARA investigators.36 
 
There were 3 neonatal deaths in the VHD group (2.3%) and none in the controls. One 
baby died as a result of complications of prematurity, having been delivered at 25 
weeks’ of gestation following thrombosis of an infected mechanical mitral valve in 
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the mother. Perinatal death risk in women with MPVs has been reported to be as high 
as 28%.93 
 
Preterm delivery, and in particular the rate of iatrogenic preterm delivery, in women 
with VHD was significantly higher than in the control group (8.4% compared with 
0.8%, OR 11.92, 95% CI 2.60-54.62, p<0.001), particularly in women with LHO 
(8.3%) or PHVs (38.9%), similar to findings in other reported studies.55,56,93,161  
 
Significantly more babies in the VHD group were SGA (20.6% versus 2.7%, OR 
9.46, 95% CI 3.99-22.40, p<0.001). Overall birth weight and customized birth weight 
centiles were lower in the valve group, especially in women with MPVs. In normal 
pregnancies a significant correlation between maternal cardiac output in the early 
third trimester and birth weight has been demonstrated.172 Pregnancies complicated by 
idiopathic fetal growth restriction (FGR) appear to be characterized by lower cardiac 
output than healthy pregnancies,173 and in women with heart disease, an association 
between conditions associated with reduced cardiac output or central cyanosis and 
lower birth weight has been observed.30,77 It is presumed that these effects are 
mediated via reduced placental perfusion and/or hypoxia. The cardiovascular 
physiological response to pregnancy in women with cardiac disease has not yet been 
reported and it is likely that any effects on fetal growth are multifactorial and cannot 
simply be explained by changes in cardiac output.
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6.7 Conclusions 
 
 
This study demonstrates that pregnancy in women with VHD is associated with 
significant rates of maternal, fetal and neonatal complications. In particular LHO and 
the presence of an MPV are associated with an increased frequency of adverse cardiac 
and perinatal events, and mechanical valve replacement is an independent predictor of 
poor perinatal outcomes. There is an urgent need for the optimal method of 
anticoagulation in these women to be tested in a randomised controlled trial.  
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Chapter 7: Left ventricular outflow tract obstruction  
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7.1 Abstract 
 
7.1.1 Aims: 
To investigate maternal and neonatal outcomes in a series of pregnancies in 
women with left ventricular outflow tract obstruction  
7.1.2 Methods: 
 Retrospective review of case records 
7.1.3 Results: 
There were eighty-six pregnancies in 47 women with left ventricular outflow 
tract obstruction. Significant cardiac complications occurred in seven 
pregnancies (8.1%). Rates of obstetric complications in the index and control 
groups were similar, although pregnancy-induced hypertension occurred more 
frequently in women with left ventricular outflow tract obstruction (OR 3.90, 
95% CI 1.27-12.04, p=0.018) and was most common in women with 
coarctation of the aorta (15.8%). Fetal/neonatal complications were more 
common women with left ventricular outflow tract obstruction, and there were 
2 neonatal deaths and 1 stillbirth. Babies born to women with left ventricular 
outflow tract obstruction were significantly more likely to be small for 
gestational age (birth weight less than 5th customized centile) (12.8% in the 
heart disease group versus 2.9% of the controls; OR 4.90, 95% CI 1.64-14.60, 
p=0.0038) 
7.1.4: Conclusions: 
Pregnancy in women with left ventricular outflow tract obstruction is 
associated with significant rates of maternal and perinatal complications. 
Aortic stenosis and maternal cigarette smoking during pregnancy are 
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independent predictors for cardiac events, use of beta-blockers is associated 
with fetal/neonatal complications. 
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7.2 Introduction 
 
Lesions that result in obstruction to the left ventricular outflow tract (LVOT) may 
occur at any point between the anatomical LVOT and the descending portion of the 
aortic arch. The association of obstructive left heart disease with adverse pregnancy 
outcomes is well documented.8,30,32,36,161 Left ventricular outflow tract obstruction 
(LVOTO) lesions in women of childbearing age are frequently related to bicuspid 
aortic valve (BAV) disease, although this lesion is less common in women than in 
men.173 
 
Congenital aortic stenosis (AS) has an incidence of 5% in patients with congenital 
heart disease.161 Obstruction can occur at the subvalvular, valvular or supravalvular 
level.161,173 Generally pregnancy is well-tolerated in women with mild to moderate 
disease and normal left ventricular systolic function. However, despite a recent series 
in pregnant AS patients reporting more favourable outcomes than in the past,8,54,55,166 
women with severe aortic stenosis continue to remain at considerable risk of 
developing complications.4,37  
 
 
Coarctation of the aorta (COA) is a narrowing in the aorta that usually occurs at the 
site of the ductus arteriosus. It accounts for 5-8% of congenital heart disease63,173 and 
as with BAV disease, predominates in males. It is often associated with other 
cardiovascular abnormalities including BAV (22-42% of cases), ventricular septal 
defect (VSD), aortic arch hypoplasia, multi-level left heart obstruction, abnormal head 
and neck vessels (5%) and intra-cerebral berry aneurysms (5-10%).173,174 Even in the 
absence of BAV, COA is associated with diffuse aortopathy, with cystic changes in 
the aortic media being described in the segment adjacent to the coarctation and the 
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ascending aorta.173-175 Most women of childbearing age will have undergone repair 
and generally do well during pregnancy94,176 although an excess of hypertensive 
disorders and miscarriage has been reported.4 Both women with unrepaired native 
COA, and those who have undergone surgical repair but have residual hypertension, 
coarctation and/or aortic aneurysm are at particular risk of significant hypertension, 
(which may be refractory to drug therapy) and of aortic rupture during pregnancy.  
 
Hypertrophic cardiomyopathy (HCM) is diagnosed in approximately 1 in 500 of the 
adult population and is often identified for the first time during pregnancy. It is the 
most common genetic cardiac disease.53,177,178 At least 40% of cases are familial, with 
an autosomal dominant inheritance, usually involving mutations of the cardiac 
sarcomere proteins.98,178 HCM is characterized by asymmetric hypertrophy of the left 
ventricle, dynamic LVOTO (which may be severe), a non-dilated left ventricular 
cavity and preserved systolic function with reduced diastolic function due to impaired 
relaxation of the left ventricle. The degree of LVOTO is directly related to the 
severity of hypertrophy of the basal septum, as this determines the contour of the 
LVOT. The phenotype is extremely heterogenous. Clinical presentation ranges from 
asymptomatic to severe events such as heart failure, clinically significant arrhythmias 
and sudden cardiac death. Treatment with beta-blockers may help mediate the 
haemodynamic burden associated with pregnancy. They are also used for rate control 
in patients with atrial fibrillation (AF) and to suppress ventricular arrhythmias.4 The 
rate of maternal morbidity is mainly related to the NYHA functional class pre-
pregnancy, with clinical deterioration and development of overt cardiac failure being 
more likely in patients with outflow obstruction than those without.98,179  Fetal and 
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neonatal outcomes also appear to be impaired in this group, particularly in women 
who develop heart failure during the pregnancy.180  
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7.3 Aims 
 
To investigate maternal and neonatal outcomes in women with LVOTO. 
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7.4 Methods 
 
Women with LVOTO cared for by the Joint Cardiac and Obstetric Service of the 
Chelsea and Westminster and Royal Brompton Hospitals, were identified from a 
database commenced in 1994. Multiple pregnancies were excluded because they pose 
special risks and the numbers were too small for meaningful analysis. For each birth 
to a woman with LVOTO there were two controls (matched for parity): the first 
woman with a parity ≤1 who delivered immediately before and after each index case. 
Fourteen women with LVOTO delivered before 1998; data for control women were 
not available prior to this date and so the first women who delivered on the same date 
in 1999 (matched for parity) were used as controls. 
 
Data were collected from a detailed review of case notes, supplemented by the 
Ciconia Maternity Information System (CMIS©, HD Clinical Ltd, Bishops Stortford, 
Herts, UK). In all women, demographic data and information on the obstetric and 
anaesthetic management during pregnancy and labour, and maternal and neonatal 
outcomes was obtained, noting cardiac, obstetric and fetal/neonatal complications and 
intra-partum events as previously described in chapter 3. The LVOTO population was 
divided into three subgroups: COA, HCM, and AS.  
 
Data were analysed using SPSS 22 and GraphPad Prism version 6.0d. Descriptive 
statistics for nominal data are expressed in absolute numbers and percentages. Mean 
value and standard deviations are presented for normally distributed continuous 
variables and for non-normally distributed continuous variables, median and range. 
Differences in outcomes between the LVOTO and control groups, and between first 
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and subsequent pregnancies in the LVOTO group, were evaluated. Continuous 
variables were compared with the Student t-test if they were normally distributed and 
the Mann-Whitney U-test if they were not. When comparing frequencies the chi-
squared test or Fisher exact test where applicable, was used. All tests were two-tailed 
and p<0.05 was considered statistically significant. Binary logistic regression was 
performed to identify patient characteristics associated with adverse pregnancy 
outcome, divided into 3 composite endpoints (as defined previously): cardiac, 
obstetric and fetal/neonatal complications. The following baseline variables were 
assessed: COA, HCM, AS, previous cardiac surgery, previous cardiac event, NYHA 
functional class pre-pregnancy, pre-existing hypertension, administration of cardiac 
medication during pregnancy, administration of beta-blockers during pregnancy and 
maternal cigarette smoking during pregnancy. Variables that were associated with an 
increased incidence of the studied endpoints (p<0.1) were brought forward to 
multivariable analysis. 
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7.5 Results 
 
Eighty-six pregnancies in 47 women with LVOTO were compared with 172 controls. 
 
7.5.1 Baseline characteristics 
Baseline characteristics for women with LVOTO and controls are shown in table 1. 
Women with LVOTO were significantly younger than the control women. Median 
age at booking in the LVOTO group was 28 years (range 14-45) compared with 33 
years (range 17-45) in the controls (p<0.0001, Mann-Whitney U-test). Women with 
LVOTO were significantly more likely to be taking cardiac medication, in particular 
beta-blockers (OR 80.74, 95% CI 4.78-1365.0, p<0.0001) or calcium channel 
blockers (OR 23.28, 95% CI 1.27-426.4, p<0.01), and were also more likely to have 
pre-existing hypertension (OR 55.58, 95% CI 12.91-239.30, p<0.0001). In the case 
women, outcomes in nulliparous (n=47) and parous (n=25) women were similar (table 
2), although as was expected nulliparous women were more likely to have an assisted 
vaginal delivery (OR 7.10, 95% CI 2.36-21.31, p<0.001). 
 
There were fifty-seven pregnancies (66.3%) in 30 women with a diagnosis of COA. 
Of these 6 were in women who had not undergone previous repair. Twenty-seven 
pregnancies were complicated by pre-existing hypertension. Beta-blockers were the 
commonest anti-hypertensive taken, (14 pregnancies, 24.6%), followed by calcium 
channel blockers (3 pregnancies, 5.3%).  
 
There were nine pregnancies (10.5%) in 6 women with HCM. One woman was 
diagnosed in the immediate postpartum period after she developed pulmonary oedema 
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at delivery. Two pregnancies occurred in women with Noonan’s syndrome. Four 
women (in whom there were 5 pregnancies) had a history of arrhythmia: one had a 
pacemaker and a second had undergone a previous unsuccessful ablation for 
supraventricular tachycardia (SVT); another woman (who had pre-existing left 
ventricular dysfunction) took verapamil (a calcium channel blocker also used as an 
anti-arrhythmic) and frusemide in both her pregnancies, while a fourth was taking 
amiodarone. 
 
Twenty pregnancies (23.2%) occurred in 12 women with AS. Two women (4 
pregnancies) had a bicuspid aortic valve, and 5 women (6 pregnancies) had subaortic 
stenosis. There were 7 pregnancies in 6 women who had previously undergone 
surgery. 
 
7.5.2 Maternal and perinatal outcomes 
Table 3 outlines the mode of delivery, gestational age, birth weight, birth weight 
centile and complications in women with LVOTO and the controls. 
  
Cardiac outcomes 
There were no maternal deaths. Significant cardiac complications occurred in 7 
pregnancies (8.1%). There were 4 adverse events in pregnancies in women with AS 
including clinically significant arrhythmia (2 - both in women with severe AS), acute 
angina (1 – in a woman with severe AS) and endocarditis (1 - in a woman with 
moderate sub-aortic stenosis). Two pregnancies in women with COA were affected 
by cardiac complications: one woman developed pulmonary oedema and left 
ventricular failure, while another suffered a clinically significant arrhythmia. A 
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further woman developed pulmonary oedema at delivery and was admitted to the 
intensive care unit, where she was subsequently diagnosed with HCM. 
 
Obstetric outcomes 
Frequencies of the different modes of deliveries were similar in case women and in 
the controls. Overall there was no statistically significant difference in rates of 
obstetric complications between the two groups (p=0.34), although women with 
LVOTO were significantly more likely to develop pregnancy-induced hypertension 
(PIH) (10.5% vs 2.9%, OR 3.90, 95% CI 1.27-12.04, p=0.018). However, they were 
also more likely to have hypertension prior to pregnancy (39% of women with 
LVOTO vs 1.2% of control women, OR 55.58, 95% CI 12.91-239.30, p=0.013) 
which is a risk factor for development of hypertensive disorders of pregnancy.   
 
Fetal and neonatal outcomes 
Neonatal complications occurred in 22 (25.6%) of the index pregnancies compared 
with 16 (9.3%) in the controls (OR 3.35, 95% CI 1.65-6.80, p=0.0007). There were 2 
neonatal deaths. One was an SGA baby born at 35 weeks of gestation to a woman 
with moderate to severe AS, following abruption and preterm labour. The other baby 
was also SGA and was born by emergency caesarean at 29 weeks of gestation for 
fetal reasons, to a mother with HCM. 1 stillbirth occurred in a woman who sustained a 
ruptured uterus during an attempt at vaginal birth after one previous caesarean 
section. 
Gestational age at delivery was lower in the LVOTO group (p=0.0049). Median birth 
weight and mean birth weight centile were also significantly lower: 3230g (range 
595-4160) and 41st centile (SD 28.4) versus 3355g (range 1500-4480) and 60th centile 
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(SD 29.0) in the controls (p=0.0079 (MWU test) and p=0.041  (t-test) respectively). 
The LVOTO babies were more likely to be SGA: eleven (12.8%) of the babies in this 
group had a birth weight less than the fifth customized centile compared with 5 
(2.9%) of babies born to the control women (OR 4.9, 95% CI 1.64-14.60, p=0.0038).  
 
7.5.3 Logistic regression 
The results of the univariable logistic regression are shown in table 5. The 
multivariable model is shown in table 6. Independent predictors associated with 
cardiac complications were AS (p=0.04) and maternal cigarette smoking during the 
pregnancy (p=0.007). None of the investigated variables were associated with 
obstetric complications. Use of beta-blockers (p=0.009) was associated with adverse 
perinatal outcomes, specifically SGA (OR 4.53, 95% CI 1.06-19.35, p=0.041).  
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Table 1: Baseline characteristics in women with LVOTO and controls 
 
 
 LVOTO Controls  
Number of women 47 172  
Number of pregnancies 86 172  
 mean (SD) mean (SD)  
Age at booking 28 (14-45) 33 (17-45) p<0.0001 
 n (%) n (%)  
Parity    
Nulliparous 47 (54.7) 94 (54.7)  
Para 1 25 (29.0) 50 (29.0)  
Para >1 14 (16.3) 28 (16.3)  
Cardiac medications    
Any 26 (30.2) 4 (2.3) OR 18.20 (6.10-54.32)*** 
β-blocker 16 (18.6) 0 (0.0) OR 80.74 (4.78-1365.0)*** 
Calcium-channel blocker 5 (5.8) 0 (0.0) OR 23.28 (1.27-426.4)** 
Diuretic 2 (2.3) 0 (0.0) 
 
Other antiarrhythmic 1 (1.2) 0 (0.0) 
 
Anticoagulant 2 (2.3) 0 (0.0) 
 
Aspirin 5 (5.8) 2 (1.2) OR 5.25 (1.01-27.64)** 
Other antihypertensive 1 (1.2) 2 (1.2) 
 
NYHA >1 2 (2.3) 0 (0.0)  
Pre-existing 
hypertension 34 (39.5) 2 (1.2) 
OR 55.58 
(12.91-239.30)*** 
Smoking 6 (7.0) 7 (4.1)  
 
LVOTO: left ventricular outflow tract obstruction; OR: odds ratio 
 
P values: Fisher’s exact test   
*p<0.05     
** p<0.01 
*** p<0.001 
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Table 2: Comparison of pregnancy outcomes in nulliparous and parous women with 
LVOTO 
 
 1st pregnancy Subsequent pregnancies  
Number of pregnancies 47 39  
 mean (SD) mean (SD)  
Age at booking (years) 27 (5.3) 30 (5.6) p=0.049 
 n (%) n (%)  
COA 30 (63.8) 27 (69.2)  
HOCM 5 (10.7) 4 (10.3)  
AS 12 (25.5) 8 (20.5)  
Previous cardiac 
surgery 
33 (70.2) 32 (82.1) 
 
Previous cardiac events 2 (4.3) 2 (5.1)  
Cardiac medications    
Any 10 (21.3) 16 (41.0)  
β-blocker 6 (12.8) 10 (25.6)  
Calcium-channel blocker 2 (4.3) 3 (7.7)  
Diuretic 1 (2.1) 1 (2.6)  
Other antiarrhythmic 0 (0.0) 0 (0.0)  
Anticoagulant 1 (2.1) 0 (0.0)  
Aspirin 1 (2.1) 3 (7.7)  
Other antihypertensive 0 (0.0) 1 (2.6)  
Pre-existing 
hypertension 12 (25.5) 22 (56.4) 
OR 0.26 
(0.11-0.66)** 
Smoking 5 (7.0) 1 (2.6)  
Mode of delivery    
SVD 9 (19.1) 21 (53.8) OR 0.20 (0.08-0.53)*** 
Assisted vaginal delivery 24 (51.1) 5 (12.8) OR 7.10 (2.36-21.31)*** 
Elective CS 3 (6.4) 8 (20.6)  
Emergency CS 11 (23.4) 5 (12.8)  
 median (range) median (range)  
Gestational age at 
delivery (weeks) 40 (26-42) 39 (29-41)  
Birth weight (g) 3240 (595-4160) 3210 (1225-4050)  
 mean (SD) mean (SD)  
Customised birth weight 
centile 
38 (26.9) 47 (29.9)  
 n(%) n(%)  
Cardiac complications 6 (12.8) 1 (2.6)  
Obstetric complications 12 (25.5) 7 (17.9)  
Neonatal complications 11 (23.4) 9 (23.1)  
 
SVD: spontaneous vaginal delivery; CS: Caesarean section; OR: odds ratio 
 
P values: Fisher’s exact test 
*p<0.05    
** p<0.01  
*** p<0.001  
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Table 3: Outcomes in all women with LVOTO vs controls 
 
 LVOTO Controls  
Number of 
pregnancies 86 172  
 n (%) n (%)  
Mode of delivery    
SVD 30 (34.9) 77 (44.8)  
Assisted vaginal 
delivery 29 (33.7) 30 (17.4) 
OR 2.41 
(1.33-4.37)** 
Elective CS 11 (12.8) 25 (14.5)  
Emergency CS 16 (18.6) 40 (23.3)  
Regional 
anaesthesia for 
vaginal delivery 
48 (81.4) 50 (46.7) OR 4.98 (2.33-10.61)*** 
 median (range) median (range)  
Gestational aged at 
delivery (weeks) 
39 
(26-42) 
40 
(31-42) p=0.0039 
Birth weight (g) 3230 (595-4160) 
3355 
(1500-4480) p=0.0079 
 mean (SD) mean (SD)  
Customised birth 
weight centile 
41 
(28.4) 
60 
(28.2) p=0.041 
 n (%) n (%)  
Cardiac 
complications 7 (8.1) 0 (0.0) 
OR 32.55 
(1.84-577.3)*** 
Obstetric 
complications 19 (22.1) 55 (32.0)  
PIH 9 (10.5) 5 (2.9) OR 3.90 (1.27-12.04)** 
Neonatal 
complications 22 (25.6) 16 (9.3) 
OR 3.35 
(1.65-6.80)** 
Iatrogenic preterm 
delivery 8 (9.3) 5 (2.9) 
OR 3.43 
(1.09-10.81)** 
SGA 11 (12.8) 5 (2.9) OR 4.90 (1.64-14.60)** 
 
LVOTO: left ventricular outflow tract obstruction; SVD: spontaneous vaginal delivery; CS: Caesarean section; 
PIH: pregnancy induced hypertension; SGA: small for gestational age; OR: odds ratio 
 
P values: Fisher’s exact test 
*p<0.05    
** p<0.01  
*** p<0.001  
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Table 4: Outcomes in women with LVOTO: subgroups 
 
 
 COA HCM AS 
Number of 
pregnancies 57 9 20 
 n (%) 
Mode of delivery    
SVD 21 (36.8) 2 (22.2) 7 (35.0) 
Assisted vaginal 
delivery 20 (35.1) 2 (22.2) 7 (35.0) 
Elective CS 5 (8.8) 2 (22.2) 4 (20.0) 
Emergency CS 11 (19.3) 3 (33.3) 2 (10.0) 
Regional 
anaesthesia for 
vaginal delivery 
35 (85.4) 2 (50.0) 12 (85.7) 
 median (range) 
Gestational aged 
at delivery (weeks) 
39 
(26-42) 
39 
(28-42) 
39 
(29-42) 
Birth weight (g) 3385 (595-4050) 
3031 
(895-4160) 
3000 
(1225-3700) 
 mean (SD) 
Customised birth 
weight centile 
46 
(29.9) 
26 
(17.7) 
35 
(24.3) 
 n (%) 
Cardiac 
complications 4 (7.0) 1 (11.1) 2 (10.0) 
Obstetric 
complications 11 (19.3) 1 (11.1) 7 (35.0) 
PIH 9 (15.8) 0 (0.0) 2 (10.0) 
Neonatal 
complications 11 (19.3) 2 (22.2) 9 (45.0) 
Iatrogenic preterm 
delivery 4 (7.0) 2 (22.2) 2 (10.0) 
SGA 7 (12.3) 0 (0.0) 4 (20.0) 
 
 
COA: coarctation of the aorta; HCM: hypertrophic cardiomyopathy; AS: aortic stenosis; SVD spontaneous 
vaginal delivery; CS: Caesarean section; PIH: pregnancy induced hypertension; SGA: small for gestational age 
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Table 5:  Univariable analysis for predictors of complications during pregnancy in 
women with LVOTO 
 
 
Complications Predictor Odds Ratio 95% CI p 
Cardiac     
 
Aortic stenosis 3.98 1.12-20.15 0.017 
 
Smoking 9.34 2.15-62.87 0.009 
 
    
Neonatal     
 Use of β-blocker 3.25 1.87-40.10 0.006 
 Previous cardiac surgery 8.47 1.68-64.27 0.042 
 
 
 
 
Table 6: Multivariable analysis for predictors of complications during pregnancy in 
women with LVOTO 
 
 
Complications Predictor Odds Ratio 95% CI p 
Cardiac     
 
Aortic stenosis 8.33 2.13-53.46) 0.040 
 
Smoking 20.25 2.24-183.14 0.007 
 
    
Neonatal     
 Use of β-blocker 4.62 1.46-14.56 0.009 
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7.6 Discussion 
 
Pregnancy in women with LVOTO is associated with increased rates of adverse 
maternal and fetal neonatal outcomes. In this series of eighty-six pregnancies in 47 
women with LVOTO, there were no maternal deaths. However, there were two 
neonatal deaths and one stillbirth, as well as a significantly higher rate of cardiac and 
fetal/neonatal complications in the LVOTO group compared with healthy control 
women. 
 
7.6.1 Baseline characteristics 
Women with LVOTO were significantly younger than the control women (median 
ages at booking 28 years (range 14-45), and 33 years (range 17-45) respectively, 
p<0.0001), which is concordant with the findings reported elsewhere in this thesis 
(chapters 4 and 5). Although there is an increasing trend among women in the UK (as 
well as in other developed nations) to delay pregnancy until later in life, it may be that 
women with heart disease are being advised to complete their families at an earlier 
age before their condition deteriorates. However, there is no evidence to support this. 
Again, as in women with valvular heart disease, there was no obvious detrimental 
effect of parity on outcomes, but as discussed previously this may reflect a selection 
bias. 
 
7.6.2 Maternal outcomes 
Cardiac complications 
There were no maternal deaths. Adverse cardiovascular events occurred in 8.1% of 
pregnancies in women with LVOTO. A systematic review by the ZAHARA 
investigators noted that cardiovascular events occurred in 11% of 2491 pregnancies in 
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women with various types of congenital heart disease,39 and left heart obstruction is 
consistently reported as a predictor for adverse cardiac outcomes.8,30,33,35-37,39 
Multivariable analysis identified AS and maternal cigarette smoking during 
pregnancy as being independently associated with cardiovascular complications 
(p=0.04 and p=0.007 respectively). This differs from the findings of the CARPREG 
and ZAHARA studies which identified maternal cigarette smoking as a risk factor for 
adverse fetal/neonatal outcomes but not for cardiovascular events. However, other 
researchers have reported an association35 and the detrimental effects of cigarette 
smoking on cardiovascular haemodynamics are well known.181,182   
 
The commonest complication was clinically significant arrhythmia. This occurred in 3 
pregnancies (4.2%), similar to the rate of arrhythmia described in 599 pregnancies in 
women with heart disease by the CARPREG team. Two arose in women with severe 
AS, which is associated with arrhythmias in 3-25% of pregnancies.55,161  The third was 
in a woman with repaired COA who had previously suffered from atrioventricular 
nodal re-entrant tachycardia (AVNRT) and who developed first degree heart block. 
Significant arrhythmias in patients with repaired COA are uncommon in the first 20 
years after repair, but thereafter the incidence increases, especially in those who 
develop ventricular dysfunction.183 Arrhythmias are common in women with HCM, 
and are one of the common precipitants of cardiac failure in these women; pre-
pregnancy arrhythmias are generally predictive of a recurrence during pregnancy.98 It 
is therefore perhaps surprising that no significant arrhythmias occurred in women 
with HCM in this series as five of the six had arrhythmias prior to pregnancy. 
However, this may be because three women took anti-arrhythmic drugs throughout 
their pregnancies (in fact, one woman took both amiodarone and verapamil), while a 
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fourth had been previously fitted with a pacemaker due to a history of atrial 
tachycardias. 
 
Two pregnancies (2.3%) were complicated by heart failure: one in a woman with 
repaired COA who was known to have left ventricular dysfunction prior to pregnancy, 
and the other in the woman who was only diagnosed with HCM when she developed 
acute pulmonary oedema immediately after delivery by caesarean section. Heart 
failure was the most common cardiovascular complication reported to the ROPAC 
registry (13.1%, 68% of whom had left sided lesions) and was documented in 7.6% of 
patients with COA (which is high when compared to other reports94) and 18% of 
patients with HCM. Delivery is a time of particular risk for women with LVOTO due 
to the marked haemodynamic changes that occur at this time. Heart failure has been 
reported to complicate up to 10% of pregnancies in women with severe AS.55,161  
 
One woman with severe AS developed acute angina at the beginning of the third 
trimester. The increase in left ventricular pressure and in the gradient across a stenotic 
aortic valve in pregnancy results in reduced systemic venous return, and thus reduced 
coronary blood flow and compromised myocardial perfusion.  
 
Finally, a woman with moderate sub-aortic stenosis developed endocarditis. 
 
Obstetric complications 
There were no statistically significant differences in mode of delivery between 
women with LVOTO and healthy controls. The rate of obstetric complications in the 
LVOTO group and the controls was also similar (22% in the case women, and 32% in 
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the controls, p=0.30) although women with LVOTO were more likely to develop PIH 
(OR 3.90, 95% CI 1.27-12.04, p=0.018). PIH occurred most frequently in women 
with COA (15.8%); however, much higher rates (up to 22%) have been 
described.94,176 In the normal population up to 8% of all gestations are affected by 
hypertensive disorders of pregnancy.94 This cohort may represent a relatively low-risk 
group of women with COA as only 6 pregnancies (10.5%) occurred in women who 
had not undergone repair, although this is a similar proportion to that reported by 
other authors.176 32% of women with COA in this series were taking antihypertensive 
medication at the start of pregnancy, and it is possible that the lower rate of 
hypertensive complications reported here is a reflection of tighter long-term blood 
pressure control. 
 
7.6.3 Fetal/neonatal outcomes 
Perinatal outcomes are impaired in women with LVOTO. Fetal/neonatal 
complications occurred in 25.6% of women with LVOTO compared with 9.3% in the 
control population (p=0.003). Obstructive left heart lesions are well known to be 
associated with high rates of fetal and neonatal complications.30  
 
There were 2 neonatal deaths (2.3%) in the LVOTO group (one following abruption 
and preterm labour at 35 weeks of gestation in a woman with moderate AS, and the 
other in a woman with HCM delivered at 29 weeks of gestation due to concerns about 
fetal growth). One stillbirth occurred following uterine rupture during labour in a 
woman with COA who had previously delivered by caesarean section. Rates of 
perinatal mortality of up to 30% have been reported in women with severe AS. COA 
and HCM are not generally associated with high rates of perinatal loss.4 The risk of an 
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adverse outcome appears to be directly related to the severity of the obstruction and 
consequent reduction in cardiac output and placental perfusion.161 
Gestational age at delivery was lower in the LVOTO group (median 39 weeks, range 
26-42) compared with the controls (median 40 weeks, range 31-42) (p=<0.0039, 
MWU test). Babies born to women with LVOTO were significantly more likely to be 
delivered prematurely for medical reasons (OR 3.43, 95% CI 1.09-10.81, p=0.005). 
Significantly more babies in the LVOTO group were SGA (13% versus 3%, OR 4.90, 
95% CI 1.64-14.60, p=0.0038). Overall birth weight and customized birth weight 
centiles were also lower (p<0.0079 and p=0.041 respectively). Multivariable analysis 
identified use of beta-blockers as being independently associated with adverse 
perinatal outcomes (p=0.009). Beta-blockers, which were taken in sixteen pregnancies 
(18.6%), reduce cardiac output via a negative inotropic effect on the myocardium. An 
association between reduced cardiac output and lower birth weight has been observed 
both in healthy pregnancies and those in women with cardiac disease.30,77,97 Use of 
beta-blockers during pregnancy has repeatedly been associated with delivery of low 
birth weight infants.77,78,109 However, this effect has mainly been studied in women 
with hypertension in pregnancy, with limited data available for women with heart 
disease. Atenolol had previously been shown to be associated with a higher incidence 
of fetal growth restriction compared with other beta-blockers.98,184 It has been 
suggested that the α/β adrenergic receptor balance may play an important role in the 
regulation of the placental vascular bed, and that β1-selective drugs are more prone to 
impair placental perfusion and cause FGR than a combined  α/β-receptor blocker such 
as labetolol.184 However, a recent study did not show that labetolol was any less likely 
to be associated with FGR than selective beta-blockers.185 Obstructive left heart 
lesions reduce the ability of the heart to increase cardiac output during pregnancy 
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which may restrict uteroplacental perfusion. It may be that pregnant women with 
more severe heart disease are more likely to require treatment with beta-blockers 
(which are administered specifically to reduce cardiac output, thereby reducing the 
strain of pregnancy on the mother’s cardiovascular system), and that these women are 
therefore more likely to develop FGR. 
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7.7 Conclusions 
 
This study demonstrates that pregnancy in women with LVOTO is significantly 
associated with adverse cardiovascular and fetal/neonatal outcomes, but not obstetric 
complications. AS and maternal cigarette smoking are independent predictors of 
cardiovascular events, while use of beta-blockers was predictive of fetal/neonatal 
complications. 
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Chapter 8: Conclusions 
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8.1 Summary of study findings 
 
 
 
This work describes maternal and perinatal outcomes in 489 pregnancies in 326 
women with heart disease between 1994 and 2011. 
 
8.1.1 Maternal mortality  
Maternal mortality was 0.8%, significantly higher than in healthy women.3 All 
maternal deaths occurred in women with conditions known to be associated with high 
levels of risk. There were 2 deaths in women with pulmonary hypertension (PH) 
(20%). Older series reported a maternal mortality of 30-56% in women with PH,51 
although more recent data suggest that outcomes may be improving, and describe 
mortality rates of 10-25%, consistent with the findings in this study.103-105 One death 
occurred in a woman with dilated cardiomyopathy (DCM) and the last was in a 
woman with a mechanical prosthetic valve (MPV). The deaths in the women with PH 
and DCM all occurred during the early postnatal period, supporting observations that 
this is a time of particularly high risk for such women.51,91  
 
8.1.2 Cardiovascular events 
A prior history of arrhythmias and the presence of an MPV were identified as 
independent predictors of cardiovascular events (p<0.0001, p=0.003 respectively). 
The commonest cardiac complication overall was arrhythmia, followed by heart 
failure. Myocardial dysfunction prior to pregnancy was an independent predictor for 
developing heart failure during pregnancy (p=0.007). Marfan syndrome (MFS) in 
particular was associated with high rates of cardiac events. One woman with a grossly 
dilated aortic root experienced a type-A dissection shortly after delivery of her second 
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baby. Two others developed impaired left-ventricular dysfunction during the 
pregnancy. Although left ventricular dilatation and impairment of left ventricular 
function have been reported in MFS patients in the absence of valvular pathology,132-
134 this is the first time such an effect has been described in pregnancy. Another 
woman required replacement of the aortic root and valve, and another had 
replacement of the aortic valve alone, both during the first 6 postnatal months. One 
woman who had an MPV due to congenital mitral stenosis (MS) required valve 
replacement during pregnancy due to valve thrombosis after she developed infective 
endocarditis. 
 
8.1.3 Intrapartum events 
There were high rates of assisted vaginal delivery (26% overall). This reflects practice 
at the Chelsea and Westminster and Royal Brompton Hospitals to recommend 
elective assisted delivery in women with serious cardiac disease to minimize the 
cardiovascular stress associated with bearing down. However, there is no evidence to 
support a benefit of this policy.78 Caesarean section rate was also high, but not 
significantly different to that in the general obstetric population at the time; (during 
the study period the Chelsea and Westminster Hospital had a somewhat permissive 
view with regard to performing elective caesarean section for maternal request with 
no medical indication).  
 
8.1.4 Obstetric complications 
Hypertensive disorders of pregnancy and postpartum haemorrhage (PPH) were the 
most frequently observed obstetric complications. Rates of hypertensive disorders 
were similar to those reported in the general population and pregnancy-induced 
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hypertension (PIH) (but not pre-eclampsia) was independently associated with pre-
existing hypertension (OR 4.14, 95% CI 1.54-11.14, p=0.005). Delivery by 
emergency Caesarean section (OR 3.25, 95% CI 1.98-5.35, p<0.001) and use of 
anticoagulants (OR 7.96, 95% CI 2.31-27.40, p=0.001) are independent predictors for 
PPH. However, there may also be an association with the low dose Syntocinon© 
infusion (to prevent the systemic hypotension associated with its use) used to manage 
the third stage of labour in women with significant cardiac disease.4,5 
 
8.1.5 Perinatal outcomes 
There were 5 stillbirths and 5 neonatal deaths in the nulliparous women studied, rates 
which are comparable to other series of women with cardiac disease,39 but higher than 
the general population of England and Wales.95,96 Adverse perinatal outcomes were 
predicted by NYHA functional class ≥ 2 (p<0.0001), use of any cardiac medication 
(p=0.022), presence of an MPV (p=0.024) and a systemic right ventricle (p=0.007). 
Birth weight below the 5th customized centile was the most common complication  
(21%), followed by preterm delivery (12%), which was frequently performed for 
medical indications. Particularly high frequencies of neonatal complications were 
seen in pregnancies in women with PH (78%), MFS (43%), cyanotic congenital heart 
disease (85-100%), complete transposition of the great arteries (TGA) (65%) and 
Ebstein’s anomaly (100%).  
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8.2 Implications of study findings 
 
Despite the continued rise in maternal death due to cardiac disease, current 
management continues to be based upon limited clinical experience (which tends to 
be clustered in tertiary centres) and an inadequate body of prospective research 
(usually observational studies). The literature is largely composed of retrospective 
case series. Further studies are required to assess the cardiovascular physiological 
response to pregnancy and delivery in women with pre-existing heart disease, as this 
has not yet been reported. There is also an urgent need for large collaborative 
randomised controlled trials to help to define optimal management. Important aspects 
of practice that need to be evaluated include: protective use of beta-blockers in 
women with aortopathy or cardiomyopathy, the ideal anticoagulant regimen in 
women with mechanical valves, mode of delivery (including whether there a 
shortened or assisted second stage is beneficial), management of the third stage and 
the impact of pregnancy on longer-term cardiac function.  
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8.3 Strengths and limitations  
 
The main strength of the data presented in this work is that the cohort of women 
described were all managed by the same core team of clinicians during the period of 
study. Most women were fully evaluated and counselled prior to embarking upon 
pregnancy, consistent with current guidelines. Relevant data were recorded in the 
Ciconia Maternity Information System (CMIS©, HD Clinical Ltd, Bishops Stortford, 
Herts, UK) contemporaneously and all presenting cases are reported, thus the cohort 
is a continuous series. The control population, where relevant, was managed in the 
same maternity unit. 
 
Most of the limitations of the study relate to the retrospective design. Although most 
data were collected contemporaneously, in some cases the data were incomplete and 
needed to be supplemented by review of the case notes. Some of the maternity notes 
were unavailable, having been destroyed in a fire at the storage facility. However, it 
was usually possible to obtain the remaining data from the cardiology notes. The 
cohort of patients studied represents patients receiving tertiary medical care from the 
Royal Brompton and Chelsea and Westminster Hospitals. It includes patients with 
complex congenital heart disease, but only one woman with ischaemic heart disease. 
A referral bias is therefore likely and caution is required when extrapolating these 
results to populations with a different distribution of cardiac disease. The use of non-
matched controls can introduce significant confounding factors. However, 
characteristics such as height, weight and body mass index may be influenced by the 
patient’s cardiac disease, or may be part of a syndrome (such as MFS). Additionally, 
patients perceived to be at particular risk (for example, those with pulmonary 
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hypertension) may have been advised against pregnancy. Women whose pregnancies 
failed to progress beyond 24 weeks of gestation were not included in the study, and it 
was therefore not possible to examine associations with miscarriage or subfertility. 
  
! "*'!
Chapter 9: Appendices 
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9.1 Publications 
 
1. Curry RA, Fletcher C, Gelson E, Gatzoulis MA, Woolnough M, Richards N, 
Swan L, Steer PJ, Johnson MR. Pulmonary hypertension and pregnancy – a 
review of 12 pregnancies in nine women. BJOG 2012 May;119(6):752-61 
 
2. Curry RA, Gelson E, Swan L, Dob D, Babu-Narayan SV, Gatzoulis MA, Steer 
PJ, Johnson MR. Marfan syndrome and pregnancy: maternal and neonatal 
outcomes. BJOG 2014 Apr;121(5):610-7. 
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